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Abstract: SUMMARY Alzheimer’s disease (AD) is the major cause of dementia and cognitive impair-
ments among older people and affects more than 30% of the population above 85 years of age. It is an
age dependent neurodegenerative disease histopathologically characterized by the deposition of extracel-
lular ￿-amyloid (A￿) plaques and the formation of intracellular neurofibrillary tangles composed of the
hyperphosphorylated protein tau. Converging evidence links abnormally high brain concentrations of
A￿, due to a shift in the balance between A￿ production and degradation, to the pathology of AD and
to cognitive deficits in transgenic mouse models. It was previously found in our lab that injection of
synthetic fibrillar A￿1-42 into mouse brains caused sustained increases in brain levels of neprilysin protein
and led to dramatic reduction of brain A￿ level, as well as prevention of amyloid plaque formation and
associated cytopathology. Because of an increase of neprilysin mRNA observed 20 weeks after injection,
we investigated the potential regulation of neprilysin expression by A￿1-42 in vitro using a luciferase
assay driven by one of the three neprilysin promoters and incubation of 293T and SH-SY5Y cells with
aggregated A￿1-42, aggregated A￿42-1 or PBS. A￿1-42 incubation did not affect neprilysin promoter ac-
tivity in vitro. However, all trans retinoic acid (RA) which is used to differentiate SH-SY5Y cells, was
shown to increase the activity of all three neprilysin promoters during SH-SY5Y differentiation. A similar
effect was also found in 293T cells and led to an increase of neprilysin protein levels. Diffusible factors
associated with microglia activation did not affect activity of neprilysin promoters in vitro and were not
responsible for the upregulation of neprilysin observed in vivo after A￿1-42 injection. Analysis of a new
group of mice, 20 weeks after similar brain injection of aggregated A￿1-42, A￿42-1 or PBS confirmed the
A￿1-42-related upregulation of neprilysin protein level but did not show any increase of total neprilysin
mRNA level and promoter specific mRNA levels when compared to A￿42-1 injected mice, suggesting that
increased protein stability may also be involved in the A￿1-42-related upregulation of neprilysin in vivo.
Searching for other A￿-degrading pathways, we also found that brain injection of aggregated A￿1-42 led
to the activation of the plasminogen system. The activity of plasmin, another A￿ degrading enzyme, was
increased 20 weeks after intracranial injection of A￿1-42 when compared to mice which received injection
of A￿42-1 or PBS. Activation of plasmin was found to be associated with an increased activity of urokinase
plasminogen activator (uPA), 9 which did not involve transcription regulation since uPA mRNA level
was unaffected. Interestingly, uPA activity strongly correlated with neprilysin protein level after A￿1-42
injection. Therefore, we investigated the possible association between both increases. A￿1-42 efficiently
increased the activity of both plasminogen activators, uPA and tissue-type plasminogen activator (tPA)
on different cell types including primary neuronal culture. However, this increase of activity was not
associated with upregulation of neprilysin. On the contrary, transgenic overexpression of neprilysin in
neurons increased activity of both uPA and tPA in the brain and strongly implied that upregulation of
neprilysin may act on the plasminogen system via pathways, which still need to be identified. Neprilysin
is the major rate-limiting peptidase involved in the physiological degradation of A￿ in the brain and
its role in amyloidosis was further investigated in vivo. We found that partial and total reduction of
neprilysin level, led to murine A￿ accumulation with plaque formation without alteration of APP level in
the brain. It was associated with signs of neurodegeneration in the hippocampus and cognitive deficits in
the conditioned taste aversion paradigm. Mice with neprilysin deletion represent the first mouse model
with endogenous murine A￿ plaque like pathology without alteration of APP processing and therefore a
valuable tool to study specifically the role of endogenous A￿. Indeed, many transgenic mice overexpressing
the mutated human amyloid precursor protein (APP) were produced and recapitulated many aspects of
AD pathology including A￿ amyloidosis and cognitive deficits. These models were used to evaluate thera-
peutic interventions for AD but could not clearly distinguish the effects related to A￿ accumulation from
overexpression of APP or its other proteolytic fragments. To investigate the potential therapeutical effect
of neprilysin upregulation against amyloidosis, we generated transgenic mice, overexpressing neprilysin
in neurons (NEP mice) and bred them with one of these mouse models of amyloidosis overexpressing
human AD-causing mutated APP in neurons (J20 mice). Neprilysin overexpression prevented the accu-
mulation of A￿ without altering neither the APP processing nor the levels of substance P, enkephalin
and somatostatin, three other major neuronal neprilysin substrates. Behavioral analysis of the NEP
mice showed a significant abnormal locomotion with slight decrease of anxiety both of which disappeared
with age. Except a lack of contextual fear conditioning, learning and memory performances were not
affected by neprilysin overexpression, suggesting that such an upregulation would present few cognitive
side effects. The hyperlocomotion, decreased anxiety and memory deficit during the conditioned taste
aversion task observed in the J20 mice were not prevented by neprilysin 10 overexpression suggesting that
either the beneficial effects of neprilysin was limited or APP and its other proteolytic fragments which
were not modified by neprilysin overexpression are responsible for these behavioral alterations. However,
neprilysin overexpression prevented the memory impairment observed in J20 mice during the Morris
water maze task, strongly supporting A￿ as the culprit responsible for this cognitive impairment and
neprilysin upregulation as a valid A￿-lowering therapeutic approach for AD. 11 ZUSAMMENFASSUNG
Die Alzheimer Demenz (AD) ist ein multifaktorielles Syndrom, welches durch eine progressive Atrophie
und die Zerstörung von Neuronen charakterisiert ist, was zu kognitiver Schwäche, Demenz und schliesslich
zum Tod führt. AD Forschung hat sich bisher hauptsächlich auf die Generierung und Ablagerung von
￿-Amyloidpeptiden (A￿) konzentriert, da die abnormal hohe A￿-Konzentration als primärer Auslöser von
AD gilt. Die extrazellulären A￿ Ablagerungen (Plaques) im Gehirn begünstigen die Entstehung von neu-
rofibrillären Läsionen, die synaptische Fehlfunktion und den Verlust von Neuronen im Gehirn der AD
Patienten. Mutationen in APP (Amyloid-Precursor Protein), Presenilin (PS) 1- und 2– Genen verur-
sachen die familiäre Form der Krankheit durch Generierung von erhöhten Mengen von A￿. Diese Effekte
werden durch das Alter verstärkt. Je länger desto mehr wird es klar, dass in den meisten Patienten
eine abnormale Akkumulation von A￿ im Gehirn durch mangelhaften Abbau dieses Peptids verursacht
wird. Arbeiten aus unserem Labor zeigten, dass die Injektion von fibrillärem A￿1-42 ins Gehirn der
Mäuse zu einem erhöhten Gehalt des A￿-abbauenden Enzyms Neprilysin in Neuronen führte, was eine sig-
nifikante Reduktion der A￿ Mengen und Plaque-Pathologie zur Folge hatte. Die Erhöhung des Neprilysins
wurde, unter anderem mechanistisch auf eine höhere Transkriptionsaktivität zurückgeführt. Deswegen
haben wir versucht, mittels Luciferase- Assay die Aktivierung von Neprilysin Promoteren durch A￿1-42 in
vitro zu untersuchen. Dabei konnte keine Aktivierung der Neprilysin-Expression durch A￿1-42 oder eine
Beteiligung der diffusionsfähigen Faktoren gezeigt werden. Wir haben aber festgestellt, dass Retinsäure,
die für neuronale Ausdifferenzierung der Neuroblastomazellen benützt wird, sich aktivierend auf alle
3 Neprilysin-Promoteren auswirkt. In weiteren in vivo Experimenten könnten wir höhere Neprilysin
mRNA and Protein-Konzentrationen nicht miteinander korrelieren. Diese Ergebnisse weisen darauf hin,
dass eine erhöhte Proteinstabilität in vivo auch zur Erhöhung des Neprilysin-Gehalts beigetragen haben
könnte. Zusätzlich zeigen wir hier, dass die A￿ Injektionen die Aktivierung von Plasmin, eines weiteren
A￿-abbauenden Enzyms, im Gehirn bewirken. Die Plasmin-Aktivierung war von einer höheren Aktiv-
ität des urokinase plasminogen activator (uPA) begleitet. uPA Transkription war jedoch unverändert.
uPA Aktivität und erhöhter Neprilysin-Gehalt zeigten eine starke Korrelation in vivo. Wir untersuchten
diesen Zusammenhang in vitro und konnten zeigen, dass A￿1-42 die Aktivität 12 beider Plasminogenakti-
vatoren uPA und tissue-type plasminogen activator (tPA) in vitro erhöht. Auch neuronale Expression von
Neprilysin in transgenen Tieren führte zur Aktivitätssteigerung von uPA und tPA in Gehirn. Neprilysin
ist das wichtigste A￿ abbauende Enzym im Gehirn. Unser Ergebnisse zeigen, dass Neprilysin defiziente
Mäuse eine Akkumulation und Ablagerung des A￿ Peptids im Gehirn aufweisen, ohne jedoch das Spal-
tungsmuster (processing) des APP Moleküls zu verändern. Neprilysin-defiziente Mäuse zeigten auch
Anzeichen einer A￿-abhängigen Neurodegeneration und kognitive Defizite. Diese Mäuse stellen das erste
Modell mit muriner A￿-Pathologie dar und ermöglichen die Untersuchung der Rolle des endogenen A￿
in Pathophysiologie von AD. Dies ist besonderes wichtig, weil die bisherigen Modelle auf der Überex-
pression des humanen APP in transgenen Tieren basieren. Eine Trennung der toxischen Einwirkungen
von A￿ im Vergleich zur Beteiligung anderer APP-Spaltprodukte ist deswegen in diesen Modellen nicht
eindeutig machbar. Um das therapeutische Potential der Neprilysin-Aktivierung gegen A￿-Pathologie
zu testen, haben wir unsere transgene Tiere mit einem Mausmodell mit erhöhter A￿ Produktion und
Ablagerung (J20) gekreuzt. Wir zeigen hier, dass die Doppelmutanten eine massive Reduktion von A￿ im
Gehirn aufweisen, während sich die Konzentrationen anderer APP-Spaltprodukten nicht ändern. Auch
2
die Konzentrationen anderer Neprilysin-Substrate (Substance P, Enkephalin, Somatostatin) waren un-
verändert. Eine marginale Verminderung der Ängstlichkeit kennzeichnete die jungen NEP Tiere, die
aber mit fortschreitendern Alter verschwand. Abgesehen davon, dass die NEP Maüse Schwirigkeiten
in einem Angst-Konditionierungstest zeigten, hatte die Überexpression von Neprilysin keinen Einfluss
auf die Lernfähigkeit und Gedächnisleistung. Dies denkt darauf hin, dass bei Neprilysin uberexpression
wenig Beeinflussungen der cognitiven Leistungen zu erwarten wären. Sowohl die verminderte Lokomo-
tion und Ängstlichkeit als auch die Defizite in konditionierter Geschmack-Aversion der J20 Mäuse wurde
durch Neprilysin Überexpression nicht behoben. Eine mögliche Erklärung dafür könnte eine ungenügende
Neprilysin-Konzentration sein, um diese Effekte rückgängig zu machen. Alternativ ist es möglich, dass
APP und seine anderen Spaltprodukte, deren Gehalt nicht durch Neprilysin reduziert wird, für die oben
beschriebenen Effekte verantwortlich sind. Im Gegenteil, die Überexpression von Neprilysin verhinderte
die Beeinträchtigung der kognitiven Gedächtnisleistung der J20 Tiere, so dass sie von den Wildtyp Tieren
nicht unterscheidbar waren. 13 Unsere Daten belegen in einem in vivo system, dass A￿ eine eigentlich tox-
ische Spezies in der AD Pathophysiologie ist, welche die kognitiven Defizite verursacht. Weil Neprilysin-
Aktivierung die Prozessierung des APP Moleküls nicht verändert, stellen wir die Hypothese auf, dass eine
Hochregulation des Neprilysins die physiologischen Funktionen des APP nicht verändert. Wir schlagen
deswegen eine neuronale Aktivierung des Neprilysins als eine wirkungsvolle Möglichkeit zur A￿-Reduktion
und AD-Therapie vor.
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SUMMARY 
 
Alzheimer’s disease (AD) is the major cause of dementia and cognitive impairments among 
older people and affects more than 30% of the population above 85 years of age. It is an age 
dependent neurodegenerative disease histopathologically characterized by the deposition of 
extracellular β-amyloid (Aβ) plaques and the formation of intracellular neurofibrillary tangles 
composed of the hyperphosphorylated protein tau. Converging evidence links abnormally 
high brain concentrations of Aβ, due to a shift in the balance between Aβ production and 
degradation, to the pathology of AD and to cognitive deficits in transgenic mouse models. 
 
It was previously found in our lab that injection of synthetic fibrillar Aβ1-42 into mouse brains 
caused sustained increases in brain levels of neprilysin protein and led to dramatic reduction 
of brain Aβ level, as well as prevention of amyloid plaque formation and associated 
cytopathology. Because of an increase of neprilysin mRNA observed 20 weeks after 
injection, we investigated the potential regulation of neprilysin expression by Aβ1-42 in vitro 
using a luciferase assay driven by one of the three neprilysin promoters and incubation of 
293T and SH-SY5Y cells with aggregated Aβ1-42, aggregated Aβ42-1 or PBS. Aβ1-42 
incubation did not affect neprilysin promoter activity in vitro. However, all trans retinoic acid 
(RA) which is used to differentiate SH-SY5Y cells, was shown to increase the activity of all 
three neprilysin promoters during SH-SY5Y differentiation. A similar effect was also found 
in 293T cells and led to an increase of neprilysin protein levels. Diffusible factors associated 
with microglia activation did not affect activity of neprilysin promoters in vitro and were not 
responsible for the upregulation of neprilysin observed in vivo after Aβ1-42 injection. Analysis 
of a new group of mice, 20 weeks after similar brain injection of aggregated Aβ1-42, Aβ42-1 or 
PBS confirmed the Aβ1-42-related upregulation of neprilysin protein level but did not show 
any increase of total neprilysin mRNA level and promoter specific mRNA levels when 
compared to Aβ42-1 injected mice, suggesting that increased protein stability may also be 
involved in the Aβ1-42-related upregulation of neprilysin in vivo.  
 
Searching for other Aβ-degrading pathways, we also found that brain injection of aggregated 
Aβ1-42 led to the activation of the plasminogen system. The activity of plasmin, another Aβ 
degrading enzyme, was increased 20 weeks after intracranial injection of Aβ1-42 when 
compared to mice which received injection of Aβ42-1 or PBS. Activation of plasmin was 
found to be associated with an increased activity of urokinase plasminogen activator (uPA), 
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which did not involve transcription regulation since uPA mRNA level was unaffected. 
Interestingly, uPA activity strongly correlated with neprilysin protein level after Aβ1-42 
injection. Therefore, we investigated the possible association between both increases. Aβ1-42 
efficiently increased the activity of both plasminogen activators, uPA and tissue-type 
plasminogen activator (tPA) on different cell types including primary neuronal culture. 
However, this increase of activity was not associated with upregulation of neprilysin.  On the 
contrary, transgenic overexpression of neprilysin in neurons increased activity of both uPA 
and tPA in the brain and strongly implied that upregulation of neprilysin may act on the 
plasminogen system via pathways, which still need to be identified. 
 
Neprilysin is the major rate-limiting peptidase involved in the physiological degradation of 
Aβ in the brain and its role in amyloidosis was further investigated in vivo. We found that 
partial and total reduction of neprilysin level, led to murine Aβ accumulation with plaque 
formation without alteration of APP level in the brain. It was associated with signs of 
neurodegeneration in the hippocampus and cognitive deficits in the conditioned taste aversion 
paradigm. Mice with neprilysin deletion represent the first mouse model with endogenous 
murine Aβ plaque like pathology without alteration of APP processing and therefore a 
valuable tool to study specifically the role of endogenous Aβ. Indeed, many transgenic mice 
overexpressing the mutated human amyloid precursor protein (APP) were produced and 
recapitulated many aspects of AD pathology including Aβ amyloidosis and cognitive deficits. 
These models were used to evaluate therapeutic interventions for AD but could not clearly 
distinguish the effects related to Aβ accumulation from overexpression of APP or its other 
proteolytic fragments. To investigate the potential therapeutical effect of neprilysin 
upregulation against amyloidosis, we generated transgenic mice, overexpressing neprilysin in 
neurons (NEP mice) and bred them with one of these mouse models of amyloidosis 
overexpressing human AD-causing mutated APP in neurons (J20 mice). Neprilysin 
overexpression prevented the accumulation of Aβ without altering neither the APP processing 
nor the levels of substance P, enkephalin and somatostatin, three other major neuronal 
neprilysin substrates. Behavioral analysis of the NEP mice showed a significant abnormal 
locomotion with slight decrease of anxiety both of which disappeared with age. Except a lack 
of contextual fear conditioning, learning and memory performances were not affected by 
neprilysin overexpression, suggesting that such an upregulation would present few cognitive 
side effects. The hyperlocomotion, decreased anxiety and memory deficit during the 
conditioned taste aversion task observed in the J20 mice were not prevented by neprilysin 
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overexpression suggesting that either the beneficial effects of neprilysin was limited or APP 
and its other proteolytic fragments which were not modified by neprilysin overexpression are 
responsible for these behavioral alterations.  However, neprilysin overexpression prevented 
the memory impairment observed in J20 mice during the Morris water maze task, strongly 
supporting Aβ as the culprit responsible for this cognitive impairment and neprilysin 
upregulation as a valid Aβ-lowering therapeutic approach for AD. 
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ZUSAMMENFASSUNG 
 
Die Alzheimer Demenz (AD) ist ein multifaktorielles Syndrom, welches durch eine 
progressive Atrophie und die Zerstörung von Neuronen charakterisiert ist, was zu kognitiver 
Schwäche, Demenz und schliesslich zum Tod führt. AD Forschung hat sich bisher 
hauptsächlich auf die Generierung und Ablagerung von β-Amyloidpeptiden (Aβ) 
konzentriert, da die abnormal hohe Aβ-Konzentration als primärer Auslöser von AD gilt. Die 
extrazellulären Aβ Ablagerungen (Plaques) im Gehirn begünstigen die Entstehung von 
neurofibrillären Läsionen, die synaptische Fehlfunktion und den Verlust von Neuronen im 
Gehirn der AD Patienten. Mutationen in APP (Amyloid-Precursor Protein), Presenilin (PS) 1- 
und 2– Genen verursachen die familiäre Form der Krankheit durch Generierung von erhöhten 
Mengen von Aβ. Diese Effekte werden durch das Alter verstärkt. Je länger desto mehr wird 
es klar, dass in den meisten Patienten eine abnormale Akkumulation von Aβ im Gehirn durch 
mangelhaften Abbau dieses Peptids verursacht wird. 
 
Arbeiten aus unserem Labor zeigten, dass die Injektion von fibrillärem Aβ1-42 ins Gehirn der 
Mäuse zu einem erhöhten Gehalt des Aβ-abbauenden Enzyms Neprilysin in Neuronen führte, 
was eine signifikante Reduktion der Aβ Mengen und Plaque-Pathologie zur Folge hatte. Die 
Erhöhung des Neprilysins wurde, unter anderem mechanistisch auf eine höhere 
Transkriptionsaktivität zurückgeführt. Deswegen haben wir versucht, mittels Luciferase-
Assay die Aktivierung von Neprilysin Promoteren durch Aβ1-42 in vitro zu untersuchen. Dabei 
konnte keine Aktivierung der Neprilysin-Expression durch Aβ1-42 oder eine Beteiligung der 
diffusionsfähigen Faktoren gezeigt werden. Wir haben aber festgestellt, dass Retinsäure, die 
für neuronale Ausdifferenzierung der Neuroblastomazellen benützt wird, sich aktivierend auf 
alle 3 Neprilysin-Promoteren auswirkt. In weiteren in vivo Experimenten könnten wir höhere 
Neprilysin mRNA and Protein-Konzentrationen nicht miteinander korrelieren. Diese 
Ergebnisse weisen darauf hin, dass eine erhöhte Proteinstabilität in vivo auch zur Erhöhung 
des Neprilysin-Gehalts beigetragen haben könnte. Zusätzlich zeigen wir hier, dass die Aβ 
Injektionen die Aktivierung von Plasmin, eines weiteren Aβ-abbauenden Enzyms, im Gehirn 
bewirken. Die Plasmin-Aktivierung war von einer höheren Aktivität des urokinase 
plasminogen activator (uPA) begleitet. uPA Transkription war jedoch unverändert. uPA 
Aktivität und erhöhter Neprilysin-Gehalt zeigten eine starke Korrelation in vivo. Wir 
untersuchten diesen Zusammenhang in vitro und konnten zeigen, dass Aβ1-42 die Aktivität 
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beider Plasminogenaktivatoren uPA und tissue-type plasminogen activator (tPA) in vitro 
erhöht. Auch neuronale Expression von Neprilysin in transgenen Tieren führte zur 
Aktivitätssteigerung von uPA und tPA in Gehirn. 
 
Neprilysin ist das wichtigste Aβ abbauende Enzym im Gehirn. Unser Ergebnisse zeigen, dass 
Neprilysin defiziente Mäuse eine Akkumulation und Ablagerung des Aβ Peptids im Gehirn 
aufweisen, ohne jedoch das Spaltungsmuster (processing) des APP Moleküls zu verändern. 
Neprilysin-defiziente Mäuse zeigten auch Anzeichen einer Aβ-abhängigen 
Neurodegeneration und kognitive Defizite. Diese Mäuse stellen das erste Modell mit muriner 
Aβ-Pathologie dar und ermöglichen die Untersuchung der Rolle des endogenen Aβ in 
Pathophysiologie von AD. Dies ist besonderes wichtig, weil die bisherigen Modelle auf der 
Überexpression des humanen APP in transgenen Tieren basieren. Eine Trennung der 
toxischen Einwirkungen von Aβ im Vergleich zur Beteiligung anderer APP-Spaltprodukte ist 
deswegen in diesen Modellen nicht eindeutig machbar. Um das therapeutische Potential der 
Neprilysin-Aktivierung gegen Aβ-Pathologie zu testen, haben wir unsere transgene Tiere mit 
einem Mausmodell mit erhöhter Aβ Produktion und Ablagerung (J20) gekreuzt. Wir zeigen 
hier, dass die Doppelmutanten eine massive Reduktion von Aβ im Gehirn aufweisen, 
während sich die Konzentrationen anderer APP-Spaltprodukten nicht ändern. Auch die 
Konzentrationen anderer Neprilysin-Substrate (Substance P, Enkephalin, Somatostatin) waren 
unverändert. Eine marginale Verminderung der Ängstlichkeit kennzeichnete die jungen NEP 
Tiere, die aber mit fortschreitendern Alter verschwand. Abgesehen davon, dass die NEP 
Maüse Schwirigkeiten in einem Angst-Konditionierungstest zeigten, hatte die Überexpression 
von Neprilysin keinen Einfluss auf die Lernfähigkeit und Gedächnisleistung. Dies denkt 
darauf hin, dass bei Neprilysin uberexpression wenig Beeinflussungen der cognitiven 
Leistungen zu erwarten wären. Sowohl die verminderte Lokomotion und Ängstlichkeit als 
auch die Defizite in konditionierter Geschmack-Aversion der J20 Mäuse wurde durch 
Neprilysin Überexpression nicht behoben. Eine mögliche Erklärung dafür könnte eine 
ungenügende Neprilysin-Konzentration sein, um diese Effekte rückgängig zu machen. 
Alternativ ist es möglich, dass APP und seine anderen Spaltprodukte, deren Gehalt nicht 
durch Neprilysin reduziert wird, für die oben beschriebenen Effekte verantwortlich sind. Im 
Gegenteil, die Überexpression von Neprilysin verhinderte die Beeinträchtigung der 
kognitiven Gedächtnisleistung der J20 Tiere, so dass sie von den Wildtyp Tieren nicht 
unterscheidbar waren. 
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Unsere Daten belegen in einem in vivo system, dass Aβ eine eigentlich toxische Spezies in 
der AD Pathophysiologie ist, welche die kognitiven Defizite verursacht. Weil Neprilysin-
Aktivierung die Prozessierung des APP Moleküls nicht verändert, stellen wir die Hypothese 
auf, dass eine Hochregulation des Neprilysins die physiologischen Funktionen des APP nicht 
verändert. Wir schlagen deswegen eine neuronale Aktivierung des Neprilysins als eine 
wirkungsvolle Möglichkeit zur Aβ-Reduktion und AD-Therapie vor. 
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I) INTRODUCTION 
 
1) Alzheimer’s disease (AD)  
 
1.1 A major health problem 
 
AD is responsible for up to 70% of all dementia cases and represents up to 85% of moderate 
or severe cognitive impairments among older people [1, 2]. The age of onset can occur as 
young as 40 years in the cases of early onset or familial AD (FAD) caused by genetic 
mutations [3] and starts around 65 years for the sporadic or late onset AD cases, which 
account for more than 95% of all cases [4]. According to the World Health Organization, the 
National Institute of Ageing, the Alzheimer’s Association and epidemiological studies [1, 2], 
AD affects 1.5% of the elderly from 65 to 69 years of age and doubles every 5 years reaching 
24% of the elderly aged 85 or more in the general western population and up to 50% in USA. 
Furthermore, with the increase of life expectancy in the developing countries, the number of 
people with AD, which represents 18 million nowdays, is expected to double by 2025. 
Following initial diagnosis, AD patients live an average of 8 years and survive half as long as 
those without dementia, making AD the 3rd cause of disease related death in the US with 
7.1% of all death in 1995 [5]. The direct annual cost of care for a patient is $30,000 in the 
USA. AD not only affects patients but also presents a heavy physical and psychological 
burden to their relatives who take care of them for most of the time while observing the 
constant, irreversible aggravation of symptoms, until hospitalization becomes inevitable. 
 
1.2 Clinical symptoms and diagnosis 
 
AD is a neurodegenerative disease with a long asymptomatic phase. It is characterized by a 
progressive loss of memory and starts with occasional episodic memory deficits, referred to 
mild cognitive impairment, including difficulties as recalling recent events of daily life [6]. 
With progression of the disease, the patients encounter difficulties in identifying common 
objects and familiar persons (agnosia), present a decline in physical coordination (apraxia), 
impairment of language functions (aphasia) and eventually lose their complete reasoning 
ability, including time and space orientation. AD patients also show dramatic personality 
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changes such as anxiety, aggressiveness, depression or hallucinations [7]. Over several years 
patients presenting a global cognitive deficit, are bedridden, completely dependent on 
caretakers and die of minor respiratory difficulties such as aspiration or pneumonia  [8]. 
A well trained clinician can nowdays diagnose an AD patient with 90% accuracy. This is 
mostly due to standardized diagnosis criteria for dementia based on the Diagnostic and 
Statistical Manual of Mental Disorders, possible and probable AD based on the criteria of the 
National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s 
Disease and related Disorders Association [9, 10]. The clinical diagnosis of AD includes 
memory deficit and at least one of the major impairments previously presented (agnosia, 
apraxia, aphasia or reasoning). It is currently based on the patient’s history, interviews with 
relatives after exclusion of other dementia diseases such as vascular dementia, frontotemporal 
dementia, dementia with Lewy bodies and Parkinson’s disease. Cognitive tests like the Mini-
Mental State exam or the Blessed Dementia Scale are also extensively used to monitor the 
development of the patient's cognitive abilities and to distinguish it from normal age-related 
decline. However, in spite of promising improvement in the in vivo detection techniques of 
one of the histopathological hallmarks of AD, known as amyloid plaques [11, 12] and the 
increased number of markers [13], the diagnosis of AD still leave an error rate of 10% in the 
best conditions. The certain diagnosis of AD can definitively be made by autopsy and the 
presence of the two molecular hallmarks of AD: extracellular amyloid plaques and 
intracellular neurofibrillary tangles (NFT). 
 
1.3 Histopathology  
 
Since their first description in 1907 by Alois Alzheimer, brain atrophy, extracellular amyloid 
plaques and intracellular NFT are still used today as the defining features for the AD.  
 
1.3.1 Neurodegeneration 
Not all brain areas are equally affected by AD pathology and the early clinical symptoms are 
due to loss of synaptic function and neuronal degeneration in brain regions responsible for 
learning and memory [14, 15]. This destructive process is characterized by a typical 
distribution pattern of brain changes that is specific with respect to area [16], lamina and even 
cell type [17]. The first area of the brain touched by this atrophy is the medial temporal lobe 
including hippocampus [15, 17] and the entorhinal cortex [14] . Compromised functions of 
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these areas correlate well with the early symptoms of the disease [16]. Then, the most 
vulnerable cells are the pyramidal cells in  lamina II and III and V of the neocortex [18], 
while interneurons seem to be spared [19]. The limbic system including the amygdaloid 
complex is also affected [20] while the striatum and cerebellum may show some degree of 
plaque formation but do not develop significant neuronal pathology [21]. This atrophy is 
accompanied by a marked gliosis and clear neuronal dysfunction with neurotransmitter 
deficits such as the cholinergic neurons in the septum and basal forebrain [22] and several 
other regions [23, 24]. 
 
1.3.2 Neurofibrillary tangles  
NFT are intracellular aggregates of the hyperphosphorylated microtubule-associated protein 
tau found in neurons (Fig. 1B). Tau binds to tubulin monomers and stabilize them [25] during 
polymerization of tubulin monomers into microtubules. Its activity is mostly controlled by 
phosphorylation involving multiples phosphatases and kinases [26, 27]. In pathological 
conditions, abnormal phosphorylation or hyperphosphorylation of tau disturbs its binding 
ability to microtubules and tau subsequently precipitates in the somatodentritic compartment. 
Destabilization of the microtubule and obstruction of the axonal transport lead to synaptic 
dysfunction, impaired energetic metabolism [28], and may contribute to the neuronal death 
[29, 30]. Following the complete degeneration of the affected neurons, the highly insoluble 
NFT remain in the brain. NFT are also present in other neurodegenerative diseases such as  
frontotemporal dementia, Pick's disease, progressive supranuclear palsy or corticobasal 
degeneration [26, 31]. 
 
1.3.3 Neuritic Plaques 
Neuritic plaques, also called senile plaques, are extracellular deposits of amyloid-β protein 
(Aβ) fibrils (Fig. 1B) intimately surrounded by dystrophic axons and dendrites, activated 
microglia and reactive astrocytes, generally found in the limbic and association cortices [32]. 
The core is predominantly composed of the fibrillary 40-42 amino acid long β-amyloid 
peptides [33] and the longer form, more hydrophobic and therefore more prone to 
aggregation, is the major species present in the core [34, 35]. The microglia are usually 
adjacent to the central amyloid core and the astrocytes located at the peripheria of the plaque. 
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The neuritic plaques are usually accompanied by so called diffused plaques which appear 
prior to them. They are exclusively formed by the aggregation of the most hydrophobic Aβ 
petide, Aβ42 [34, 35] and still lack the associated neuritic and glial cytopathology [36]. They 
also occur in cognitively normal, elderly healthy individuals [37] and so, are believed to be a 
presymptomatic feature of AD [38]. 
The extracellular plaque pathology and the intraneuronal formation of NFT evolve 
independently and their distribution pattern differs during the disease progression [39, 40]. 
The relationship between the β-amyloid plaques and NFT pathologies in AD is not yet clearly 
understood. However, using transgenic mouse models, it was shown that the amyloid 
pathology and more particularly Aβ42 increases NFT formation in vivo [41-43]. 
 
 
Figure 1. Major histopathological hallmarks of AD. (A) Representation of extracellular amyloid plaques 
formed by β-amyloid aggregation and (B) intracellular neurofibrillary tangles formed by hyperphosphorylated 
tau protein. 
 
1.4 Amyloid precursor protein (APP) and function of its proteolytic fragments 
 
1.4.1 APP and its putative functions 
APP is a type I transmembrane protein, with a long extracellular N-terminal fragment, a 
single transmembrane region and a short intracellular tail [44]. APP presents a high degree of 
evolutionary conservation [45, 46], is ubiquitously expressed in widespread tissue and cell 
types including neurons [45, 47] and play an important role in the central nervous system 
(CNS) (reviewed in [48]). In the adult brain, APP shows widespread expression in the 
synaptic compartment and in vesicular structures of the cell body, axon and dendrites [49]. 
Different APP isoforms are derived from a single gene by alternative splicing [50], the most 
A B
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common being APP695, AP751 and APP770 [45, 50]. The extracellular part of APP presents 
multiple binding domains for copper [51], zinc [52], heparin [53], collagen [54] and lamilin 
[55]. APP 751 and 770 also contain a Kunitz type protease inhibitor domain (KPI) which may 
regulate coagulation factor in the peripheria [56] whereas APP 695, the major isoform found 
in the brain, lacks the KPI domain [57]. APP can also be  N- and O- glycosylated, 
phosphorylated and sulfated [58, 59]. Two APP gene homologues have also been identified, 
amyloid precursor like proteins (APLP) 1 and 2 which lack the Aβ region [60]. While APLP2 
knockout (KO) mice appear healthy [61], deletion of the APP gene induces decreased 
locomotion [62], a strong decrease of synaptic protein such as synaptophysin or synapsin, and 
present a long term potentiation (LTP) impairment associated with memory impairment [61, 
63, 64]. Finally, double KO mice for APP and APLP2 are lethal [61, 65] and present reduced 
synaptic vesicle density and size of the active zone [66]. These data suggest a functional 
redundancy between APLP2 and APP [61], and an important role for APP in neuronal 
development, viability and cognitive functions. Indeed, APP is involved in multiple functions, 
including learning and memory (reviewed in [67]). Disruption or decrease of synaptophysin 
immunoreactivity, impaired synaptic plasticity with decreased LTP and deficits in cognitive 
functions were also found in mice expressing wild type APP [68] and mutated APP [69, 70]. 
APP structurally looks like a potential receptor [44] and is targeted to the plasma membrane 
[44]. APP has been implicated in signal transduction involved in neuronal migration and 
positioning [71], cell proliferation, neuroprotection and neurite outgrowth [72-74]. APP was 
also found in one study to bind to kinesin-1 and to be involved in fast anterograde axonal 
transport of vesicles [75] but this function was recently challenged by Lazarov et al.[76].  
 
1.4.2 APP processing  
APP undergoes endoproteolytic cleavage by three secretases named α, β and γ-secretases. 
APP is initially cleaved by α or β-secretases leading to the non-amyloidogenic and 
amyloidogenic pathways, respectively (Fig. 2).  
Most APP molecules undergo non-amyloidogenic processing [77]. α-secretase cleaves APP 
between amino acids 687 and 688 of the full length isoform 770 APP, 12 amino acids from 
the plasma membrane, which correspond to amino acids 16-17 of Aβ, precluding Aβ 
formation. It induces the release of the large soluble ectodomain of APP (sAPPα) into the 
extracellular space and produces an 83 amino acid C-terminal fragment (CTFα) which 
remains in the membrane [77, 78]. The amyloidogenic pathway involves the cleavage of APP 
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by β-secretase between amino acids 671 and 672, generating a slightly smaller extracellular 
fragment (sAPPβ) and the membrane bound fragment C99 (CTFβ), starting at amino acid 1 of 
Aβ. TACE (TNFα converting enzyme, also called ADAM 17) and ADAM (a disintegrin and 
metalloprotease) 9 and 10 are the major membrane-bound proteases found with α-secretase 
activity [79-81], but ADAM 10 is believed to be the major one involved in the processing of 
APP in the brain due to a better overlapping expression [79]. BACE1 (β-site APP cleavage 
enzyme, also known as Asp2 or memapsin2) and BACE2 have β-secretase activity [82, 83] 
but evidence that BACE1 was the major β-secretase in brain was confirmed by KO approach 
[84]. 
The membrane bound fragments C83 and C99 resulting from α and β-secretase cleavage 
respectively, can then be further cleaved within the transmembrane region at residue 711 or 
713 of the 770 amino acids’ isoform of APP by the γ-secretase complex releasing the non- 
amyloidogenic p3 fragment [85] from the C83 fragment or Aβ1-40 and Aβ1-42 from the C99 
fragment and the APP intracellular domain a cytosolic C-terminal fragment of 57 or 59 amino 
acids (CTFγ). 
The γ-secretase is a multiple protein complex containing presenilin 1 or 2 (PSEN1, 2) as 
catalytic subunits and different factors such as nicastrin, APH1 and PEN2 [86-88]. However, 
in spite of being the major enzymes containing the catalytic subunit of the complex, other 
proteins may also be involved [89]. 
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Figure 2. Proteolytic processing of APP. APP can be cleaved by α-secretase in the Aβ domain to producing 
soluble APPα (sAPPα) and a membrane bound C-terminal fragment (CTFα). Alternatively, APP can also be 
cleaved by β-secretase producing sAPPβ and CTFβ. Both CTF are further processed by the γ-secretase complex 
leading to intracellular release of CTFγ and extracellular release of either p3 or Aβ fragment. 
 
1.4.3 Roles of secreted APP in neuronal function 
Two forms of secreted APP fragments are produced during the cleavage of APP: sAPPα and 
sAPPβ (Fig. 2), with sAPPα being the major form produced. sAPP are present in brain tissues 
and circulate in the cerebrospinal fluid (CSF) [90]. Neuronal activity (induced by excitatory 
neurotransmitters and membrane depolarization) leads to sAPPα release from cultured neural 
cells [91], hippocampal slices [92] and hippocampal cells in vivo [93], suggesting roles for 
sAPPα in activity-dependent processes. In fact, both sAPP share similar domains which 
exerts neurotrophic and neuroprotective effects in vitro, such as neurite outgrowth [94, 95] 
and increase synaptic density [96]. However, sAPPα protected neurons with a 100 fold 
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greater potency than sAPPβ against death induced by glucose deprivation, excess glutamate 
and Aβ toxicity in vitro [74, 97, 98]. The C-terminal 666-686 region of sAPPα, based on the 
sequence of the 770 amino acids isoform of APP, contains a heparin binding site that is 
lacking in sAPPβ and is responsible for the neuroprotective effect of sAPPα via binding to 
receptors, activation of K+ channels leading to hyperpolarization of the cells and decreased 
calcium release [97]. Intracerebroventricular (ICV) injection of sAPPα also protected neurons 
from ischemic injury in vivo [99]. On the contrary, mice expressing APP with mutations 
which preclude the formation of sAPPα displayed severe neuronal degeneration and 
premature death suggesting that absence of sAPPα is deleterious to the neurons [100]. 
These growth-promoting properties, together with its structural similarities with cysteine-rich 
growth factors [101], suggest that sAPP may function as a growth factor in vivo. Interestingly, 
infusion of sAPP into the brain increases synaptic density and improves memory retention 
[96, 102], its level in the CSF also correlates with performances on memory tasks [103] and 
the level of sAPP is significantly decreased in the CSF of AD patients [104, 105]. The 
receptor for sAPP is still unknown but sAPPα was shown to selectively suppress N-methyl-
D-aspartate (NMDA) receptor current without affecting currents induced by α-amino-3-
hydroxy-5-methylisoxazole-4-propionate (AMPA) or kainate receptors in hippocampal 
neurons [106] and it is able to modify the properties required for LTD and LTP on 
hippocampal slices [107], suggesting that sAPPα contributes to various physiological and 
pathophysiological processes in which NMDA receptors participate. 
 
1.4.4 Roles of amyloid-β in neuronal function  
Aβ is a soluble metabolite endogenously produced [47, 108] which has received a lot of 
attention as a key player in AD. The two major forms are Aβ1-40 and Aβ1-42. Although Aβ1-42 
only accounts for 10% of total Aβ, its increased hydrophobicity makes it more prone to 
aggregation [109, 110] and seems to be the more pathogenic specie involved in AD [111]. 
The physiological function of Aβ is still unclear. It is proposed to function as a regulator of 
synaptic transmission and plasticity. Indeed, neuronal activity has been shown to modulate 
the formation and secretion of Aβ peptides in hippocampal slice neurons that overexpress 
APP. In turn, Aβ selectively depresses excitatory synaptic transmission via NMDAR onto 
neurons that overexpress APP, as well as nearby neurons that do not [112]. Aβ also impaired 
LTP in the same study [113]. Many studies have confirmed the neurotoxic functions of Aβ on 
various cell types (reviewed in [114]), including primary neuronal [115, 116] and brain slice 
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cultures [117, 118]. The Aβ toxicity involves multiple mechanisms (reviewed in [119]) such 
as microglia activation [120], production of reactive oxygen species [121, 122], increased 
intracellular calcium [123, 124], formation of ion pores [125, 126] and interactions with cell 
surface receptors [113, 127]. 
Aβ can be found in various aggregation states, and exists as monomers, dimers, oligomers, 
while further aggregation yields formation of protofibrils and finally plaques. It is still unclear 
in which state Aβ is the most toxic in vivo. However, transgenic mice showing neuronal 
dysfunctions, including memory deficits, prior to β-amyloid plaque formation [68, 128, 129] 
and the lack of correlation between β-amyloid plaque load and cognitive deficits [37, 130-
132] suggest that the Aβ fibril intermediates rather than amyloid plaques are the major cause 
of neuronal dysfunction and cognitive deficits in vivo. Recently, ICV injection of different 
forms of Aβ strongly suggested that oligomers of Aβ were more potent than monomers to 
block LTP [133] and to induce memory impairment [134]. 
 
1.4.5 Roles of CTFα and CTFβ in neuronal function 
The functions of C83 and C99 fragments, prior to γ-secretase cleavage and release of Aβ or 
p3 and AICD, are unclear due to the impossibility to dissociate the effects of these fragments 
from their cleavage products. However, transgenic models and ICV injections provide 
evidence of their negative effects on neurons and cognitive functions. Overexpression of 
different C-terminal fragments of APP such as C100 or C104 in mice induced the formation 
of Aβ deposits [135], impaired LTP [136], neurodegeneration [137, 138] and cognitive 
impairments in Morris water maze and Y-maze paradigms [137]. 
Interestingly, ICV injection of C105 in mice induced a greater cognitive impairment in 
Morris water maze and Y-maze, cholinergic dysfunction and decrease of mitochondrial 
pyruvate dehydrogenase levels than Aβ1-42 [139], suggesting that γ-secretase inhibitors that 
decrease Aβ formation  but increase CTFs may not be a good therapeutic approach in AD. 
However, it is unknown if these effects are extracellular or involve reinternalization. 
 
1.4.6 Roles of CTFγ in neuronal function 
The CTFγ fragment formed by 59 or 57 amino acids, is released after cleavage by γ-secretase 
and its generation is independent of Aβ formation [140, 141]. This is a very labile fragment 
quickly degraded by the insulin degrading enzyme (IDE) [142, 143] or by the proteasome 
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[144]. However, it has been shown that CTFγ also interact via a YENPTY motif with 
multiple adaptor proteins (reviewed in [145]), which increase its stability, induce its 
translocation into the nucleus and allow transcription regulation by CTFγ [146-150]. C59 but 
not C57 was initially found to repress retinoic acid-responsive gene expression in vitro [148, 
151] suggesting that genes activated by retinoic acid such as APP [152, 153] or BACE [154] 
were negatively controlled by the CTFγ. It was, however, recently found in our lab that 
overexpression of the C50 fragment activated the transcription of APP, BACE, the histone 
acetyltransferases Tip60, the glycogen synthase kinase 3β GSK3β and the tumor metastasis 
suppressor KAI1 in vitro [146]. Complex formation with CTFγ, translocation into the nucleus 
and regulation of gene expression was also confirmed for KAI1 in vivo [150]. CTFγ is 
involved in the regulation of phosphoinositide-mediated calcium signalling in vitro [155] and 
exert neurotoxicity on different cell types including differentiated PC12 cells and rat primary 
cortical neurons by inducing the expression of GSK-3β [156, 157]. 
APP processing, signalling and functions of CTFγ are difficult to apprehend due to potential 
competition between the different adaptor proteins [158] for the binding site of CTFγ, leading 
to either the inhibition of its release by stabilizing or modulating the localization of APP or 
formation of different transcription complexes activating different pools of genes. 
Furthermore, CTFγ also competes with other proteins for the adaptor proteins such as Fe65 or 
Numb. CTFγ was shown to repress transcription mediated by the Notch intracellular domain 
by binding to Numb in vitro [159]. Similarly the low density lipoprotein receptor-related 
protein (LRP) intracellular domain inhibited the CTFγ-related transcription of KAI1 by 
binding to Fe65 in vivo [160]. 
 
1.5 Genetics of AD 
 
The etiology of AD is complex, heterogenous and involves non genetic as well as genetic 
factors. Based on twin studies, the latter were found to represent 50% to 75% of the risk to 
develop AD [161-163] confirmed by the fact that after age, family history is the second 
greatest risk factor for AD [164]. In spite of a similar phenotype, early onset familial AD 
(EOFAD) with onset age younger than 60 years and late onset AD (LOAD) with onset ages 
older than 60 can be distinguished among AD cases. 
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1.5.1 Early onset familial Alzheimer disease  
EOFAD accounts for less than 5% of all AD and is attributed to rare but fully penetrant 
mutations expressed in an autosomal dominant manner [165], in three different genes: APP 
on chromosome 21 [166], PSEN1 on chromosome 14 [167] and PSEN2 on chromosome 1 
[168, 169]. At least 16 mutations in APP, 140 in PSEN1 and 10 in PSEN2 have been 
determined so far (AD mutation database; http://www.molgen.ua.ac.be/ADmutations). 
Mutations in the APP gene are estimated to account for less than 5% of FAD, the most 
frequently mutated gene, PSEN1, accounts for 50% of all EOFAD cases with onset prior to 
age 50 [170, 171]. While these AD-causing mutations occur in 3 different genes, they all 
share a common biochemical pathway: they all affect the proteolytic cleavage of APP leading 
to an increased production of Aβ or a relative overabundance of the Aβ42 compared to the 
Aβ40 species, which eventually results in neuronal cell death and dementia. Interestingly, 
Down syndrome is caused by the triplication of chromosome 21, which includes the genes 
BACE2 and APP. With plaque formation observed in the brain of Down syndrome patients as 
young as 8 years old, all individuals develop sufficient neuropathology for a diagnosis of AD 
by the age of 40 [172]. 
 
1.5.2 Late onset Alzheimer disease 
In contrast with EOFAD, LOAD represents the majority of all AD cases and is due to 
polymorphisms with low penetrance but high prevalence. Due to the major role of genetic 
factors in this form of AD [161, 164], multiple genomic scanning of LOAD patients were 
performed to determine the genes involved [173, 174]. 
Until now, only one genetic risk factor for LOAD was confirmed in multiple studies from 
different ethnic groups and populations [175]: the ε4 allele of the apolipoprotein E (apoE) 
gene on chromosome 19 [176, 177]. ApoE exists in three major isoforms, ε2, ε3 and ε4. The 
ε4 allele is only present in 15% of the population and carrying one or two copies of ε4 is 
neither necessary nor sufficient to cause AD. However, its presence decreases the mean age 
of onset of 16 years [178] in a dose dependant manner [179, 180], a carrier of one copy and 
two copies being  3 and 8 times more likely to be affected than controls [178]. 
ApoE is secreted by glial cells [181, 182] and modulate neuronal plasticity by transporting 
lipids into neurons through specific receptors, LRP being the major one [183]. ApoE ε2 and 
apoE ε3 isoforms were found to induce neurite extension in neurons, whereas apoE ε4 
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inhibited outgrowth [184, 185] via binding to LRP [186]. Similarly apoE ε3 but not ε4 
prevented Aβ-induced neurotoxicity by a similar process [187]. ApoE also binds Aβ [176] 
and play a role in its clearance and deposition. The mechanism by which apoE contributes to 
AD pathology is unclear but carriers of the ApoE ε4 isoform present a greater number of Aβ 
plaques when compared to ApoE ε3 carriers [188]. Similarly, overexpression of human apoE 
ε4 in transgenic mice overexpressing human APP leads to increase Aβ deposition, compared 
to expressing human ApoE ε3 [189]. In vitro studies suggest that apoE ε4 is less efficient than 
apoE ε3 to inhibit Aβ aggregation [190, 191]. 
Among the other potential risks factors, alpha-2 macroglobulin (α-2M) and LRP, on 
chromosome 12 were associated with LOAD [192, 193]. α-2M is a plasma protein, produced 
in the brain where it binds multiple extracellular ligands including proteases and is 
internalized by neurons and astrocytes via the LRP receptor. It also binds Aβ with high 
specificity and prevents its toxicity in neuronal cell culture by internalization via LRP [194, 
195]. In AD patients, α-2M is localized in the neuritic but not the diffuse plaques [196]. LRP 
is a multifunctional scavenger and signaling receptor able to bind many ligands including 
apoE, APP, α-2M, Aβ and plasminogen (reviewed in [197]). LRP, initially found to mediate 
the neuronal uptake of astrocyte-derived cholesterol [198], is also involved in removal of 
protease-protease inhibitor complexes [197]. Increasing evidence also suggest that LRP is 
involved in the clearance of Aβ and mediates its efflux from the brain to the periphery at the 
blood brain barrier (reviewed in [199-202]). The Aβ peptide binds avidly to LRP ligands, 
such as α-2M and apoE, and LRP-mediated clearance of the complex contributes to a 
reduction in Aβ levels [201, 203]. 
Among the other candidates potentially associated with LOAD, insulin degrading enzyme 
[204, 205], neprilysin [206-208] and angiotensin-converting enzyme (ACE) [209, 210] have 
all been directly involved in the degradation of Aβ. However, these associations could not be 
always reproduced [211-213], suggesting that the association is not strong and may vary 
based on the population analyzed. 
 
1.6 Amyloid cascade hypothesis 
 
The amyloid cascade hypothesis was initiated  by Glenner et al. after identification of the 
peptide present in the core of the senile plaques from Down syndrome patients and the 
prediction of an AD gene on chromosome 21 [214]. The hypothesis postulates that the 
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accumulation of Aβ, due to an imbalance between its generation and clearance, initiates the 
pathologic cascade in AD leading to inflammation, neurodegeneration, amyloid plaque and 
NFT. 
The main support for the amyloid hypothesis derives from genetic studies. All mutations 
responsible for EOFAD were found in APP itself and in the presenilins [165]. They all were 
shown in vitro and in vivo to directly alter the production of Aβ in a manner that promotes 
amyloid formation. Most mutations on APP and presenilins selectively increase the 
production of the more toxic [111] and more amyloidogenic Aβ42 peptide [109, 110]. 
Similarly, the only known risk factor for LOAD, apoE ε4, increases Aβ deposition in the 
brain of AD and transgenic mouse models [177, 188, 215] and the other genes implicated, 
such as LRP and α-2M are also involved in Aβ clearance [194, 203]. The major risk factor in 
AD is aging. All EOFAD present an early age of onset and Down syndrome patients with 
three copies of the APP gene, develop sufficient neuropathology for a diagnosis of AD by the 
age of 40 years [172]. 
The second main support of the amyloid cascade hypothesis comes from biochemical and 
neuropathological studies. Many studies have confirmed the neurotoxic functions of Aβ on 
various cell types in vitro and in vivo (cf. 1.4.4). Transgenic mouse models overexpressing 
human AD-causing mutated APP develop with aging the major features of AD: first diffuse 
then fibrillar Aβ plaques, associated with neuronal and microglial damage leading to 
cognitive deficits (reviewed in [216-218]). Furthermore, brains of Down syndrome patients 
and apoE ε4 carriers present increased level of Aβ and amyloid plaques formation prior to 
NFT formation and cognitive deficits [219, 220]. 
Initial arguments against the amyloid hypothesis included the lack of massive neuronal loss  
and NFT formation in transgenic mouse models overexpressing the AD causing mutated 
human APP, exhibiting extensive amyloid deposits [218, 221, 222], the lack of correlation 
between the degree of dementia and the number of plaques in patients [37, 131, 132] and 
transgenic mouse models [68, 128, 130] and the different spatiotemporal distribution of Aβ 
and tau pathologies [39, 40]. In spite of the fact that mouse lifespan may be a limiting factor 
in determining the degree of pathology and mice may not respond to Aβ accumulation the 
way humans do, most of these aspects were recently challenged. The lack of 
neurodegeneration in the transgenic mouse overexpressing mutated APP can also be 
explained by the neuroprotective effects of APP (cf. 1.4.1) and sAPPα (cf. 1.4.3) 
overexpression, which are also present in these mice and temper the neurotoxic properties of 
  
27
Aβ. They were shown in vivo to activate the transcription of genes such as transthyretin and 
the insulin pathways [223], which are involved in the clearance of Aβ and therefore prevent 
the neurotoxicity of Aβ [224, 225]. Finally, mice overexpressing the C-terminal fragment of 
APP lacking the sAPPα domain presented signs of neurodegeneration [137, 138]. 
The second major argument against the amyloid cascade hypothesis concerns the 
pathophysiological relation between amyloid plaques and NFT formation. It has been shown 
using transgenic models that the amyloid pathology and more particularly Aβ1-42 was 
responsible for the increase of NFT formation [41-43]. Crossbreeding of mice overexpressing 
human AD-causing mutated APP and human mutated tau associated with FTDP-17 led to 
high increase of NFT formation [42]. Similarly, stereotaxic injection of Aβ1-42 fibrils into the 
hippocampus of a tau transgenic mouse caused 5 fold increase in the number of NFT in the 
amygdala [41]. Even if the relation between the two major hallmarks of AD is not yet fully 
elucidated, Aβ increases the tau pathology and more specifically the NFT formation.  
Finally, a modified amyloid hypothesis was proposed to better take into account the 
discrepancies between histological lesions and cognitive functions. Indeed, studies on 
transgenic mice showed that neuronal dysfunctions, including memory deficits, appeared 
before β-amyloid plaque formation [68, 128, 129], suggesting Aβ fibril intermediates other 
than amyloid plaques as the major cause of neuronal dysfunction and cognitive abnormalities. 
Different studies suggested that oligomers of Aβ are more toxic than monomers in vitro [226] 
and more potent in inducing neuronal [133, 227, 228] and cognitive dysfunctions [134] in 
vivo. Oligomers or other preaggregates of Aβ, diffusible and invisible to standard procedures 
used to visualize amyloid plaques, may be responsible for the discrepancies observed. 
With more evidence that increased levels of Aβ initiates the pathologic cascade in AD, 
therapeutic approach aiming at decreasing its production or increasing its clearance and 
catabolism are investigated. Among the enzyme involved in Aβ catabolism, neprilysin 
appears as the major rate limiting factor  [229, 230]. 
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2) Neprilysin 
 
2.1 Gene structure and transcription regulation 
 
2.1.1 Gene structure 
In humans, the neprilysin gene (Mme) is located on chromosome 3q25.1-q25.2 within a 
candidate locus associated with LOAD cases [231, 232]. The neprilysin gene spans more than 
80 kb and is composed of 22 coding exons [233], four 5’ untranslated exons and a 3’ 
untranslated region (UTR). The 5' UTR of neprilysin is alternatively spliced, resulting in 5 
separate potential mRNA transcripts (Fig. 3). 
The presence of three human neprilysin cDNAs each containing different untranslated 5’ 
sequences but a common coding sequence was initially reported [233]. Using a human 
placental genomic library, these three mRNA species, called type 1, type 2a and type 2b were 
found to derive from two non-coding exons, exon 1 and 2, the type 2a and 2b mRNA being 
expressed by alternative splicing of exon 2 [234]. A fourth non-coding exon, exon 1b located 
between exon 1 and exon 2 was further identified using a human leukocyte genomic library 
[235]. Finally the existence of a fifth non-coding exon, called exon 3 and located between 
exon 2 and the first coding exon, was demonstrated by RT-PCR of RNA from human kidney 
and lung [236]. 
With 90% identity to the human neprilysin sequence [237], these 5’ sequences are highly 
homologous to rat and rabbit cDNA [238, 239]. For example, mRNAs corresponding to type 
1, 2b and 3 have been observed in rat kidney [236, 240]  
Expression of neprilysin is transcriptionally regulated via 3 distinct regulatory regions located 
upstream to exon 1, 2 and 3 of 1200 bp, 550 bp and 3400 bp, respectively [235, 236, 240]. 
These promoters are characterized by the presence of multiple transcription initiation sites 
and the absence of classic TATA boxes and consensus initiation elements [241]. Promoter 1 
also presents multiple putative binding sites for transcription factors such as Sp1, NF-IL6, 
NF-κB, PU.1 and ets binding motifs. The promoter 2 contains a GC rich regulatory region 
with multiple Sp1 binding sites, a retinoblastoma control element and an inverted CCAAT 
box [235, 241]. 
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Figure 3. Organization of the 5’ region of human 
neprilysin gene. (A) Three distinct promoters (1, 2 and 3) 
regulate the transcription of NEP mRNA. Exons 1 to 3 are 
non-coding while exon 4 represents the first coding exon. 
(B) All five types of NEP mRNAs were generated in human, 
while rat expressed types 1, 2b and 3. 
 
 
2.1.2 Regulation of neprilysin transcription 
Neprilysin gene transcription is regulated in a cell and tissue-specific manner [241] via the 
three different promoters. Type 1, 2b and 3 transcripts represented in rat brain 67, 18, 15% 
and in rat kidney 11, 70, 20%, respectively [240]. In rat brain, in situ hybridization confirmed 
a major neuronal expression of the type 1 transcript in neurons  and type 3 mRNA expression 
in oligodendrocytes [240]. 
Analysis of the promoters confirmed the binding of multiple transcription factors. Using 
bronchial epithelial, lymphoblastic leukemia, lymphoma and non small cell lung cancer cell 
lines, CBF/NF-YA transcription factors isoforms were found to bind on promoter 2 and 
activate neprilysin transcription in a cell specific manner [242]. Using prostate cancer cells, 
two androgen response element (ARE) were found to activate neprilysin transcription: one in 
promoter 2 which preferentially binds androgen receptor and one located in the 3’ UTR 
which binds androgen, glucocorticoid and progesterone receptors [243]. It correlates with the 
enhanced neprilysin expression in vitro by steroid hormone treatment such as progesterone 
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[244] or glucocorticoids [245-247]. Using leukemia cells, a functionally important 
transcription factor binding site was found in the 5’ region of promoter 2 and was shown to be 
bound by Sp1 [248]. The potential Sp1-binding sites are common in promoters lacking a 
TATA box since Sp1 is important for the initiation of transcription from TATA less 
promoters [249] and the protection of CpG islands [250] from methylation [251] (reviewed in 
[252]). Importantly, the methylation of neprilysin promoters was found in human prostate 
cancer in vitro and in vivo leading to inhibition of transcription [253, 254] and the subsequent 
progression of androgen-independent prostate cancer cells [253, 255]. 
Neprilysin mRNA and protein level are also regulated by a variety of cytokines: interleukin-
1β (IL-1β) and tumor necrosis factor-alpha (TNFα) increased neprilysin mRNA and protein 
level in human bronchial epithelial cells [245] while interleukin-1α (IL-1α), TNF-α, 
transforming growth factor (TGF) and interleukin-6 (IL-6) increased neprilysin activity on the 
surface of intact lung fibroblasts [256] via a mechanism involving cAMP signalling  pathway 
[245, 256]. 
Upregulation of neprilysin expression and enzymatic activity were also observed during 
forskolin-induced differentiation of human choriocarcinoma cells [257] via the cAMP 
signalling pathway [258, 259] and phorbol ester-induced differentiation of choriocarcinoma 
cells via the protein kinase C signalling pathway [260]. 
 
2.2 Protein and structure 
 
Neprilysin (EC 3.4.24.11) also known as neutral endopeptidase 24.11, enkephalinase, 
common acute lymphoblastic leukemia antigen (CALLA) and CD10 is a 94 kilodaltons (kd) 
type II integral plasma membrane zinc metalloendopeptidase, classified as a member of the 
M13 family implicated in inactivation of several biologically active peptides. 
Neprilysin consists of a short N-terminal cytoplasmic domain (27 amino acids), a single 
membrane-spanning segment (23 amino acids) and a large extracellular domain (700 amino 
acids) containing the active site [261, 262].  
It presents 6 N-linked glycosylation sites, 3 of which are glycosylated [263], 12 cysteine 
residues, all involved in disulfide bridges [262, 263] necessary for the maintenance of the 
structure and the activity [264]. As a zinc metalloprotease, the catalytic site consists of the 
canonical HExxH zinc binding motif as well as a conserved consensus sequence ExxA/GD in 
which the glutamate serves as the third zinc ligand. 
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Its crystal structure complexed with inhibitors was determined and confirmed the functional 
motifs involved in catalytic activity and stability [263, 265]. Neprilysin is also a highly 
conserved protein among the mammalian species. Murine, rat and rabbit neprilysin amino 
acids sequences present more than 90% identity to the human neprilysin sequence, 95% when 
compared one at a time, and 100% conservation of critical amino acids and functional motifs 
[237]. 
Neprilysin belongs to the M13 subfamily of mammalian neutral endopeptidase, which 
includes other zinc dependant endopeptidases such as endothelin-converting enzymes ECE-1 
[266, 267], ECE-2 [268], the erythrocyte surface antigen KELL [269], the phosphate 
regulating gene on the X chromosome PEX, the damage induced neuronal endopeptidase 
DINE [270] also called X-converting enzyme [271] and NEP2 [272] also called soluble 
secreted endopeptidase (SEP) [273] or neprilysin like peptidase (NEPL1) [274]. The overall 
homology between neprilysin and these other members is 35, 30, 31, 25, 48 and 65%, 
respectively. The homology increases when only the 250 C-terminal residues containing the 
important amino acids necessary for neprilysin activity are taken into account [263, 271, 
272]. They all present specific pattern of expression and degrades substrates with different 
affinity [275, 276]. 
 
2.3 Localization 
 
Originally discovered in the brush border membrane of rabbit kidney [277], neprilysin is 
widely distributed in mammalian tissues including the CNS [278, 279], male genital tract 
[280], epithelia of intestine and lung [281, 282], fibroblasts [281] and neutrophils [283]. 
Neprilysin is also present on leukemic cells of pre-B phenotype, which represent 85% of all 
human acute lymphocytic leukemia (ALL) and therefore is an important cell surface marker 
in the diagnosis of ALL [284, 285]. 
Neprilysin is broadly expressed in the brain [286, 287] and neprilysin immunoreactivity was 
found in the striatum, substantia nigra, choroids plexus and at a lower level in areas including 
the hippocampus, neocortex, colliculi, amygdala and central gray matter [288-290]. 
Localization of neprilysin is mainly neuronal [278, 289, 290] but can also be found in glial 
cells [240, 290]. It presents a synaptic and axonal localization in hippocampal and neocortical 
neurons with preference for GABAergic and mGluR2/3-positive neurons [288]. 
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2.4 Substrates 
 
Neprilysin preferentially hydrolyzes peptide bonds involving the amino group of hydrophobic 
residues [277] and cleaves on the N-terminal side of hydrophobic amino acid residues [236]. 
Thereby, neprilysin is able to cleave a broad range of proteins but preferentially degrades 
small peptides due to its conformation which restricts access to the active site, therefore, 
limiting the size of the substrate that can enter and be cleaved [263]. 
Purified neprilysin was shown to degrade a wide rage of bioactive peptides in tubo [291, 292] 
including substance P (SP) [293], enkephalins [279, 294, 295], atrial natriuretic peptides 
[296], bombesin-like peptides [297], neurotensin, luliberin and cholecystokinin [294], 
endothelin [298], angiotensins [299], somatostatin [300-302] and more recently β-amyloid 
[229, 303].  
The number of peptides supposed to be cleaved was, however, smaller than originally 
anticipated in vivo [292] and the physiological function of neprilysin is mostly determined by 
its cellular localization, the availability of the substrates and of other potential enzymes to 
competing for the same substrates. 
For example, a detailed immunohistochemical mapping of neprilysin in CNS, in comparison 
with SP and enkephalins, two alleged neuropeptide substrates, has brought to light several 
discrepancies [278, 290]. This illustrates the importance of colocalization between the 
enzyme and its substrate and suggests that other peptidases, such as ACE [304], ECE-1 [286, 
305] or NEP2 [272, 306] probably remain to be characterized as candidates in the metabolism 
of SP and enkephalins in the CNS. 
 
2.5 Investigation of neprilysin functions 
 
Three different approaches have been used to investigate neprilysin functions. The most 
popular is the inhibition of neprilysin activity with specific inhibitors such as 
phosphoramidon [307, 308] and thiorphan [309]. Such inhibitors allow the analysis of the 
function of the endogenous neprilysin at a specific time in a specific system. They also 
represent potential therapeutic tools in conditions where neprilysin inhibition is researched, 
such as cardiovascular regulation [310, 311], and allow the investigation of potential side 
effects.  
The two other approaches involve overexpression and genetic deletion of neprilysin. The 
overexpression of neprilysin is a specific tool to determine neprilysin functions including the 
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degradation of specific substrates in vitro and in vivo. However, it does not reproduce the 
specific localization of the endogenous protein nor does it take into account the competition 
with other enzymes for the same substrate. For example, in spite of neprilysin function, ACE 
was shown to be the major bradykinin degrading enzyme in cardiac membranes [312] and 
cathepsin G, the major inactivator of SP in human neutrophils [313]. 
The targeted deletion of the neprilysin gene (NEP KO or NEP-/-) in mice [314] offers the 
opportunity to study the effects of a complete and long-term elimination of endogenous 
neprilysin activity and its effect on substrate levels in vivo. The only weakness of this model 
is the adaptation of the system and presence of potential biochemical compensatory strategies.  
 
2.5.1 The use of inhibitors and their specificity 
Neprilysin inhibition was shown to potentiate the SP-mediated neurogenic inflammation in 
the lung [315], natriuretic factor mediated natriuresis and diuresis in kidney [316], regulation 
of cellular proliferation in the lung [297] and prostate cancer [255], enkephalin-mediated 
analgesia [309] and accumulation of Aβ in the CNS [317]. 
However, with the discovery of new metalloproteases and the better understanding of the 
systems involved, the specificity of these inhibitors and their action appear questionable. 
Initially used to confirm the degradation of substrates by neprilysin in vitro, neprilysin 
inhibitors are usually used at final micromolar concentrations. With a constant of inhibition 
(IC50) of approximatively 2 nM for neprilysin [318, 319] and 295 nM for angiotensin-
converting enzyme (ACE) [318], thiorphan at the micromolar concentration most likely 
inhibited also the widely distributed ACE in several published studies [304]. ACE is known 
to degrade a wide range of substrate such as bradykinin, SP, enkephalin and angiotensin I 
[320] and is mainly involved in the cardiovascular system and blood pressure by conversion 
of angiotensin I into the vasoconstrictor angiotensin II and inactivation of the vasodilator 
bradykinin [321]. Furthermore, phosphoramidon also inhibits ECE-1, with an IC50 of 1.5 µM 
compared to 34nM for neprilysin [322, 323]. ECE is another widespread member of the M13 
family including endothelial cells [324], smooth muscles [325] and neurons in the brain [286, 
305, 326] involved in the degradation of a broad range of substrate including, angiotensin I, 
SP, neurotensin, bradykinin but is mostly known for its cleavage of big endothelin into the 
potent vasoconstrictor endothelin-1 (reviewed in [275, 327]) and its role in the regulation of 
the cardiovascular homeostasis [328]. Similarly, a new endothelin-1 inactivating 
metalloendopeptidase, mainly localized in the kidney where it mostly degrades the potent 
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vasoconstrictor endothelin-1 [329], was inhibited by thiorphan and phosphoramidon with an 
IC50 of 0.28 nM and 0.55 nM, respectively [329, 330]. 10 µM of phosphoramidon or 
thiorphan similarly inhibited totally neprilysin and DINE [331], a neuron-specific 
endopeptidase whose expression is highly increased in response to axonal injury in both the 
CNS and peripheral nervous system [270, 271]. 
Another member of the M13 family presents a high degree of functional homology with 
neprilysin: NEP2 [272]. Its two most abundant isoforms lead to the formation of either a 
membrane-bound or secreted protein, which are mainly present in the brain and the testis, 
respectively [272]. Due to a 97% homology in the active site, recombinant NEP2 isoforms 
were shown to cleave the same substrates as neprilysin with similar cleavage site, similar 
specificity constants and inhibitory patterns [306], suggesting that NEP2 may, in fact, possess 
some functions previously attributed to neprilysin in the brain. However, they display a rather 
distinct expression pattern in the brain, suggesting specific functions for each one due to 
substrates availability and region specificity [286]. 
Homologues of neprilysin have also been identified in simpler organisms, including 
prokaryotes [332, 333] and more than 20 neprilysin-like proteins are present in 
Caenorhabditis elegans and Drosophilia melanogaster [275, 334]. It confirms the important 
role of these endopeptidases through evolution and suggests that more mammalian 
homologues of neprilysin could be characterized. 
 
2.5.2 Neprilysin and enkephalin mediated analgesia 
Inhibition of brain enkephalin degradation by ICV injection of neprilysin inhibitors resulted 
in analgesia in various nociceptive tests [307, 335, 336] reversible by opioid receptor 
inhibitors [337]. These inhibitors enhanced the recovery of enkephalins whose release from 
rat striatal slices was evoked by potassium [338]. Furthermore, thiorphan protected 
exogenous enkephalins from degradation in rat brain slices [339], in mouse brain in vivo 
[340] and was associated with an elevation of extracellular enkephalin levels in the CNS 
[309] or in the peripheria [341]. 
However, the antinociceptive effects of thiorphan was not always inhibited by an opioid 
receptor antagonist and did not always correlate with an enkephalin increase [342], 
suggesting that thiorphan may also induce analgesia in an enkephalin independent manner.  
This idea was further suggested by the use of isomers of thiorphan, which were equipotent as 
neprilysin inhibitors (IC50 = 1 nM) but had significantly different analgesic profiles when 
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injected ICV [336]. Furthermore, other analogs of thiorphan, less potent inhibitors of 
neprilysin (IC50 = 0.1µM and IC50 = 100 µM), produced analgesia and potentiated analgesia 
induced by an enkephalin analog at doses comparable to thiorphan [336]. Similarly, different 
analogs of a neprilysin inhibitor injected ICV produced analgesia with or without alteration of 
endogenous enkephalin level in the striatum [343]. These studies suggest that thiorphan 
produce analgesia through a pharmacological mechanism which is not directly related to 
inhibition of neprilysin and/or enkephalin degradation. 
Genetic elimination of Mme also resulted in controversial results. Saria et al. found that 
inactivation of the Mme gene in mice, induced analgesia characterized by an increase in the 
thermonociceptive threshold in the hot plate paradigm [344]. Although neprilysin, previously 
termed enkephalinase, is a potent enkephalin-degrading enzyme in a test tube paradigm, the 
phenotype was not associated with modification of enkephalins levels in the cortex, brain 
stem or striatum. More surprisingly, a reduced enkephalin content in hypothalamus and spinal 
cord of NEP KO mice further suggests potential biochemical compensatory strategies [344]. 
Fisher et al., to the contrary, could not reproduce in NEP KO mice the opioid-mediated 
analgesia observed after pharmaceutical neprilysin inhibition and neprilysin deletion led to 
hyperalgesia in a model of visceral pain associated with an accumulation of the hyperalgesic 
peptide bradykinin [345]. Furthermore, quantification of striatal proenkephalin-mRNA levels 
in NEP KO compared with WT mice did not show any difference [345]. Only a 21% 
reduction of mu receptor density in crude brain homogenates of NEP KO mice was observed, 
while delta- and kappa-opioid receptor densities were unchanged [345]. 
These data suggest that enkephalins levels are not increased in the brain of neprilysin 
deficient mice and that neprilysin inhibitors-mediated analgesia may involve other substrates. 
 
2.5.3 Anti-inflammatory function of neprilysin  
Neurogenic inflammation is regulated by sensory nerves and characterized by extravasation 
of plasma proteins and infiltration of neutrophils from post-capillary venules and arteriolar 
vasodilatation. It is well established that SP and bradykinin can interacts with the neurokinin 
1 receptor (NK1R) and the bradykinin receptors respectively to initiate neurogenic 
inflammation. While bradykinin most likely sensitizes nerves to further inflammatory stimuli, 
SP is the major bioactive mediator of neurogenetic inflammation [346-349]. 
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Administration of neprilysin inhibitors potentiates neurogenic inflammation in the airway by 
preventing the degradation of SP [315] and overexpression of neprilysin accelerated the 
degradation of SP by intact epithelial cells and by membrane preparations [350]. 
Neprilysin deletion in mice markedly increased the basal level of SP in the colon (2.5 fold) 
[351] and diminished degradation of SP and bradykinin by the intestine membrane [352], 
suggesting increased bioavailability of substance neurogenic substrates. This is accompanied 
by an increased protein extravasation in the colon [351] and the intestine [352] without 
evidence of overt inflammation at the tissue level [351]. Similarly, NEP KO mice also 
presented widespread basal plasma extravasation in postcapillary venular endothelia [353]. 
The anti inflammatory function of neprilysin was further investigated in a different model of 
inflammation. Neprilysin deletion exacerbated induced intestinal inflammation [352, 354] and 
increased the severity of induced-colitis [351], increased infiltration of inflammatory 
leukocytes and skin inflammation in a model of allergic contact dermatitis [355]. All these 
effects were prevented or reversed by exogenous recombinant neprilysin and antagonists of 
SP (NK1) and bradykinin (B2) receptors, [351-355]. Similarly, delivery of recombinant 
neprilysin reduced the tackykinins related neurogenic inflammatory response in the 
respiratory tract [356-358] leading to inhibition of cough induced by exposure to SP [359] 
and prevented the SP-induced plasma extravasation in the skin [360]. 
Taken together, these studies confirm the major role of neprilysin in inflammation regulation 
in different organs. 
 
2.5.4 Neprilysin and cancer proliferation 
 
Lung cancer 
Lung cancer is the most common form of cancer in the world, both in terms of incidence 
(1.35 million new cases or 12.4% of all new cancers detected for the year 2002) and mortality 
(1.18 million deaths or 17.6% of all cancer-related deaths for the year 2002) [361, 362] with 
smoking as the leading cause for 86% of men and 49% of women worldwide [362]. Tobacco 
smoke was shown to decrease the level of neprilysin at the bronchial cell surface [363] and 
increase the levels of bombesin-like peptides (BLP) in the respiratory tract of smokers [364].  
BLP are potently mitogenic in normal bronchial epithelial [365] and fibroblasts cells [366] 
and stimulate the growth of many small cell carcinomas (sCCa) from the lung [367]. Their 
importance in lung cancer proliferation was further confirmed with the inhibition of sCCa 
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colony formation and tumorigenesis in nude mice after anti-BLP antibody treatment [367]. 
Neprilysin is highly expressed in the different cell types of the lung [281]. It was shown to act 
as a tumor repressor and prevent the proliferation of sCCa cells by degrading BLP in vitro 
[297, 368]. Furthermore, recombinant neprilysin prevented the growth of lung cancer cells in 
vivo in athymic nude mice by inactivating the peptides involved in lung cancer signal 
transduction [368].  
 
Prostate cancer 
Similarly, neprilysin is expressed in prostatic epithelial cells and was shown to prevent 
prostate cancer proliferation by degrading the mitogen bombesin and endothelin-1 peptides 
[369, 370]. Loss of neprilysin is a frequent and early event in human prostate cancer (PC) 
[254, 371] and its downregulation in metastatic human PC contributes to the development of 
androgen-independent PC cells [255] by allowing them to use mitogenic peptides such as 
bombesin and endothelin-1 as an alternate source to androgen in order to stimulate cell 
proliferation [255, 369, 372]. In PC, two types of cells can be distinguished: the androgen 
sensitive PC cells present a high level of neprilysin, low level of phosphorylated focal 
adhesion kinase (FAK) and a slow cell migration rate, and the androgen independent PC 
cells, which present a low level of neprilysin, high level of phosphorylated FAK and a high 
cell migration rate [255, 373]. Overexpression of neprilysin in androgen independent PC cells 
prevented their growth and tumorigenicity in vitro and in vivo [373-375]. Two mechanisms 
were involved in vitro: neprilysin cleaved and inactivated bombesin and endothelin-1, 
preventing their activation of the Src kinase and subsequent phosphorylation of FAK [373]. 
Independently of its enzymatic activity, neprilysin also interacted via the lyn kinase with the 
p85 subunit of PI3K preventing the phosphorylation of FAK and the subsequent cell 
migration in androgen independent PC cells [373]. Neprilysin, therefore, may provide a novel 
approach to the treatment of PC. 
 
Ovarian and breast cancer 
Other studies have shown that neprilysin is also involved in neoplastic transformation and 
tumor progression in other human malignancies, including ovarian and breast carcinomas, by 
inactivating ET-1 or bombesin [376, 377], which are autocrine growth factors for these tumors 
[378, 379]. While neprilysin expression is decreased and endothelin-1 level increased in 
ovarian carcinoma as the grade of the tumor avances [380, 381], overexpression of neprilysin 
suppressed the progression of ovarian carcinoma in vitro and in vivo [376]. The role of 
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neprilysin in breast cancer is less clear since its effect on cancer progression was only shown 
in vitro using inhibitors [377]. Interestingly, the level of neprilysin correlated with the degree 
of malignancy [382, 383], suggesting that neprilysin may be a useful adjunct in assessing 
malignancy in mammary fibroepithelial lesions, but also that neprilysin overexpression may 
not be efficient in all types of cancer. 
 
2.6 Neprilysin and AD 
 
2.6.1 Neprilysin degrades Aβ 
Most of AD research has focused on the mechanism by which APP is processed to form Aβ 
but the steady state concentrations of this actively processed peptide [384] is determined by 
the dynamic balance between its production and its clearance. In contrast to the FAD cases 
and mouse models of Aβ amyloidosis where the anabolism of Aβ is genetically increased, the 
accumulation of Aβ in sporadic AD cases may also be due to a reduced catabolism of Aβ 
[385]. In the last few years, a variety of Aβ degrading enzymes have been proposed (reviewed 
in [386]) with neprilysin being the most potent Aβ degrading enzyme identified and the major 
rate-limiting factor in Aβ degradation in vivo (reviewed in [230], [229, 317, 387]). Neprilysin 
was initially shown to degrade Aβ but not APP in vitro [303]. Neprilysin can cleave Aβ1-40 in 
vitro and in vivo at 5 different positions (Fig. 4): Glu3-Phe4, Gly9-Tyr10, Phe19-Phe20, Ala30-
Ile31 and Gly33-Leu34 [303] with the initial cleavage being Gly9-Tyr10 [317, 331], and is also 
able to degrade monomers and oligomers of Aβ40 and Aβ42 in vitro [331, 388].  
 
Aβ
Cell membrane
Extracellular Intracellular
NH2 COOH
APP
β-secretase γ-secretase
Aβ40 or 42
VKM DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV IA TVIVITLVMLKK
α-secretase
Swedish
mutation NL
Indiana
mutationF
Neprilysin cleavage sites
  
39
 
Figure 4. Human APP sequence including Aβ, α,β and γ-secretases and neprilysin cleavage sites. Once 
secreted, Aβ is cleaved by neprilysin (lower arrows) at position 3-4, 9-10, 19-20, 30-31 and 33-34, 9-10 being 
the major one. Swedish and Indiana FAD causing mutations, known to increase Aβ production and Aβ42 
cleavage, respectively, are represented. 
 
2.6.2 Decrease of neprilysin activity associated with Aβ pathology in AD 
Intracranial infusion of neprilysin inhibitors led to increased half life of radiolabeled Aβ 
injected into rat hippocampus, increased levels of endogenous Aβ and formation of diffuse 
plaques in rats [317]. A similar increase of Aβ levels was reproduced in rabbit [389] and APP 
transgenic mice brains [317, 390]. 
Neprilysin deficiency in mice also resulted in defects both in the degradation of exogenously 
injected Aβ and in the metabolic suppression of the endogenous Aβ in the brain including 
hippocampus, cortex, striatum and cerebellum. With 1.5 and 2 fold increase of endogenous 
Aβ40 and Aβ42 in the heterozygote and homozygote mice, respectively, this effect was dose 
dependent [229], suggesting that partial downregulation of neprilysin activity may contribute 
to AD development by promoting Aβ accumulation. 
Consistent with this hypothesis, neprilysin expression and protein level inversely correlated 
with the vulnerability to Aβ deposition in the brain of sporadic AD patients [391, 392]. 
Expression and protein level of neprilysin were reduced by approximatively 50% in the 
hippocampus and midtemporal gyrus of AD patients, as compared to age-matched controls, 
but were unchanged in brain areas with moderate or low plaque burden [392]. 
Neprilysin was also found decreased in the vasculature of AD brains and inversely correlated 
with the Aβ levels in the vasculature [393]. Moreover, neprilysin did not efficiently degraded 
Aβ carrying EOFAD mutations involved in presenile cerebral amyloid angiopathy such as 
Dutch, Flemish, Italian and Arctic mutations of APP in vitro [394]. A genetic study also 
associated a genetic polymorphism of neprilysin with risk of cerebral amyloid angiopathy 
[395], further suggesting that neprilysin may be implicated in cerebral amyloid angiopathy. 
With age as the major risk factor for AD, it is also interesting that activity and protein level of 
neprilysin were decreased upon aging in the hippocampal formation of WT mice and humans 
[396, 397]. Neprilysin downregulation with normal aging may play an important role in the 
initial accumulation of Aβ and the development of AD. In spite some negative data [212, 398, 
399], several recent studies have shown an association of the neprilysin gene, Mme, with 
LOAD [206-208, 400]. 
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2.6.3 Neprilysin as a therapeutic approach for AD  
Viral expression of neprilysin in primary neurons led to significant clearance in both the Aβ40 
and Aβ42 levels in the culture media and the cell associated Aβ. [401]. Similarly, hippocampal 
injection of viral vectors expressing human neprilysin decreased Aβ levels in NEP KO mice 
and mouse model of Aβ amyloidosis in vivo [402, 403]. It also resulted in a 50% decrease in 
the ipsilateral plaque formation in a plaque-bearing transgenic mouse model of cerebral 
amyloidosis compared to the contralateral cortex [402], showing that neprilysin 
overexpression could also induce the degradation of pre-existing plaques. However, this last 
finding is contradictory with our data showing that biochemical increase of endogenous brain 
neprilysin levels in aged SwAPP mice with pre-existing plaque pathology did not result in a 
significant reduction of plaque pathology [404]. Explanations for the observed differences 
include the cell types that upregulated neprilysin, accessibility to the plaques, inflammation 
and system adaptation to long term versus short term neprilysin upregulation. Furthermore, 
transgenic overexpression of neprilysin in a mouse model of Aβ amyloidosis significantly 
reduced brain Aβ levels, prevented amyloid plaque formation and its associated 
cytopathology [405]. 
 
2.6.4 Aβ injection increases neprilysin and prevent Aβ pathology prior to plaque 
formation 
It was recently found in our laboratory that injection of aggregated Aβ1-42 prior to plaque 
formation into brains of transgenic mice that expressed the disease-causing Swedish double 
mutation of APP (SwAPP) as well as into WT littermates caused increases in brain levels of 
neprilysin mRNA 20 weeks after injection (Fig. 5C) and a sustained increase of protein in a 
specific manner as early as 3 weeks and at least until 20 weeks after initial injection (Fig. 
5A). These increases were associated with dramatically reduced brain concentrations of Aβ as 
well as with prevention of brain amyloid plaque formation (Fig. 5B) and reduced astrogliosis 
in the SwAPP mice [406]. Similar treatment of aged SwAPP mice, already containing 
numerous amyloid plaques, also caused an Aβ1-42 specific sustained increase of neprilysin 20 
weeks after injection. Unlike the young mice, however, this treatment could not significantly 
reduce brain Aβ levels or remove the existing amyloid plaques from brains of aged mice 
[404]. This difference suggested that neprilysin preferentially degraded Aβ prior to 
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fibrillization and plaque formation but may also be due to age-dependent biological 
adaptations to high levels of human Aβ and neprilysin upregulation or the implication of 
other pathways influencing Aβ degradation.  
There is much evidence that neprilysin is able to degrade Aβ. While neprilysin 
downregulation can play an important role in the development of AD, its upregulation is a 
promising therapeutic approach.  
 
 
Figure 5. Intracranial injection of Aβ1-42 increased neprilysin levels and prevented amyloid plaque 
formation in transgenic Swedish APP mice. (A) Western blot analysis illustrating the Aβ1-42 specific increase 
of neprilysin level after different post-injection time compared to Aβ42-1 (Aβ42R) injected mice. (B) 20 weeks 
after injection, mice which received a cranial injection of Aβ1-42 showed a significant reduction of 4G8-positive 
amyloid plaques compared to phosphate buffered saline solution (PBS) injected mice. (C) When compared to 
those of uninjected group (set as 100%), the levels of NEP mRNA were significantly higher one week after the 
injections in all groups. 20 weeks after the injections, however, mRNA levels of the control-injected mice did 
not differ from those of the uninjected mice, whereas this value was still high in Aβ1-42-injected mice. *: p≤0.05 
for comparison to uninjected group. ns: not significant. 
 
 
 
 
 
PBS injected Aβ1-42 injected
A B
1 week
20 weeks
490 (±190)
57 (±290)
ns
%
Aβ42-1  (±SD)
490 (±180)
58 (±160)
ns
%
PBS (±SD)
420 (±110)
490 (±120)
*
%
Aβ1-42 (±SD)
460 (±150)
110 (±200)
ns
%
BSA (±SD)
100 (±160)
100 (±110)
ns
%
uninjected (±SD)
C
  
42
3) The plasminogen system in AD 
 
3.1 The plasminogen system 
 
Plasminogen is an inactive serine protease, mainly synthesized in the liver [407] and secreted 
in the circulation. To be activated into plasmin, it needs to be cleaved by either the tissue-type 
plasminogen activator (tPA) or urokinase plasminogen activator (uPA) [408]. The system is 
further controlled by plasminogen activator inhibitors (PAI) [409] and plasmin inhibitors (α2-
plasmin and α2-macroglobulin) [410].  
Plasmin acts primarly as a thrombolytic enzyme, involved in degradation of fibrin in the 
blood [411, 412] and cell migration by degradation of many components of the extracellular 
matrix (ECM) such as laminin, fibrin and fibronectin [413], either directly or through the 
activation of matrix-degrading metalloproteases [414]. In the brain, plasminogen and its 
proteolytic fragment plasmin are abundant in the hippocampus [415] and are involved in 
neuronal plasticity [416], long term potentiation by degradation of laminin [417], activation 
of brain derived neurotrophic factor (BDNF) [418], and learning and memory [419, 420]. 
Plasmin has also been recently implicated in the degradation of Aβ [421, 422]. 
tPA is secreted as an active enzyme, binds to the extracellular matrix components such as 
laminin and fibronectin [423, 424] and its activity is highly increased after cleavage by 
plasmin or binding to cross-β structure such as fibrin or Aβ in vitro [425-427]. tPA plays a 
major role in plasmin generation required for fibrinolysis in the peripheria but is also 
expressed in neurons [428] of various brain regions of the mouse, including the hippocampus, 
amygdala, cerebellum and hypothalamus [429], where it participates in synaptic plasticity, 
LTP [430] and learning [419]. tPA also presents plasmin-independent activity and was shown 
to increase vascular permeability of the blood brain barrier by binding to LRP receptor [431] 
and may be directly involved in neurotoxicity [432, 433]. 
uPA is secreted in its inactive form, pro-uPA [434] and needs to be cleaved by plasmin to be 
activated. The presence of active uPA in mice lacking plasminogen (Plg KO) mice [435] 
suggests the presence of other pro-uPA activators. Among them, cathepsins B, C, G and L 
[436-438] and different members of the kallikrein family [438-441] have been shown to 
activate pro-uPA. The binding of pro-uPA to a specific cell surface receptor, uPAR (reviewed 
in [442, 443]), facilitates its activation by plasmin and therefore targeting plasmin generation 
and further proteolysis to the cell surface. The complex uPA-uPAR is involved in tissue and 
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synaptic plasticity and brain development in a plasmin dependent and independent manner 
via the activation of intracellular pathways through uPAR [443-445]. 
 
3.2 The plasminogen system and AD 
 
Several studies have suggested an involvement of the plasminogen system in AD. Purified 
plasmin was initially shown to degrade monomers and fibrils of Aβ [421, 427]. It  cleaves 
Aβ1-40 at Arg5-His6, Lys16-Leu17 and Lys28-Gly29 [421]. Similarly, it was shown that after 
cleavage of Aβ1-42, the formation of β-sheet structures was prevented [446]. 
The expression of the two plasminogen activators, tPA and uPA were increased in primary 
neuronal cultures incubated with aggregated Aβ and in APP overexpressing mice [421]. Aβ 
was also shown to increase tPA activity in vitro [426, 427], which in turn led to an increase of 
plasmin activation [447] and subsequent Aβ degradation [448]. Furthermore, the addition of 
plasminogen inhibited the Aβ associated neurotoxicity [448]. Similarly, Aβ was shown to 
increase the expression of uPA and its receptor uPAR and cell surface localization and 
activity of uPA in human cerebrovascular smooth muscle cells. Plasminogen activation 
further protected the cells from Aβ toxicity [449]. Both tPA and uPA required plasminogen to 
modulate Aβ neurotoxicity and deposition in vitro [448, 450]. Addition of plasmin or tPA to 
hippocampal neurons expressing human APP also increased the amount of α cleavage of APP 
[451] and may represent another potential neuroprotective pathway for AD. 
 
The role of plasmin in Aβ degradation was further investigated using plasminogen and tPA 
KO mice in vivo. In spite the lack of Aβ increase in the brain of plasminogen deficient mice 
[452], indicating the involvement of others degradation pathways, degradation of Aβ injected 
into the hippocampus of tPA and plasminogen KO mice was slowed down and more activated 
microglial cells and neuronal damage were observed when compared to WT controls [422]. 
This confirms that plasmin helps in the clearance of Aβ in vivo and suggests that a reduced 
activity of this system may contribute to the progression of AD. In fact, level of plasmin was 
found decreased in the brain of AD patients, especially in the hippocampus [451, 453], 
indicating that plasmin may be physiologically relevant as a protective factor in AD. The 
gene encoding uPA, PLAU, is located in an important region on chromosome 10, which has 
been linked to LOAD and was found associated with it in some studies [454, 455] but not in 
others [456-458]. 
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II) MATERIAL AND METHODS 
 
1) Engineering, extraction, purification and analysis of DNA 
 
1.1 Plasmid DNA preparation 
 
1.1.1 Preparation and transformation of competent E. coli cells 
To transform DNA into Escherichia coli (E. coli), the cell membranes have to be porous. This 
can be achieved by treating the cells with Ca2+. The addition of DNA leads to the formation 
of DNA-Ca2+ complexes that enter the cells following a short heat-shock.  
To generate chemically competent bacteria, cultures of DH5α or XL10 gold cells (Life 
Technologies) were grown in Luria Bertani (LB) medium at 37°C overnight and harvested 
when an optical density (OD) at 600 nm of 0.4 was reached. The cells were pelleted on a 
5417R centrifuge (Eppendorf) at 4,000 g at 4 °C for 1 min, resuspended in 10 ml of a 0.1 M 
CaCl2 solution and kept on ice for 1 h. Cells were collected by centrifugation at 4,000 g at 4 
°C, resuspended in 0.1 M CaCl2, 0.02 M MgCl2 and 15% glycerol. Aliquots of competent 
cells were immediately frozen in liquid nitrogen and stored at –80 °C. 
To transform cells, diluted plasmid DNA or 5 µl of a ligation reaction were added to 50 µl of 
thawed competent E. coli and incubated on ice for 20 min. Following a heat shock of 45 s at 
42 °C the cells were chilled on ice for 2 min. After addition of 950 µl of preheated LB 
medium at 37 °C, the cells were incubated on a thermomixer (Ependorf) at 300 rpm for 1 h at 
37 °C. Cells were then plated on 37 °C prewarmed LB agarose (Becton Dickinson) plates 
containing the appropriate antibiotic: ampicillin (Sigma) with a final concentration of 50 
µg/ml for selection and were incubated overnight at 37 °C. 
LB medium: 10 g/l Bacto tryptone (Becton Dickinson), 5 g/l Bacto yeast extract (Becton 
Dickinson), 10 g/l NaCl, pH=7.0 
 
1.1.2 Preparation of plasmid DNA 
On the following day, colonies that contained the ampicillin resistance marker and therefore 
could grow on the ampicillin containing plate, were picked and grown in 15 ml Falcon tubes 
containing 2 ml LB medium and ampicillin (Sigma) 50 µg/ml in a C25 incubator shaker 
(New Brunswick Scientific) at 250 rpm, 37 °C overnight. Large scale production was then 
performed using 0.5 ml of the previous mini-culture added to 200 ml LB medium containing 
200 µl of 50 mg/ml ampicillin and was incubated in a shaking incubator at 37 °C overnight.  
To extract plasmids from E. coli, Qiagen (12125 and 12165) or Sigma (PLN-350 and PLX-
50) plasmid purification kits and protocols were used. The principle of these kits is based on 
selective alkaline denaturation, alkaline lysis of the cells in combination with the anionic 
detergent sodium dodecyl sulfate (SDS): cell walls are broken and proteins, as well as high 
molecular weight genomic DNA, is denatured. In contrast, covalently closed circular DNA 
remains double stranded, stays in solution and can be recovered from the supernatant by 
binding to an anion-exchange resin. Plasmid DNA was isolated from small scale (2 ml) and 
large scale (200 ml) bacterial cultures following the manufacturer’s protocols. The yield of a 
plasmid DNA preparation was measured at an OD of 260 nm and its purity accepted when the 
ratio between the absorption at 260 nm and the absorption at 280 nm was between 1.8 and 
2.0. 
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1.1.3 Phenol/chloroform extraction of DNA 
To remove contaminating proteins from nucleic acid preparations, an equal volume of 
phenol:chloroform:isoamylalcohol (25:24:1) is added to the nucleic acid solution and mixed 
well on a vortex. The DNA is recovered from the aqueous phase while denatured proteins 
stay in the organic phase. The tube is centrifuged for 5 min at 20,000 g. The aqueous phase 
containing the DNA was transferred to a fresh tube and precipitated using NaAc and ethanol. 
 
1.1.4 Ethanol precipitation of DNA  
To isolate or concentrate DNA from solution it can be precipitated with ethanol under high-
salt condition. The addition of ethanol depletes the hydration shell of the negative charged 
phosphate groups in the backbone of the DNA. Positively charged ions bind to these groups 
so that a precipitate can form. DNA was precipitated from solution by adding 1/10 volume of 
3 M sodium acetate (pH=5.2) and 2.5 volumes of cold 100% ethanol, incubation at -20 °C for 
30 min and centrifugation at 20,000 g for 20 min at 4 °C. After two washes with cold 70% 
ethanol, the DNA pellet was dried for 5-10 min at room temperature (RT) and resuspended in 
10 mM Tris (pH=8.0). 
 
1.2 Cloning 
 
To overexpress neprilysin in a neuronal specific manner, the 2.25 kb NEP-HA cDNA 
previously inserted in a pBluescript II KS (+/-) at the Sma I site of the multiple cloning site 
was first removed using the restriction enzymes Hind III and Spe I, separated by agarose gel 
electrophoresis and further purified (Fig. 6). The psub PDGF WPRE plasmid (gift from Dr. 
Hansruedi Büeler, University of Zürich) was linearized by the Nhe I restriction enzyme which 
presents a cohesive end with the Nhe I cleavage site, dephosphorylated and purified on an 
agarose gel. After ligation of the two cohesive ends, the ends of the new linearized plasmid 
were blunted. Once more purifed, the linearized plasmid was finally ligated. Presence of 
intact ITRs and the correct insertion of NEP-HA were confirmed by restriction enzyme and 
agarose gel analysis. 
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Figure 6. Cloning of neprilysin-HA into the psub expression vector. Schematic representation of the 
restriction enzymes used (in blue) to remove the neprilysin HA tagged cDNA from the original pBluescript II 
KS (+/-) and to linearize the psub PDGF WPRE plasmid. After cloning, the restriction sites used were lost. 
 
1.2.1 Restriction enzyme analysis of DNA 
For digestion of DNA, type II restriction endonucleases, recognizing and cleaving 
palindromic sequences of 4 to 8 base pairs (bp) of the DNA, were used. Digestion of 0.2 to 5 
µg DNA in a total volume of 20 to 40 µl was performed for 2 h or overnight with 1 U of the 
restriction enzyme(s), 1X bovine serum albumin (BSA) if required under buffer and 
temperature conditions as recommended by the manufacturers. 200 ng for analytical purposes 
and 1 to 5 µg of plasmid DNA for preparative purposes were analyzed by agarose gel 
electrophoresis. With DNA ladders (New England Biolabs), the length of DNA fragments 
could be determined. 
 
1.2.2 Agarose gel electrophoresis  
To analyze or isolate DNA fragments or PCR products, separation by agarose gel 
electrophoresis was performed. Due to the negatively charged phosphate groups in the 
backbone of nucleic acids, DNA migrates towards the positive anode when exposed to an 
electric field with a migration rate dependly mainly on their size. Depending on the size range 
of linear DNA to be resolved, 0.4, 0.7 or 2.0% (w/v) agarose (Invitrogen), for a detection of 
2,000 to 30,000 bp, 1,000 to 15,000 bp and 100 to 2,500 bp, respectively, was dissolved in 
Tris-acetate (TAE) buffer by heating the mixture. When cooled down to 50 °C, the gel was 
complemented with 1 µg/ml ethidium bromide (Sigma) which intercalates between bases of 
DNA and fluoresces under ultra violet (UV) light. The length of DNA fragments could then 
be determined by comparison with a DNA ladder marker. When DNA fragments had to be 
recovered from the gel, 2 mg/ml crystal violet (Sigma,) was preferred over ethidium bromide. 
It allowed a weaker but direct visual detection without exposition of the DNA to the 
damaging effects of UV light. 
TAE buffer: 40 mM Tris-acetate (pH=7.6), 1 mM EDTA 
 
1.2.3 Recovery of DNA fragments from agarose gels 
After having resolved DNA fragments by electrophoresis the band containing the DNA of 
interest was cut out from the gel using a scalpel and purified using the QIAquick Gel 
Extraction kit (28706, Qiagen) according to the company’s protocol. 
 
1.2.4 Blunting of cohesive ends 
Blunting of sticky DNA ends was performed by DNA polymerase I (New England Biolabs). 
This polymerase fills-in the 5’ overhangs and removes the 3’ overhangs to form blunt ends. 
The blunting reaction was performed for 15 min at RT in the EcoPol buffer supplemented 
with 1 mM DTT, 4 mM dNTP (Sigma) and 1 U of klenow per µg of DNA.) 
 
1.2.5 Dephosphorylation of plasmid DNA 
Digested plasmid DNA containing complementary cohesive ends or blunt ends tend to self-
ligate producing empty vectors. In order to suppress such self-ligation, shrimp alkaline 
phosphatase (SAP, Roche) was used to remove terminal 5’ phosphate groups from DNA. For 
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the hydrolysis of 5’-phosphate groups 1 µg DNA fragments and 5 U of SAP were incubated 
at 37 °C for 1 h in the appropriate buffer according to the manufacturers. Before ligation, 
vectors were purified with the GenElute PCR clean up kit (NA1020, Sigma) and eluted in 50 
µl H2O. 
 
1.2.6 Ligation 
DNA fragments can be ligated to linearized plasmid DNA in an ATP consuming enzymatic 
process. The E. coli T4 DNA ligase catalyzes the ligation of two DNA strands at the 5’ 
phosphate and the 3’ hydroxy groups. Depending on the size of the vector and insert, the 
amount of vector and insert varied. In general, 0.3 pmol (300 ng) were mixed with 3 pmol of 
inserts. This mixture was incubated with 400 U of T4 DNA ligase in T4 ligation buffer (New 
England Biolabs) at 4 °C overnight. 
 
1.3 Genotyping of mice 
 
1.3.1 Preparation of genomic DNA from mouse tails 
5 mm of a mouse-tail biopsy was lysed and the DNA extracted using the Gen Elute 
Mammalian Genomic DNA MiniPrep Kit (G1N-350, Sigma) following manufacturer’s 
protocols. Isolated genomic DNA was stored at 4 °C. 
A simplified mammalian DNA isolation was used when genotyping of neprilysin 
overexpression alone had to be performed: 5 mm of a mouse-tail biopsy was incubated with 
22 µl lysis buffer for 1-2 h at 55 °C on a thermomixer (Eppendorf). Following this incubation, 
178 µl of double distilled water (ddH20) was added and Proteinase K denatured at 99 °C for 5 
min at 500 rpm in the same thermomixer. The samples were then centrifuged for 5 min at 
22,800 g and the supernatant kept at 4 °C. 
Lysis-Buffer: 50 mM Tris-HCl (pH=8.0), 1 mM EDTA, 0.1% (w/v) SDS, 20 mM NaCl, 1 
mg/ml proteinase K (Roche recombinant PCR kit #3115 844). 
 
1.3.2 Polymerase chain reaction amplification 
The polymerase chain reaction (PCR) is a method to amplify DNA sequences of interest [459, 
460]. To produce multiple copies of DNA, two specific primers are used that are 
complementary to one of the two strands and define the sequence to be amplified. 
Denaturation of the DNA at 95 °C is followed by a decrease in temperature such that the 
primers can anneal to their complementary sequence on the DNA. Heat stable DNA 
polymerase catalyses the replication of the DNA by adding deoxynucleotides (dNTP) to the 
3’-ends of the primer sequences. By repeating these steps several times the DNA sequence of 
interest is amplified exponentially. 
Transgenic J20 mice overexpressing the Swedish and Indiana mutated human APP under the 
control of the glial fibrillary acidic protein (GFAP) promoter, were screened with primers 
PDAPP 1F (5’ GGT GAG TTT GTA AGT GAT GCC 3’) and PDAPP 2R (5’ TCT TCT TCT 
TCC ACC TCA GC 3’). Briefly, 2 µL (10 to 200 ng) of genomic DNA was added to PCR 
mix (0.75 U of the Ampli-Taq Gold (Roche), 1X PCR Buffer II (Roche), 2.5 mM MgCl2, 
1mM dNTP (Sigma), 20 pmol of each primer in a final volume of 27 µl). Using a GeneAmp 
PCR system 9700 machine (Applied Biosystem), the reaction was heated to 95 °C for 12 min 
before a series of 10 single cycles (1 min denaturation at 94 °C, annealing of the primers for 2 
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min at decreasing temperature starting at 65 °C during the first cycle and finishing at 56 °C 
during the 10th cycle and 2 min at 72 °C at the end of each cycle) followed by 25 further 
cycles (1 min denaturation at 94 °C, annealing of the primers at 55 °C and 1.5 min at 72 °C), 
followed by a final incubation at 72 °C for 10 min, then kept at 4 °C. For sequencing purpose, 
two different primers were used APP2041 (5’ AAC ACA GAA AAC GAA GTT 3’) and APP 
2520 (5’ CCG ATG GGT AGT GAA GCA) to amplify a 480 bp fragment containing the Aβ 
part of human APP. The same PCR protocol was followed. 
Transgenic NEP mice overexpressing neprilysin under the control of the Prion protein 
promoter (Prp) were screened with oligonucleotides Prp5-(5-3) (5’ CAG AAC TGA ACC 
ATT TCA AC 3’) and NEP125-100 (5’ CTA TGA TGG TGA GGA GCA GGA CAA G 3’). 
1 µl of genomic DNA was mixed with 1 U of the Red Taq polymerase (Sigma), 1X 
corresponding PCR Buffer, 1 mM dNTP (Sigma), 10 pmol of each primer in a final volume 
of 20 µl. The reaction was heated to 95 °C for 2 min before a series of 35 cycles (30 s at 94 
°C, 30 s at 52 °C, 50 s at 72 °C), then kept at 72 °C for 7min and cooled to 4 °C. 
Screening of the NEP KO mice heterozygous and homozygous with depletion of the 
neprilysin gene [314] was performed using 2 pairs of primers: the oligonucleotides 5’ TCA 
TTC AGC TGG TCA AA 3’ and 5’ CTT GCG GAA AGC ATT TC 3’ were specific for 
detection of the WT neprilysin allele, whereas 5’ TCA TTC AGC TGG TCA AA 3’ and 5’ 
ATC AGA AGC TTA TCG AT 3’ recognized the targeted depleted neprilysin allele. 1 µl of 
genomic DNA was mixed with 1 U of the Red Taq polymerase, 1X corresponding PCR 
Buffer, 1 mM dNTP, 10 pmol of each primer in a final volume of 20 µl. The reaction was 
heated to 95 °C for 5 min before a series of 35 cycles (30 s at 95 °C, 30 s at 48 °C, 30 s at 72 
°C), then kept at 72 °C for 7 min and cooled to 4 °C. 
Transgenic SwAPP mice overexpressing mutated hAPP expressing the Swedish double 
mutations under the control of the Prp promoter were screened with oligonucleotides 5' GTG 
GAT AAC CCC TCC CCC AGC CTA GAC CA 3' and 5' CTG ACC ACT CGA CCA GGT 
TCT GGG T 3'. 1 µL of genomic DNA was mixed with 1 U of the Red Taq polymerase, 1X 
corresponding PCR Buffer, 1 mM dNTP, 10 pmol of each primer in a final volume of 20 µL. 
The reaction was heated to 95 °C for 2 min followed by 35 cycles (45 s at 95 °C, 1 min at 63 
°C, 45 s at 72 °C), then kept at 72 °C for 7min and cooled to 4 °C. 
 
1.4 DNA sequencing  
 
To confirm the presence of the Swedish and the Indiana mutation in the human APP sequence 
of the J20 mice, the PCR product containing the Aβ sequence of interest was sequenced. 
DNA cycle sequencing is based on the dideoxy method developed by Sanger et al. [461]. In 
the cycle sequencing reaction all four deoxynucleotides (A, T, G, C) labeled with different 
dyes are added to an excess of deoxynucleotides. When one of the dideoxynucleotides is 
incorporated the elongation of the chain is terminated because these nucleotides lack the 3’- 
hydroxyl group. The products were gel-electrophoretically separated in a capillar according to 
their molecular weight. Different wavelengths are used to excite each dye and thus to identify 
the sequence of the DNA. 
Using the Big Dye Terminator v.1.1 Cycle Sequencing kit (4336776, Applied Biosystems), 
200 ng PCR product, 3.2 pmol of one of the primer Ab-F (5’ CCA GGT TCT GGG TTG 
ACA AA 3’) or Ab-B (5’ACC ACA CCA TGA ATG GA 3’), 4 µl Ready Mix and ddH2O 
added up to a volume of 20 µl, were mixed in a reaction tube. The DNA cycle sequencing 
reaction was carried out using the following program: 96 °C for 1 min followed by 25 cycles 
(96 °C 10 s, 50 °C 5 s, 60 °C 4 min) and finally kept at 4 °C. The DNA was purified by 
ethanol precipitation. The DNA pellet was resuspended in 20 µl HPLC-grade water (Aldrich) 
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and was analyzed with the ABI Prism 310 Genetic Analyzer and ABI Prism 7700 Sequence 
Detector (Applied Biosystems). Sequence readouts of 200-400 bp by the Sequence detection 
software 1.9.1 (Applied Biosystems) were transformed to and computationally analyzed with 
the programs SeqMan II and MegAlign 4.00 (DNASTAR). 
 
1.5 Production of the recombinant adeno-associated virus (rAAV) 
 
RAAV is an attractive approach for gene therapy. It allows a high transfection rate of cells 
including post mitotic cells such as neurons, stably insert the transgene of interest in the DNA 
of the cells infected likely promoting long-term expression. RAAV are non-pathogenic and 
replication-deficit viruses. The delivery of therapeutic transgenes is performed in the absence 
of viral genes and therefore preclude any potent humoral immune response due to recognition 
of viral particles. 
 
1.5.1 Production of the rAAV 
One day before transfection, 20 to 30 15 cm2 plates were plated with 1.7 x 107 HEK 293T 
cells/plate in 25 ml Dulbecco’s modified Eagle medium (DMEM, Invitrogen) supplemented 
with 10% Foetal calf serum (FCS) and 50 U/ml penicillin and 50 µg/ml streptomycin (P/S). 
The next day, 80% confluent 293T cells were transiently cotransfected with rAAV vector 
plasmid expressing either NEP haemagglutinin-tagged (HA) under the control of the platelet-
derived growth factor (PDGF) promoter or the enhanced green fluorescent protein (EGFP) 
under the control of the PDGF or the cytomegalovirus (CMV) promoter and a helper plasmid 
pDG which expresses all the virus proteins required for the production of the virus proteins. 
All rAAV vector plasmid contained a post-transcriptional regulatory element (WPRE) which 
is known to enhance transgene expression [462, 463]. The medium was first replaced with 25 
ml fresh DMEM + 10% FCS without P/S. The calcium phosphate transfection was performed 
3 h later. The cells were transfected with a DNA/CaCl2 mix containing 582 µg of the pDG 
helper plasmid, 285 µg of the rAAV plasmid were mixed in 1.5 ml 2.5 M CaCl2 solution and 
filled up to 12.5 ml with ddH20 (protocol for 10 15 cm2 plates).  
12 ml polystyrene snap cap tubes (352057, Bector Dickinson) containing 2.5 ml 2x HeBS 
buffer (pH=7.12) were prepared. 2.5 ml of DNA/CaCl2 mix was added dropwise to the 2.5 ml 
2x HeBS buffer, mixed gently on a vortex genie 2 (Scientific Industries) and incubated 2 min 
at RT. 2.5 ml of this mixture were distributed dropwise to each of the two plates without 
delay. Then the plates were gently mixed and incubated at 37 °C with 5% CO2. The next 
morning, the medium was replaced with 25 mL DMEM 10% FCS with P/S. 
48 h after transfection, the cells were pipetted and centrifuged at 370 g for 5 min at 4 °C. 
The supernatant was removed and the cell pellet containing the virus particles frozen at -80 
°C. 
2x HeBS buffer: 16.4 g NaCl, 11.9 g N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
(HEPES), 0.249 g Na2HPO4.2H2O, 800 ml ddH20, pH adjusted to 7.12 with 5 M NaOH, filled 
up to 1 L). 
1.5.2 Purification and concentration of the rAAV 
 
Lysis of the cells  
The virus purification was performed according to a protocol published by Auricchio [464]. 
The cell pellet of 10 15 cm2 plates were resuspended in 14 ml buffer containing 0.15 M NaCl, 
50 mM Tris-HCl pH=8.5 and freeze/thaw 2 times from liquid nitrogen to a 37 °C bath. After 
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each round, the cells are resuspended with a flamed Pasteur pipette and finally incubated 30 
min at 37 °C with 0.1 mg of DNAse I and RNAse A each (Sigma) for each initial 15 cm2 
plate. After 15 min of centrifugation at 1,400 g at 4 °C, the supernatant containing the virus 
was transferred into a new tube and incubated with 0.5% (final concentration) of deoxycholic 
acid for 30 min at 37 °C to increase the binding of the virus to the following heparin column. 
 
Heparin column purification 
6 ml of a heparin-agarose suspension (H6508, Sigma) was pipetted into a 2.5 cm diameter 
glass column (C4669, Sigma) equipped with a luer lock (S7396, Sigma). After the agarose 
suspension had flown through, a filtration membrane (S7271, Sigma) was placed on top of 
the agarose bedding. The matrix was afterwards equilibrated with 25 ml of PBS. The virus 
preparation was then sequentially filtered through a 5 µm pore size filter and a 0.8 µm pore 
size filter (Millex) before it was applied to the column and the lock opened allowing a flow 
speed of one drop per second. The matrix was then washed twice at the same flow rate with 
25 ml of PBS plus 0.1 M NaCl (final NaCl concentration = 0.254 M). The virus was then 
eluted at the same flow rate with 15 ml of PBS plus 1.3 M NaCl (final concentration 1.454 M 
NaCl). 
PBS: 0.154 M NaCl, 0.0027 M KCl, 0.01 M Na2HPO4.2 H20, 0.0018 M KH2PO4 adjusted to 
pH=7.4 
 
Concentration of the rAAV 
The eluate was first concentrated to about 1 ml by centrifugation at 1,800 g at 4 °C with a 
Millipore Biomax-100K NMWL filter device (UFV2BHK40, Milipore) pretreated overnight 
at 4 °C with murine serum. To adjust the NaCl concentration to physiological levels, the filter 
device was refilled with PBS, and the virus concentrated to 400 µl. After removal of the virus 
containing solution, the membrane of the filter device was washed three times with 100 µl 
PBS. The purified virus was then aliquoted and stored at -80 °C. 
 
1.5.3 Titration by slot blot hybridization  
 
Southern blotting is a method to detect and quantify specific DNA sequences [465]. Single 
stranded DNA or denatured double stranded DNA is transferred and tightly bound onto a 
membrane. Sequences of interest are detected by incubation of a radiolabeled DNA probe 
hybridizing to the target DNA followed by autoradiography and quantification. 
 
Preparation of the samples and standards 
To quantify the concentration of the intact virus particles in our preparations and potential 
loss, 5 µl of the virus preparation and other solutions used during the purification steps were 
analyzed by slot blot hybridization. The samples were treated in 200 µl serum free DMEM 
(Invitrogen) with 5 U DNAse I (Sigma) at 37 °C for 1 h to avoid contamination from DNA 
released by the destroyed virus particles. 200 µl of 2X proteinase K buffer (20 mM Tris-HCl 
pH=8.0, 20 mM EDTA, 1% SDS) and 100 µg proteinase K (5 µl of 20 mg/ml stock, 
Biotechnica) were added and incubated for an extra hour. 
The DNA from the originally intact virus was then extracted by phenol/chloroform and 
purified by ethanol precipitation and ressuspended in 400 µL of 0.4 M NaOH solution 
containing 10 mM EDTA. 
The standards were obtained via a 2 fold serial dilution of the AAV vector plasmid used to 
generate the rAAV. 40 ng to 0.3125 ng of the plasmid was resuspended in a total of 400 µl of 
0.4 M NaOH solution containing 10 mM EDTA. 
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Before loading, the samples were denatured at 95 °C for 5 min and kept on ice for 1 min. 
 
Fixation of the samples on the membrane 
The slot blot apparatus (SL-8125, Scotlab) and a Hybond-N+ membrane (Amersham) were 
assembled following manufacturer protocol; 400 µl of ddH2O was added in each well and 
removed via a vacuum pump minivac P1 (Axon Lab AG). The samples were first loaded in 
the chosen wells. Afterwards, 400 µL of 0.4 M NaOH, 10 mM EDTA added in the empty 
wells and the membrane dried up by vacuum pump. The membrane was then incubated 2 min 
in 2X SSC solution containing 300 mM NaCl, 30 mM NaCitrate at pH=7.0 and the DNA 
cross linked for 50 s at 120 mJ with the UV Stratalinker 1800 (Stratagene). 
 
Preparation of the radioactive probe  
Random labeling of DNA was carried out using the Stratagene Prime-it labelling kit. A part 
of the target DNA was used as a template for a random synthesis of DNA fragments in the 
presence of short primers (hexanucleotides) and α32P-radiolabeled dCTP (Hartman 
Analytic), so that newly synthesized DNA harbours the radioactive nucleotide. 
10 ng of target DNA was denatured at 95 °C for 5 min in 45 µl Tris EDTA (TE) buffer 
containing 10 mM Tris pH=8.0 and 0.1 mM EDTA. The sample was chilled on ice for 5 min 
and added to the reaction tube, containing hexanucleotides, dATP, dGTP, dTTP and the 
Klenow fragment of DNA polymerase I (New England Biolabs). After the addition of 5 µl 
α32P-dCTP with a specific activity of 3,000 Ci/mmol the solution was incubated at 37 °C for 
30 min. The QIAGEN Nucleotide Removal kit was used to remove nucleotides that were not 
incorporated during the reaction and short oligonucleotides (< 100 bp). 
 
Hybridization 
The Hybond-N+ membrane was placed in a roller bottle and pre-hybridized in 10 ml 
prehybridization solution containing 10 µg/ml salmon sperm (Roche) for 2 h at 65 °C. The 
labelled probe was denatured for 5 min at 95 °C, chilled on ice for 5 min and added to the 
prehybridization solution. The hybridization was carried out at 65 °C overnight. The 
hybridization solution was discarded and the blot first washed twice with RT 2X SSC, 1% 
SDS for 30 min each time at 65 °C then twice with 65 °C preheated 0.2X SSC, 1% SDS for 
15 min each time at 65 °C. The membrane was finally washed briefly in 2X SSC and exposed 
onto a X-ray LS film (Kodak) for 6 to 60 h. 
prehybridization solution: 0.2 g BSA, 6.84 ml Na2HPO4 1 M, 3.16 ml NaH2PO4 1 M, 10 µl 
EDTA 0.5 M, 3 ml deionized fromamide and 7 ml SDS 20% 
 
2) Isolation, purification and analysis of RNA 
 
Special care was taken to use RNase free conditions. Most glassware were baked, surfaces 
treated with RnaseAway (Catalsys) and all aqueous solutions were treated with Diethyl 
pyrocarbonate (DEPC, Sigma) and autoclaved.  
 
2.1 Total RNA extraction from brain tissue 
 
Total RNA was extracted from frontal brain tissue by using a technique adapted from 
Chomczynski [466]. Mice were sacrificed by decapitation and the brains were removed. The 
frontal part of the brain was quickly homogenized on ice in 2 ml of TRIzol reagent 
(Invitrogen) and total RNA was obtained following the TRIzol Protocol (Gibco BRL). 
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TRizol reagent is a monophasic solution containing phenol and guanidium isothiocyanate that 
preserves RNA integrity during cell lysis and homogenization, and dissolves cellular 
components. Addition of chloroform followed by centrifugation separates the solution into an 
aqueous and an organic phase. RNA remains exclusively in the aqueous phase from where it 
is recovered by precipitation with isopropyl alcohol, resuspended in DEPC treated water 
(Ambion) and stored in aliquots at -80 °C. 
 
2.2 Quality assessment of total RNA 
 
The purity, integrity and concentration of total RNA was analyzed with the RNA 6000 nano 
LabChip kit (Agilent) enabling the detection of RNA ranging from 25-500 ng/µl. 1.5 µl of the 
extracted samples were analyzed following manufacturer’s protocol. The chip supports 16 
wells connected to capillaries filled with an acrylamide-like matrix mixed with an RNA dye. 
All wells were fitted with a mini-electrode upon closing the lid and RNA samples mixed with 
a fluorescent marker that signals the beginning of an electrophoretic run from a specific well. 
Transcripts of different size were separated while migrating through the matrix-filled 
capillaries. 3 wells were used as controls and one for the RNA ladder. This allows accurate 
quantitation and size measurement of RNA transcripts from the samples. The output is an 
electropherogram where the relative abundance of the two ribosomal 18S and 28S spikes is 
used to quantify and evaluate the quality of the RNA samples. The absence of other spikes 
also confirms the integrity of the RNA population in the sample. 
 
2.3 Quantitative real time PCR 
 
Quantitative real time PCR (qRT-PCR) allows relative quantification of mRNA by measuring 
the increase in fluorescence caused by the incorporation of a quencher (Taqman from Applied 
Biosystems/ABI) or the binding of SYBR Green (LightCycler, Roche Diagnostics) to double 
stranded complementary DNA (cDNA) formed during PCR. The number of PCR cycles 
required for the accumulation of a specific amount of product (during the exponential phase 
of the reaction) is a reflection of the relative amount of nucleic acid template present 
originally in the sample. 
First the reverse transcription of 4 µg of RNA was performed using the SuperScript First-
Strand Synthesis System for RT-PCR (11904-018, Life Technologies) and random hexamers 
as primers (Invitrogen) following manufacturer’s instructions. The polymerization was 
performed at 42 °C for 50 min and terminated at 70 °C. The RNA template was subsequently 
destroyed by the addition of RNAse H (Invitrogen) for 20 min at 37 °C. 
For detection during qRT-PCR, the following gene specific HPLC-purified primers 
(Metabion) were designed to amplify 70-90 bp at the 5' end of the open reading frame (ORF) 
when possible, using the primer design software Primer Express 1.5 (Applied Biosystems): 
 
Mouse uPA: F 5'-TAT GCA GCC CCA CTA CTA TGG CTC-3' 
Mouse uPA: R 5'-GAA GTG TGA GAC TCT CGT GTA GAC-3' 
 
Mouse tPA: F 5'-CTA CAG AGC GAC CTG CAG AGA T-3' 
Mouse tPA: R 5'-AAT ACA GGG CCT GCT GAC ACG T-3' 
 
Mouse uPAR: F 5'-ACT ACC GTG CTT CGG GAA TG-3' 
Mouse uPAR: R 5'-ACG GTC TCT GTC AGG CTG ATG-3' 
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Mouse NEP: F 5'-TAA GCA GCC TCA GCC GAA ACT ACA A-3'-3' 
Mouse NEP: R 5'-GAC TAC AGC TGC TCC ACT TAT CCA CTC A-3' 
 
Mouse β-actin: F 5'-TGG AAC GGT GAA GGT GAC A-3' 
Mouse β-actin: R 5'-GGC AAG GGA CTT CCT GTA A-3' 
 
Mouse NEP exon 1: F 5’-GGA GAT GTG CAA GTG GAG GAG-3’ 
Mouse NEP exon 1: R 5’-CCT TAG CCG CTC TGC AGC T-3’ 
 
Mouse NEP exon2: F 5’-CTG TTT GGT GAC CGA GAG CA-3’ 
Mouse NEP exon 2: R 5’-TTC CCA GCC CCC AAA TG-3’ 
 
Mouse NEP exon 3: F 5’-CAA CTC TTT CTG AGA TCT TCA GTG ATA GA-3’ 
Mouse NEP exon 3: R 5’-CCA ATC AAC TTT TTT ATT CTT TTG TTT TT-3’ 
 
The specificity of the sequence and lack of homology was confirmed by blasting the primer 
sequences against mouse specific sequences 
(http://www.ncbi.nlm.nih.gov/genome/seq/MmBlast.html) 
 
2.3.1 Lightcycler 
Light Cycler quantitative real time PCR (LC-PCR) was performed with a RNA SYBR Green 
kit (Roche Diagnostics) following the manufacturer’s instructions. In brief, 1µl of 10 µM 
primers and 50 ng of template DNA were mixed in a final volume of 20 µL containing 1X 
LightCycler-DNA Master Sybr Green I. For signal detection, the ABI Prism 7700 Sequence 
Detector System (Applied Biosystems) was programmed with an initial sterilization step of 2 
min at 50 °C, followed by 10 min denaturation and polymerase activation at 95 °C and 40 
temperature cycles of 15 s at 95 °C and 1 min at 60 °C. The Sequence Detection Software 
1.9.1 (Applied Biosystems) was used for the analysis of raw data and cycle threshold (Ct) 
values were determined using the standard curve method according to the manufacturer’s 
guidelines (Applied Biosystems). All measurements were performed in triplicate and the 
relative amount of all RNAs was then calculated by comparing the Ct values of the genes of 
interest after normalization to the β-actin’s Ct values of the samples.  
 
2.3.2 Taqman  
qRT-PCR for the exons 1, 2 and 3 of neprilysin was also performed with HPLC-purified 
primers (Metabion) and TaqMan probes (Biosearch Technologies). The PBGD gene with its 
specific primers and quencher was used as reference and Ct values were determined. Black 
Hole Quencher™ TaqMan™ probes were also designed with the Primer Express 1.5 
software.  
The PCR reaction was carried out using the TaqMan Universal PCR Master Mix (4304437, 
Applied Biosystems), 333 nM oligonucleotide primers, 200 nM fluorogenic probe and 1 µl 
(50 ng) of template cDNA or HPLC-H20 as control in a final volume of 25 µL. For signal 
detection, the ABI Prism 7700 Sequence Detector System (Applied Biosystems) was 
programmed with the same program used for the LightCycler analysis. All measurements 
were performed in triplicate and Ct value of each sample for each exon was normalized with 
the Ct value for PBGD: The relative amount of RNA was then determined by comparision of 
the Ct values for each treatment. 
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Mouse PBGD: F 5’-GCT ATG TCC ACC ACG GGA GA-3’ 
Mouse PBGD: R 5’-TAC ACG TGG GAG AGG GAC AAG-3’ 
 
Probes for the taqman qRT-PCR: 
Mouse NEP exon 1: 5’-ACG GAG TGC AGG CGT-3’ 
Mouse NEP exon 2: 5’-CGC TGC CAA ATT GCA CCG GG-3’ 
Mouse NEP exon 3: 5’-ATA TGT CTA TTC TTC CTT CAA ATC TCA TGC ACT TGT 
GTG-3’ 
Mouse PBGD: 5’-AAG ATT GTT GAT ACT GCA CTC TCT AAG GTA ACG CCA-3’ 
 
3) Protein extraction, fractionation and analysis 
 
3.1 Protein extraction from cell cultures  
 
The medium was first removed and the plated cells were washed twice with PBS. The cells 
were then scraped in 4 °C lysis buffer containing 100 mM Tris, 150 mM NaCl, 1% Triton X-
100, pH=7.8 and 1x complete protease inhibitor cocktail (Roche). The cells were removed 
and homogenated on ice by 12 passages through a 16G and a 26G needle (Becton Dickinson). 
The samples were then centrifuged at 20,000 g for 10 min on a centrifuge 5417R (Eppendorf) 
and the supernatant was removed, aliquoted and frozen at -25 °C. 
 
3.2 Protein extraction and fractionation from mouse tissue 
 
The homogenization of mouse tissues was performed in a glass homogenizer kept on ice 
using an electronic homogenizer (RZR2101, Heidolph) at a speed of 300 rpm. 
For assessing transgenic neprilysin expression by immunoblotting, different areas of the brain 
such as cortex, cerebellum, pons, hippocampus, amygdala and peripherical organs such as 
kidney, liver and heart tissues were homogenized for 5 min in 25X volume/original weight 
(v/w) in lysis buffer A containing 100 mM Tris, 150 mM NaCl, 1% Triton X-100 and 1X 
complete protease inhibitor cocktail (Roche) pH=7.8. Homogenates were centrifuged at 
20,000 g for 10 min on a centrifuge 5417 R (Eppendorf) and the supernatant was removed, 
aliquoted and frozen at -25 °C. Brain of mice treated with intraperitoneal (ip) injection of all 
trans retinoic acid (RA) were prepared similarly. Amygdala homogeneization was also 
performed similarly in 12 v/w lysis A with 2% SDS. 
To determine neprilysin activity, the frontal brain tissues were not frozen after dissection but 
immediately homogenized with the lysis buffer A in absence of protease inhibitors. 
After completion of the behavioral analysis by the 7 months cohort at 10 months of age for 
the J20 and NEPxJ20 mice and at 11 months of age for the NEP and WT mice, for combined 
Western blotting and Aβ enzyme-linked immunosorbent assay (ELISA), frozen frontal brain 
tissue was homogenized in 25X v/w lysis buffer A. Homogenates were centrifuged at 100,000 
g for 45 min at 4 °C in an Optima Ultracentrifuge (Beckman Coulter) in adapted centrifuge 
tubes (343778, Beckman). Pellets were dissolved in lysis buffer B (lysis buffer A containing 
2% SDS) (6 times the original weight) and centrifuged similarly. The SDS insoluble pellet 
was finally dissolved in 3 times the original weight of 70% formic acid (FA) and neutralized 
with 1.6 volume of 10 N NaOH. 
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After completion of the behavioral analysis by the 15 months old mice at the age of 18 
months, the brain tissue was first homogenized in 12 v/w with a buffer containing 100 mM 
Tris, 150 mM NaCl and 1x complete protease inhibitor cocktail (Roche) pH=7.8 and 
centrifuged. The subsequent pellet was homogenized in 12 volumes /original weight of lysis 
buffer A and centrifuged as before. The triton insoluble pellet was further homogenized with 
8 v/w of lysis buffer B and centriguged. Finally, the SDS insoluble pellet was resuspended in 
6 v/w of 70% FA and neutralized.  
The brain tissue from mice which received an intracranial treatment (Aβ1-42 or Aβ42-1) were 
homogenized in either lysis buffer containing 250 mM sucrose, 10 mM Tris, 1% Triton X-
100, 1% SDS, pH=8, and 1X complete proteinase inhibitor mixture for the mice treated prior 
to amyloid plaque formation [406] or lysis buffer A for the mice treated after amyloid plaque 
formation [404]. All samples were analyzed by zymography and while samples from the first 
group were used for the RayBio Mouse Angiogenesis Antibody Array, samples from the 
second group were used for plasmin activity (SDS inhibited the enzymatic assay). 
To investigate plasminogen activators activity, cortex and hippocampus of NEP (n=4) and 
WT littermates (n=4) were also removed, homogenized in buffer B without protease 
inhibitors and centrifuged at 20,000 g for 10 min at 4 °C. 
 
3.3 Measurement of protein concentration 
 
Protein concentrations of cell or tissue extracts were measured using the DC protein assay 
(500-0113, BioRad). Proteins react with an alkaline copper tartrate solution and reduce folin 
reagent. The reduced folin species have a characteristic blue color with an optimal absorption 
at 750 nm. Following the instruction manual, protein concentrations were calculated based on 
the absorptions of a standard curve. The standard curve was recorded with different dilutions 
of a BSA standard from 0.25 mg/ml to about 2 mg/ml in the corresponding sample buffer. 
 
3.4 Immunoblotting of proteins 
 
Immunoblotting is a method to quantify and determine the size of a protein of interest in a 
protein extract. Proteins are separated by SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and electrophoratically transferred from the gel to a nitrocellulose membrane where 
they are immobilized and can be detected by specific antibodies. 
 
3.4.1 SDS polyacrylamide gel electrophoresis  
By reduction of the disulfide bonds with β-mercaptoethanol, the proteins are dissociated into 
their polypeptide subunits which are denaturated using the anionic detergent SDS and heat. 
SDS binds to hydrophobic regions of the polypeptides so that they become negatively 
charged and migrate to the anode. The amount of SDS bound is proportional to the molecular 
weight of the protein subunits. This means that the charge density of all polypeptides is the 
same and they migrate with the same force but different exclusion volumes through the gel, 
leading to the separation of the polypeptides according to their size (smaller peptides 
migrating further than bigger ones).  
The samples were heated at 95 °C for 5 min in the protein sample buffer, separated on 10-
20% Tris-Glycine and 10-20% Tris-Tricine gels (Invitrogen) following the manufacturer’s 
instructions. Equal amounts of protein were loaded to each lane when comparision was 
  
56
required. Gels were run at 90 V for 2-3 h at RT in the Tris-glycine or tricine running buffer as 
recommended by the manufacturer. 
For the separation of small molecular weight proteins such as Aβ, 10-20% Tris-Tricine 
gradient gels were used. 
2X sample buffer: 450 mM Tris-HCl pH=8.45, 12% (v/v) Glycerol, 4% (w/v) SDS, 7.5‰ 
Coomassie brillant Blue (Merck) and 2.5‰ Phenol Red 
1X tricine running buffer: 100 mM Tris-base, 100 mM Tricine, 0.1% SDS, pH=8.3 
1X Tris glycine running buffer: 25 mM Tris-base, 192 mM glycine, 0.1% SDS, pH=8.3 
1X NU PAGE running buffer: 50 mM Tris-base, 50 mM Tricine, 0.1% SDS, pH=8.3 
 
3.4.2 Transfer of proteins 
Following SDS-PAGE the stacking gel was removed and the running gel equilibrated in 
transfer buffer for 3 min. Whatman papers and nitro-cellulose membranes (Trans-Blot 
Transfer medium 0.45 µm, Biorad) are cut to the size of the gel and soaked in transfer buffer. 
The gel and the membrane are sandwiched between Whatman paper (3030917, Whatman) 
soaked pieces of sponge and perforated plastic plates. Transfer was carried out in a blotting 
tank (Novex) for 1h30 at 380 mA at 4 °C with the transfer buffer.  
For the detection of β-amyloid, the special nitrocellulose transfer membrane PROTRAN 
(Bioscience) was used. 
Transfer buffer: 3 mM Tris-base, 19.2 mM glycine, 20 % (v/v) methanol 0.02% SDS. 
 
3.4.3 Immunological detection of proteins 
After electrophoretical transfer of proteins, the membrane was blocked at RT for at least 1 h 
in TBST (10X TBST: 0.2 M Tris, 2.5 M NaCl, 1% (v/v) Tween 20) containing 5 % 
weight/volume (w/v) dry skim milk to prevent unspecific binding of antibodies. The primary 
antibody was diluted in TBST with 5% milk to an appropriate concentration and the blot was 
incubated at RT for 2 h or overnight at 4 °C. To remove all traces of unspecifically bound 
primary antibodies the membrane was washed 5X for 5 min in TBST. Incubation of the blot 
with the secondary antibody conjugated to horseradish peroxidase in 5% milk TBST was 
carried out for 2 h at RT. The blot was then washed again 5X for 5 min in TBST. The ECL 
Western Blotting Detection Reagents (RPN 2106, Amersham Biosciences) or the SuperSignal 
West Femto Maximum Sensitivity Substrate kit (34095, Pierce) were used following 
manufacturer protocol and bands visualized by chemiluminescence using X-omat LS films or 
Light film (Kodak) and the Kodak X-OMAT 2000 Processor. 
For the detection of Aβ, the membrane was boiled for 5 min in PBS and cooled down prior to 
the blocking.  
The effective overexpression of neprilysin in the NEP mice was investigated using the rat HA 
antibody (1867423, Roche, 1/1000) and the mouse neprilysin antibody 56C6 (Novocastra, 
1/100) recognizing human and murine neprilysin [406]. The rabbit C-terminal APP antibody 
(Sigma, 1/5000) and the mouse 6E10 antibody (Signet Laboratories, 1/500) were used to 
analyze full length APP (flAPP), C-terminal fragments of APP and Aβ levels in NEPxJ20 and 
J20 mice. The blots were probed for β-actin (Abcam, Cambridge, UK, 1/5000) as a loading 
control. The secondary antibodies used were the anti-mouse HRP conjugated (NA931, 
Amersham, 1/5000), the anti-rabbit HRP conjugated (NA934, Amersham, 1/5000) and the 
anti-rat (NA935, Amersham, 1/5000) antibodies. 
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3.5 Neprilysin activity assay 
 
Frontal brain tissues from NEP (n=4) and WT (n=4) mice were homogenized in lysis buffer A 
without protease inhibitors (see 3.2). 34 µg proteins were incubated for 1 h at 37 °C with 100 
µM Z-Ala-Ala-Leu-p-nitroanilide (ZAAL-pNA; Bachem) in 50 mM HEPES buffer (pH=7.2). 
Thereafter, 0.8 mU leucine aminopeptidase (Sigma) was added to the reaction mixtures, 
incubated for an additional 20 min at 37 °C and OD was measured at 405 nm. To inhibit 
neprilysin activity, 40 µM thiorphan (Sigma) were added for 5 min at RT before the addition 
of ZAAL-pNA. To improve the quantification of the test, different concentrations of NEP 
samples diluted in similarly prepared brain homogenate of a NEP KO mouse [314] that 
exhibits no neprilysin enzyme activity were also measured. 
 
3.6 Zymography 
 
An overlay gel containing the inactive plasminogen, precusor of the active enzyme plasmin, 
and milk casein, an opaque substrate of plasmin, allow the detection and quantification of 
plasminogen activators. When in contact to the opaque gel, the plasminogen activators 
activate plasminogen into plasmin leading to the degradation of the casein which makes the 
gel transparent. 
The overlay mixture consisted of 0.5 ml of an 8% commercial instant nonfat dry milk 
solution (the 8% stock solution in PBS was heated at 95 °C for 30 min, centrifuged 10 min at 
3,000 g, and the supernatant collected), 0.75 ml of PBS containing 0.9 mM Ca2+ and 1 mM 
Mg2+, 20 µl of a 4 mg/ml solution of purified human plasminogen (gift from Dr. Rime 
Madani and Prof. JD Vassalli [429, 467]) and 0.7 ml of a 2.5% agarose (50080, Cambrex) 
solution in ddH20. Each solution was preheated at 52 °C and mixed in the order specified. 
Identical experiments were carried out with overlay mixtures containing 1 mM amiloride (A-
7410, Sigma), a specific inhibitor of uPA [468]. 
For zymography on cryostat tissue sections, 80 µl of the overlay mixture was applied to 
prewarmed 10 µm thick cryostat tissue sections mounted on poly-L-lysine-coated slides, and 
spread evenly under 24 x 32 mm glass coverslips. Slides were incubated at 37 °C in humid 
chambers and zymograms were allowed to develop for 2 to 6 h. 
For the enzymatic assay, brain homogenates, cells homogenates and controls (actilyse, 
medium from cells overexpressing uPA [469], kidney homogenate and urine samples) were 
subjected to SDS−PAGE under non-reducing conditions. Since aprotinin, one of the standard 
markers, is a protease inhibitor, and SDS present in the gel can induce degradation of the 
milk, the marker was cut and the gel was washed first 3X for 10 min in a solution containing 
2.5% triton in ddH2O then 3X for 10 min in a special PBS solution (1 L PBS containing 0.132 
g of CaCl2 and 0.2 g of MgCl2.6H2O). The gel was then added on an underlay gel formed by 
the mixture which was cooled down to RT for 10 min on a glass plate. Special care was taken 
in obtaining a homogenous thickness for the overlay. 
The zymogram was wraped into saranwrap to avoid dehydratation and was allowed to 
develop from 1 h to overnight at 37 °C.  
 
3.7 Plasmin activity assay 
12 weeks post injection brain homogenates from mice which were intracranially injected with 
1 µl of PBS (n=3), a suspension of aggregated synthetic Aβ1-42 (n=4) or Aβ42-1 (n=6) [406] 
were tested for plasmin activity. 
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Plasmin enzymatic activity was assayed using the chromogenic substrate S-2251 
(Chromogenix) specific for this protease included in the COAMATIC plasminogen kit (82 
2452 63, Chromogenix) following the manufacturer protocol. 150 µg of brain homogenates 
were placed in a 96 multiwell plate in the presence of 2 mM chromogenic peptide to measure 
endogenous plasmin activity. Absorbance was measured at 37 °C and 405 nm with a Victor2 
1420 multilable counter (Wallace) every 3 min for 45 min. The background activity was 
determined with 150 µg Plg KO brain homogenate and the linearity of the system 
investigated via sequential dilution of pure human plasminogen activated by streptokinase in 
plasminogen KO sample. The absorbance of the plg KO brain homogenate was removed from 
the analyzed samples and fold increase activity was determined by normalization of the 
sample absorbance with the absorbance of the PBS injected brain homogenates. 
 
3.8 Enzyme-linked immunosorbent assay (ELISA)  
 
3.8.1 Total murine Aβ ELISA 
Frontal brain tissue was weighed and homogenized on ice at a 1/10 (w/v) dilution in 50 mM 
Tris pH=8.0, 150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 0.8 µg/ml pepstatin and complete 
protease inhibitor cocktail (Roche) by 10 strokes at 1,000 rpm in a potter homogenizer. Brain 
homogenates were then centrifuged at 135,000 g for 1 h at 4 °C. The supernatant was 
collected and used for quantitation of murine Aβ levels by an established sandwich ELISA 
[470]. 
Rodent Aβ40 and Aβ42 standards (American Peptide Company, Sunnyvale, CA, USA) used in 
the ELISA were dissolved in dimethyl sulfoxide (DMSO) at 1 mg/ml, and further diluted to 5 
µg/ml in buffer EC (20 mM sodium phosphate, 2 mM EDTA, 400 mM NaCl, 0.2% BSA 
(Sigma), 0.05% CHAPS, 0.4% casein, 0.05% NaN3, pH=7.0) and stored at -70°C. Nunc U-
bottom high-binding 96 well microtiter plates (Life Technology) were coated with a mouse 
monoclonal antibody (100 µl at 5 µg/ml) that specifically recognize Aβ amino acid residue 
17-24 (4G8, Senetek Research) [471].  
Plates were washed 5 times with 200 µl per well of PBS using a Titertek M96 microplate 
washer (Titertek). 150 µl of the blocking solution consisting of 1 % casein in PBS was then 
added to each well for 30 min at 37 °C. 
Before incubation on coated ELISA plates, brain extracts and standards were thawed and 
diluted in casein buffer containing 0.1% casein in PBS, 5 mM EDTA, 1 mM PMSF, 0.8 
µg/ml pepstatin and complete protease inhibitor cocktail. Samples were diluted up to 1/20 or 
1/40 and the standard curve covered the Aβ concentration between 1 to 0.016 ng/ml. ELISA 
plates were washed with the casein buffer before loading samples, standards, and JRF/rAβ/2-
HRP (mouse monoclonal to Aβ1-15) labeled antibody (1/2,000 in casein buffer). Incubation 
was carried out overnight at 25°C. Plates were then washed and assays were developed with 
tetramethyl benzidine/hydrogen peroxide (TMB/H2O2) substrate (Pierce) according to the 
manufacturer's specifications. The color reaction was stopped with 1 M phosphoric acid and 
the reaction product was quantified on a Molecular Devices microplate reader at 450 nm.  
 
3.8.2 Human Aβ40 and Aβ42 ELISA 
Brain Aβ40 and Aβ42 concentrations were quantified using commercially available ELISA 
kits, purchased from the Genetics Company (Schlieren, Switzerland) and Innogenetics 
(Ghent, Belgium), respectively. The capture and detection antibodies of the Aβ40 kit are 
reactive to amino acid residues 31-40 and 4-10, respectively and don’t cross-react with Aβ42. 
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Similarly, the capture and detection antibodies of the Aβ42 kit are reactive to amino acid 
residues X-42 and 1-5, respectively and don’t cross-react with Aβ40. 
The different fractions of the brain homogenates were first acetone precipitated to eliminate 
the detergents. 4 volumes of -20 °C acetone were added for each volume of sample, mixed 
and kept at least 2 h at -20 °C. The sample were then centrifuged at 20,000 g for 15 min at 4 
°C, the supernatant discarded and the pellet dried by speed vacuum and finally resuspended in 
the buffer of the ELISA kit for Aβ40 on ice in a glass homogenizer using a Heidolph 
electronic homogenizer at 300 rpm. 
 
3.9 Radioimmunoassay (RIA) 
 
3.9.1 Peptides and chemicals  
The synthetic peptide SP was acquired from Sigma Aldrich and Neosystems (Strasbourg, 
France), respectively. The enkephalin heptapeptide Met-enkephalin-Arg-Phe (MEAP) was 
obtained from Bachem (Bubendorf, Switzerland). The chromatographic material (SP-
Sephadex C-25) was obtained from Pharmacia Biotech AB (Uppsala, Sweden). The iodinated 
SP used in RIA was prepared from Tyr8-substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Tyr-
Gly-Leu-Met-NH2) was from Sigma Aldrich. 
3.9.2 Tissue preparation for radioimmunoassay 
The collected mouse brains were weighed and suspended in an Eppendorf tubes containing 1 
M acetic acid (1 ml per 100 mg tissue, minimal volume 500 µl) and heated at 95 °C in a water 
bath for 5 min. The samples were subsequently cooled on ice for 2 min prior to 
homogenization by ultrasonification. The homogenates were centrifuged at 14,000 g for 10 
min at 95 °C and the supernatants were taken for further processing. 
 
3.9.3 Pre-separation procedure using anion exchangers 
Prior to RIA, the samples from the previous step were diluted with buffer I containing 0.018 
M pyridine and 0.1 M FA, pH=3.1 and purified using ion exchange chromatography. Small 
plastic columns were packed with 1 ml SP-Sephadex C-25 gel (Pharmacia) and equilibrated 
with 20 ml of buffer I. Before application onto the columns the samples were diluted by 
addition of 3 ml buffer I. After additional washing with 10 ml of buffer I, the columns were 
subsequently washed with 5 ml of 0.1 M pyridine/0.1M FA, pH=4.4 before elution was 
carried out with 4 ml of 1.6 M pyridine/1.6 M FA, pH=4.4. All buffers contained 0.01% β-
mercaptoethanol. The eluates were kept in volumes suitable for the subsequent assay (0.5 ml 
for MEAP, 1 ml for SP) and evaporated in a Speed Vac vacuum centrifuge (Savant). The 
dried samples were analyzed by RIA. Before RIA, samples and standards to be assayed for 
MEAP were oxidized using H2O2. Unknown samples were dissolved with 100 µl 1 M acetic 
acid and added with 10 µl of 30% H2O2. Samples were allowed to incubate in a water bath at 
37 °C for 30 min and thereafter dried in a Speed Vac centrifuge. A stock solution with MEAP 
(9.10-6 M) to be used for the standard curve was treated in a similar fashion with the 
exception higher concentration of H2O2 was used. 
 
3.9.4 RIA  
The RIA for SP and MEAP were based on the charcoal absorption technique and were 
conducted as described [472-475]. For all RIA, the antibodies were raised in rabbits against 
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the peptide-thyroglobulin conjugate and the 125-I-labelled synthetic peptides or peptide 
analogues (see above) were used as tracers. Details (including cross-reactivity and detection 
limits) for the various RIA are given in the above cited references. Each individual RIA value 
is given as a mean from triplicate determination. 
The RIA for somatostatin was performed using a kit supplied by Euro-Diagnostica (Medeon) 
and was conducted according to the description given by the manufacturer. The material 
obtained from the pre-separation on SP-Sephadex mini-columns (0.5 ml of material eluted 
with 1.6 M pyridine/1.6 M FA, pH=4.4) was dried as above, subsequently redissolved in the 
assay diluent (included in the kit) and thereafter analyzed by RIA, which was based on a 
double antibody procedure. 
 
3.10 RayBio Mouse Angiogenesis Antibody Array 
 
To determine the potential role of inflammation in the Aβ-related neprilysin and uPA activity 
upregulation in vivo, 500 µg of brain homogenate from 4 mice which were killed 20 weeks 
after Aβ1-42 of Aβ42-1 injection (2 mice per group) were analyzed with the RayBio Mouse 
Angiogenesis Antibody Array1.1 (M0319801, RayBiotech) allowing the detection and 
quantification of 24 different angiogenesis factors (Fig. 7).  
Preparation of the samples, incubation and detection were performed following 
manufacturer’s instructions: membranes were blocked for 1 h and incubated with 500 µg 
brain homogenate overnight at 4°C and then washed for 30 mn and incubated with a 1 to 250 
dilution of biotin-conjugated antibody mix for 2 h. After consecutive washes, a 1/1’000 
dilution of streptavidin-conjugated peroxidase was added and incubated for 2 h RT. The 
membranes were further washed and exposed to peroxidase substrate prior to detection by 
exposing the membranes to a x-ray film for 1 mn and development. 
 
 
Figure 7. Location and name of the factors analyzed by the RayBio Mouse Cytokine Antibody Array. 
After determination of the background intensity obtained by negative spots (NEG) and blank spots, the 
quantification of the factors can be performed by comparing their intensity with the one from positive spots 
(POS). Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF), granulocyte, 
macrophage and granulocyte-macrophage colony-stimulating factors (G-CSF, M-CSF and GM-CSF, 
respectively),  interferon γ (IFN γ) and monokine induced by IFN- γ (MIG), insulin growth factor II (IGF-II), 
macrophage chemoattractant protein (MCP1), platelet factor 4 (PF-4), interleukins (IL: IL-1α, IL-1β, IL-12 
p40/p70 recognizing both p40 and p70, IL-12 p70, IL-13, IL-6 and IL-9), tumor necrosis factor α (TNFα), , 
tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) are among the factors analyzed. 
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4) Cell culture  
 
4.1 Culture and storage of cell lines 
 
The following neuronal and non-neuronal mammalian cell lines have been used from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); Human embryonic 
kidney HEK-293 cells (DSMZ # ACC 305), HEK-293T cells (DSMZ # ACC 305), human 
neuroblastoma SH-SY5Y cells (DSMZ # ACC 209). Human microglial cells (MIC) were 
initially produced by Janabi et al. [476]. 
All cell lines were cultivated at 37 °C/ 5% CO2/ 95% humidity in their specific culture 
medium. When confluency was reached and dilution required, the cells were washed with 
PBS, released from the dish by incubation with trypsin/EDTA for 3 min, singled with a 
flamed Pasteur pipette, centrifuged 5 min at 1,000 g, resuspended in culture medium and 
plated at ratios of 1/3 to 1/10 depending on the purpose. 
For storage, the cells were resuspended in freezing medium and immediately chilled on dry 
ice and frozen at -80 °C in a Styrofoam box. After one day at -80 °C the aliquots were 
transferred to liquid nitrogen and kept for long time storage.  
To recultivate frozen cells, cell aliquots were thawed quickly in a water bath at 37 °C, and 
cells were immediately resuspended in cultivation medium and pelleted by centrifugation. 
After resuspension, cells were plated on dishes at a seeding density corresponding to 50% 
confluency. SH-SY5Y cells can also be triggered to differentiate to a neuronal-like phenotype 
[477]. For differentiation, SH-SY5Y cells were seeded on collagen type I (Sigma) coated 
dishes at a density of 0.3 – 2.0x104 cells/cm2. To induce neuronal differentiation, cells were 
incubated in medium containing RA for five days, followed by an additional five days in 
serum free medium supplemented with BDNF (Preprotech). 
 
- culture medium for the HEK-293T cells: DMEM (Invitrogen), 10% (v/v) FCS, 50 U/ml 
penicillin and 50 µg/ml streptomycin. 
- culture medium for the SH-SY5Y cells: DMEM-F12 medium (Invitrogen), 2 mM L-
glutamine, 1 mM sodium pyruvate, 10% FCS, 5% HS, 50 U/ml penicillin and 50 µg/ml 
streptomycin. 
- culture medium for the MIC cells: DMEM with Glutamax 1 (Invitrogen), 10% (v/v) heat 
inactivated FCS, 50 U/ml penicillin and 50 µg/ml streptomycin. 
- Differentiation medium I (days 1-5): DMEM-F12, 2 % FCS, 2 mM L-glutamine, 20 µM 
RA. 
- Differentiation medium II (days 5-10): DMEM-F12, 2 mM L-glutamine, 50 ng/ml BDNF. 
- Freezing medium: DMEM or DMEM-F12, 20 % (v/v) FCS, 5% HS, 10 % (v/v) DMSO. 
 
4.2 Primary neuronal culture 
 
24 well plates were previously coated with 50 µg/mL poly-D-lysine (P-2636, Sigma) in 0.1 M 
borate buffer overnight in the cell incubator. The plates were then rinsed with ddH20 prior to 
plating. 
Primary neuronal cultures were prepared from embryonic C57Bl/6 mice at the developmental 
stage of 16 to 18 days. Cerebral cortices were dissected from the brains of the embryos in ice-
cold Hank's balanced salt solution without Ca2+ and Mg2+ (HBSS; 10 mM HEPES, 50U/ml 
penicillin and 50µg/ml streptomycin, pH=7.3) (Gibco) and the hippocampi removed and 
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freed from meninges in a similar buffer. The hippocampi were incubated at 37 °C for 30 min 
in pre-heated Hank’s medium containing Ca2+ and Mg2+ to which 0.25% trypsin (Gibco) and 
0.05% DNase I (Sigma) were added. The tissues were dissociated to single cells by gentle 
trituration using flamed Pasteur pipettes. The cell suspension was mixed with Neurobasal 
medium supplemented with 2% B27 (Gibco), 0.5mM glutamine, 50 U/ml penicillin, and 50 
µg/ml streptomycin. The cell suspension was centrifuged at 310 g for 3 min and the resulting 
pellets were resuspended in the medium described above and plated onto coated 12 or 24-
well. The cells were cultured in a CO2 incubator (5% (v/v), 37 °C) for 10 days before 
treatment. Half the medium was removed each 2-3 days and replaced with Neurobasal 
medium supplemented with 2% B27 (Gibco), 0.5 mM glutamine, 50 U/ml penicillin, and 
50µg/ml streptomycin. During the 5 days incubation with Aβ, half the medium was changed 
as usual without further addition of Aβ before cell lysis. 
Borate buffer: 1.24 g boric acid, 1.9 g sodium tetraborate in 400 ml ddH2O pH=8.5, filtered 
and sterilized. 
 
4.3 Transient transfection and luciferase assay 
 
After transfection of a plasmid expressing luciferase under the control of a promoter of 
interest, the activation of the promoter correlated with the luciferase activity present in the 
sample. This system allowed a simple and high sensitive method to quantify reporter activity 
after a specific treatment. 
Transfection of 90% confluent cultures, grown in 24 well plates, was performed with 
lipofectamine 2000 (Invitrogen), using 1 µg DNA per well and following manufacturer’s 
protocol. Each treatment was performed in three independent wells. Firefly luciferase 
expressing constructs under the control of one of the three neprilysin promoters or deletions 
of promoter 1, were transfected alone. Generally 6 h after transfection, the medium was 
removed and replaced with the adequate culture medium containing the additional substance 
to be tested. Depending on the cell type and the purpose of the experiment, the cells were 
harvested from 12 to 72 h after transfection with the passive lysis buffer of the Luciferase 
assay system (Promega E1500). The luciferase activity was measured according to the 
manufacturer's protocol using a photoluminometer LB 9507 (Berthold) and normalized by 
dividing it with the protein concentration of the sample analyzed. When the effect of the 
differentiating agent, RA, was assessed on SH-SY5Y cells, luciferase activity was not 
normalized with the protein concentration to avoid overestimating the effect due to higher 
levels of proteins in the untreated plates. Because of low level of luciferase activity in SH-
SY5Y cells, the background activity level determined in non-transfected cells was substracted 
from all readings. 
The Dual Luciferase Reporter Assay System (Promega E1910) used specific buffers which 
allowed the measurement of firefly and renilla luciferase activities from the same sample 
without interation between the two luciferases. Firefly luciferase expressing constructs were 
co-transfected in a molar ratio of 150:1 with pRL-TK renilla luciferase vector (Promega) as 
the internal control for transfection efficiency. The cells were harvested with the passive lysis 
buffer of the Dual Luciferase system (Promega) and the luciferase activities were measured 
according to the manufacturer's protocol. 
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4.4 Experimental conditions and treatments 
 
4.4.1 Aβ preparation and incubation 
Aβ1-42 and Aβ42-1 were purchased from Bachem, reconstituted in PBS at calculated 
concentrations of 220 µM were shaken at 1,000 rpm for 24 h at 37 °C in a thermomixer 
(Eppendorf). Suspensions of Aβ1-42 preparations corresponding to 5, 10 and 15 µM soluble 
peptide were added to each culture for incubations periods ranging from 12 h to 3 days for the 
cell lines and 5 days for the primary neuronal culture. 
 
 
4.4.2 All trans retinoic acid (RA) incubation 
To test the effect of RA and BDNF on neprilysin promoter activation, SH-SY5Y cells and 
293T cells were incubated for 12 h to 5 days in their standard medium containing 10 µM RA 
(Sigma), or the solvent (DMSO) as control. 
 
4.5 Cell viability 
 
The general cell viability of the cells treated with Aβ1-42 and Aβ42-1 was analyzed by trypan 
blue staining of the cells. 0.8 mM of trypan blue in PBS was added to the plates, incubated 5 
min at RT and washed. Viable cells exclude trypan blue, while dead cells stain blue due to 
trypan blue uptake. 
 
5) Transgenic and knockout mice 
 
5.1 Generation of the NEP transgenic mice  
 
Genetically modified mice, overexpressing neprilysin in the CNS neurons, were generated by 
the following method: a hemagglutinin (HA) tag was fused to the C-terminus of human 
neprilysin cDNA [331]. This fragment was then inserted into the XhoI site of the MoPrP 
expression vector [478] to ensure neuronal expression. A standard pronuclear injection of the 
DNA construct was then undertaken in C57BL/6xDBA/2 embryos. The presence of the 
transgene was confirmed by PCR analysis of genomic DNA. Several transgenic lines were 
produced and one line designated NEP was established and kept on 50%x50% 
C57BL/6xDBA/2 background.  
 
5.2 Other transgenic mice used and breedings 
 
- Mice with targeted depletion of the neprilysin gene were a gift from Dr. Bao Lu [314]. They 
were crossbred for 10 generations with the C57BL/6 background. 
- uPA KO mice lacking uPA protein and activity, mice with a similar background and Plg KO 
mice lacking an active plasminogen were a gift from Dr. Peter Carmeliet, Center for 
Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for 
Biotechnology, Leuven, Belgium. 
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- J20 mice, expressing the Swedish and Indiana mutated human APP in neurons [70], were 
donated by Dr. Lennart Mucke, Gladstone Institute, UCSF. They were maintained on a pure 
C57BL/6 background. 
For behavioral and biochemical analysis of the effect of neprilysin overexpression on the Aβ-
related pathology, NEP males were mated with J20 females. Their progeny consisting of 
NEP, J20, WT and NEPxJ20 mice, all littermates with a 75% C57BL/6 25% DAB/2 
background were analyzed. All mice were housed under a light cycle of 12 h with dry food 
pellets and water available ad libitum, when not mentioned differently. 
Animal experiments and husbandry were performed in compliance with national guidelines. 
 
5.3 Treatments 
 
5.3.1 Stereotaxic injection of β-amyloid 
 
Synthetic Aβ1–42 and reverse Aβ, Aβ42–1 were purchased from Bachem, reconstituted in PBS 
at a final concentration of 350 µM and shaken at 1,000 rpm for 48 h at 37 °C in an Eppendorf 
thermomixer (Vaudaux-Eppendorf AG) to allow aggregation. 
At the age of 1 year, SwAPP mice received a unilateral intracranial injection of 1 µl 350 µM 
stock concentration fibrillar Aβ1-42 (n=5, Aβ high dose group) or 35 µM stock concentration 
(n=4, Aβ low dose group) in the hippocampus (caudal -1.9 mm, lateral -1.2 mm and ventral -
1.9 mm) as described [404, 406]. Control groups consisted of SwAPP littermates which 
received injections of 1 µL 350 µM stock concentration Aβ42–1 (n=6, Aβ42–1 high dose group) 
or did not receive any injection. 
Mice were anesthetized with a mixture of 2% xylazine and 10% ketamine (10 µl/g body 
weight, Streuli-Pharma), placed in a stereotaxic instrument (Stoelting) (Fig. 6), and an 
incision was made along the midline of the head to expose the skull. 
The calvarium was perforated with a drill (Fine Science Tools) at the positions: caudal -1.9 
mm, lateral -1.2 mm (Fig. 8). 
A 10 µl Hamilton syringe was slowly inserted 2.4 mm into the cortex at (caudal -1.9 mm, 
lateral -1.2 mm and ventral -1.9 mm) the same coordinates. After 2 min, a total volume of 1.5 
µl Aβ1-42 or reverse Aβ42-1 was injected into the CA1 region of the hippocampus with an 
injection speed of 0.15 µl/min using a mini pump. The needle was kept in the injection site 
for another 2 min before slowly being withdrawn. The wound was closed with surgical 
staples and the mice kept on a heating pad for 3 h. 
  
65
 
5.3.2 Stereotaxic injection of rAAV 
The same protocol was used to inject 2 µl the rAAV preparations in the CA1 region (caudal -
1.9 mm, lateral -1.2 mm and ventral -1.9 mm) or the dentate gyrus area (caudal -1.9 mm, 
lateral -1.2 mm and ventral -2.5 mm) of the hippocampus. 
 
5.3.3 Treatment with RA 
A first group of mice was treated chronically during 5 days with 3 µg of RA. A second group 
was similarly treated with 125 µg RA. Subcutaneous RA tablettes shown to release a constant 
RA level every day were also implanted during 3 weeks in WT and transgenic mouse models 
of amyloidosis. 
5.4 Tissue preparation  
 
Once under deep anesthesia induced by ip injection of a solution containing 2% xylazine and 
10% ketamine (10 µl/g body weight) (Streuli-Pharma) mice are perfused transcardially using 
a peristaltic pump connected to two reservoirs containing saline and fixative solution, 
respectively. A cut along the sternum is made in order to expose the end of the sternum, then, 
with sharp scissors, a cut is made through the skin, diaphragm and laterally on both sides 
upward across the ribs and parallel to the lungs; the cannula was then inserted through the left 
ventricle into the ascending aorta. Immediately, the right auricle was punctured to allow the 
escape of return circulation. Perfusion was performed with PBS during 6 min. Brains were 
removed, dissected into various areas including frontal brain area sectioned at the bregma line 
[479], hippocampus, cerebellum and subcortical areas, and frozen immediately on dry ice. 
Similarly peripherical organs such as kidney, heart and liver were removed and frozen on dry 
ice. 
For dissection of the amygdala, 400 µm frontal brain sections beginning at -0.94 mm and 
ending at -2.18 posterior to bregma according to a stereological brain atlas [479] were 
Figure 8. Stereotaxic injection of Aβ 
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obtained using a tissue chopper (Bachofer GmbH). Amygdalae were dissected under a light 
microscope with scalpels and frozen immediately on dry ice and stored at –20 °C. 
Following completion of the behavior testing, the brain of the mice was removed following 
the same procedure. The frontal parts of the brain were sectioned at the bregma level, divided 
into the sagittal halves and frozen immediately. The dorsal part of the brain was fixed for 24 h 
in 4% paraformaldehyde (PFA) in PBS at 4 °C. The brains were then dehydrated in an 
ascending series of ethanol (70%, 96%, 100%; each 3 h, by changing every hour), left 
overnight in xylol, subsequently immersed in liquid paraffin at 60 °C for 5 h and finally 
embedded in paraffin. 
For cryostat sectioning, after overnight fixation in PFA, brains were cryprotected by 
incubation overnight in 10%, overday in 20% and overnight in 30% sucrose, then fixed in 
tissue freezing medium (Jung) and kept at -30 °C. 
For paraffin sections, tissue was subsequently dehydrated in an ascending ethanol series of 
ethanol (70%, 96%, 100%; each 3 h, by changing every hour), left overnight in xylol, 
subsequently immersed in liquid paraffin at 60 °C for 5 h and finally embedded in paraffin. 
 
5.5 Immunohistochemistry 
 
5.5.1 Immunostaining of paraffin sections 
Immunohistochemistry was done on coronal 5 µm thin paraffin sections obtained with a 
microtome RM2135 (Leica) and brain areas were mapped based on the mouse atlas [479].To 
allow antibodies to penetrate fixed tissue embedded in paraffin, sections were dewaxed 3X in 
xylol and rehydrated in a descending series of ethanol (2X in 100%, 1X in 96%, 1X in 70%) 
and 2X in ddH2O (5 min each). 
To detect an antigen, specific primary antibodies and secondary antibodies (conjugated to 
fluorescent dyes or biotin) were used. The sections were washed well in PBS (fluorescence) 
or TBS (DAB) and permeabilized with 0.1% Triton X-100 in TBS (TBST) for 10 min at 
37°C. To detect the signal of the HA and neprilysin antibody, further permeabilization with 
methanol at –20 °C for 5 min or 10 min of microwave at 95 °C in a sodium-citrate buffer 0.01 
M, pH=5.8, were tried. Neprilysin staining was observed after 5 mn permeabilisation at 120 
°C using a pressure cooker in sodium-citrate buffer 0.01 M, pH=5.8. 
Sections were then blocked for 30 min in PBS or TBS containing 10% normal serum and 4% 
milk. Sections were then incubated with the primary antibody diluted in PBS or TBS 
containing 5% normal serum and 2% milk overnight at 4 °C. Sections were washed 4 times 
with PBS or TBS were incubated with the secondary antibody for 2 h at RT, and were washed 
again. The fluorescence stained sections were mounted directly with Moviol (Hoechst) while 
vectastain ABC reagent (Vector Laboratories) was added to the DAB labeled sections for 30 
min. These sections were washed again and were incubated with peroxidase substrate solution 
(DAB) (Pierce) for 10 min. The immunostained sections were mounted with antifading 
medium (Moviol, Clariant) and microscopically analyzed by conventional 
immunofluorescence. 
 
5.5.2 Immunostaining of cryostat sections 
10 µM frozen sections, cut on a cryotome Leica CM 1900 (Leica), were washed twice with 
PBS and permeabilized with PBS containing 0.1% Triton X-100 for 30 min and blocked for 2 
h with 5% goat serum diluted in PBS RT. The primary antibody was diluted in blocking 
buffer and incubated with the sections overnight in a wet chamber at 4 °C. The brain slides 
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were then washed 5X with 0.05% Tween-20 in PBS for 10 min. The secondary antibody, 
conjugated with a fluorescence marker, was diluted in blocking buffer, added to the sections 
and incubated at room temperature for 2 h in the dark. The sections were then washed three 
times with PBS for 5 min and embedded in Moviol before immunofluorescent detection 
under a microscope using the specific filter required. 
To detect the signal of the HA and neprilysin antibody, further treatment of the sections 
including 5 mn incubation in -20 °C methanol, 10 min heat induced antigen retrival at 95 °C 
in a microwave or 5 mn at 120 °C in a pressure cooker using a sodium-citrate buffer, 0.01 M,  
pH=5.8 were investigated. 
 
5.5.3 Antibodies 
 
Antibodies used for immunohistochemical detection of HA or neprilysin in NEP mice were 
the mouse HA (2362, Cell Signalling, 1/200), the goat HA (Ab1266, Abcam, 1/100), the rat 
HA (1867 423, Roche, 1/100), the mouse neprilysin (CL CD10-270, Novocastra, 1/100) and 
the rabbit neprilysin (AB5458, Juro, 1/100) antibodies. Only the mouse neprilysin antibody 
worked for immunohistochemistry. While Aβ staining was investigated with the mouse 4G8 
antibody ( 200-05, Signet, 1/500), astrocytes and microglia activations were stained with the 
guinea pig GFAP (031223, Advanced Immunochemicals, 1/100) and the Iba I ([480, 481], 
1/500) antibodies. Secondary antibodies included the Cy3 anti-mouse (115-165-146, Jackson, 
1/200), the Cy3 anti-rat (712-165-153, Jackson, 1/200), the Cy3 anti-rabbit (111-165-144, 
Jackson, 1/1000), the Cy3 anti-goat (706-165-148, Jackson, 1/100) and the Cy2 anti-guinea 
pig (706-225-148, Jackson, 1/50). 
 
5.5.4 Electron microscopy 
Aged NEP KO and WT littermates (18-20 months, n=3 each) were perfused transcardially 
with 0.05 M Na-Cacodylat-buffer containing 2 % Glutaraldehyde and postfixed overnight in 
the same solution. Subsequently the hippocampus was carefully removed and cut into 
fragments of approximately 1 mm3. The samples were then postfixed in 0.1 M Na-cacodylate 
buffer containing 1% OsO4, dehydrated in an alcohol series and embedded into epon. 
Semithin sections were stained with Toluidin blue and ultrathin sections (50 nm thick) were 
contrasted with uranyl acetate and lead citrate. 
 
6) Behavioral analysis 
 
6.1 Animals  
 
Eighteen months old NEP KO, also termed NEP-/- (n=10) as well as NEP heterozygous 
termed NEP+/- (n=7) and WT littermates (n=8) were subjected to conditioned taste aversion 
(CTA). 
NEP males, kept on a C57BL/6xDBA/2 background (50/50), were mated with J20 female 
kept on a pure C57BL/6 background. We investigated their progeny at two different ages. 
First, 17 WT, 16 NEP, 17 J20 and 13 NEPxJ20 male littermates with similar background 
(75% C57BL/6x 25% DBA/2) were tested in the CTA at 4.5 months of age (19.5 ± 0.2 
weeks). After completion of the CTA, 17 WT, 15 NEP, 17 J20 and 11 NEPxJ20 male mice 
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were then tested at 7 months of age (30 ± 0.2 weeks) in the open field, the elevated zero 
maze, the Morris water maze and the puzzle box tests.  
At 10 months of age (41 weeks), a bigger group of mice of both genders, including the mice 
from the 7 months cohort (31 WT, 28 NEP, 31 J20, 26 NEPxJ20) were analyzed in the light-
dark test. Finally the J20 and NEPxJ20 males of the first group were biochemicaly analyzed. 
NEP (n=15) and WT (n=17) littermates were further analyzed in emergence, object 
exploration, Y maze, rotarod, hot plate and fear conditioning tests.  
Another group of mice were tested at 15 months of age, balanced for gender and formed by 
16 WT, 15 NEP, 16 J20 and 14 NEPxJ20, were analyzed in the open field, the elevated zero 
maze, the Morris water maze, emergence and object exploration, hot plate and puzzle box 
tests. The mice were sequentially analyzed in two sets, which were balanced for the genotype. 
Data were pooled, as no statistically significant differences were found between sets. 
During the experimental period, animals were single-housed in standard mouse cages and 
kept under an inverted 12 h light/dark cycle. Standard mouse food, water and nesting material 
were available ad libitum. Thirty min before each test session, the mice were transferred to 
the behavioral room and dry surfaces of apparatus were thoroughly cleaned with 70% ethanol 
before releasing the animal. Animal experiments and husbandry were performed in 
compliance with national guidelines. 
 
6.2 Exploratory behavior and anxiety 
 
6.2.1 Open field test 
The round open-field arena had a diameter of 150 cm, a smooth white plastic floor and 35 cm 
high side walls made of white polypropylene. Illumination was done by indirect diffuse room 
light (four 40 W bulbs, 12 lux). Each subject was released near the side wall and observed for 
10 min. The same procedure was repeated the following day, resulting in a total observation 
time of 20 min, partitioned into 4 bins of 5 min for time course analysis. Paths were tracked 
and the arena was divided into an outer zone (within 7 cm of the wall), an inner zone (inner 
circle with a diameter of 110 cm), and an intermediate zone (Fig. 9A). 
Locomotor activity was assessed by measuring the total distance travelled and the total 
number of zone transitions. Thigmotaxis, defined as moving along the wall, was quantified by 
measuring the time spent in the outer zone. To determine measures of anxiety and exploratory 
behavior, the following parameters were assessed: number of visits to the inner zone, average 
distance to inner zone, and the number of activity state changes. Three activity states were 
distinguished: progression (periods with a locomotion speed above the progression threshold 
of 0.085 m/s and a minimal distance moved exceeding 0.05 m), resting (periods lasting at 
least 2 s with a speed below 0.025 m/s) and lingering (periods meeting neither resting nor 
progression criteria). 
 
6.2.2 Emergence test 
Frames of nonreflective aluminum (37 cm high) were used to partition the earlier described 
open field into four square 50x50 cm arenas, allowing concurrent observation of 4 animals. 
Each arena had a 12x8x4 cm plastic home box with an opening of 8x4 cm2, positioned in a 
corner at 5 cm from the nearest walls, with the opening facing away from the wall (Fig. 9B). 
24 h prior to testing, a thoroughly cleaned home box was placed in the home cage of each test 
subject. The next day, test subjects and home boxes were introduced into the arenas and 
observed for 30 min. For time course analysis, this period was partitioned into 3 bins of 10 
  
69
min. The definitions of the three zones were a home zone of 18x22 cm2 surrounding the home 
box and extended to the nearest portions of the sidewall, a 5 cm wide wall zone extending 
along the rest of the sidewalls and the center of the arena as exploration zone. Motion state, 
exploration index were calculated as in the open field test.  
 
 
 
Figure 9. Representation of open field (A) and emergence test (B) arena. Levels of spontaneous locomotor 
activity, anxiety-like behavior and exploration were assessed by recording the mouse activity state and time 
spend in the different zones. 
 
6.2.3 Object exploration 
Arenas were the same as for the emergence test, but without the home box. The novel object 
was a 12x4 cm semitransparent 50 ml Falcon tube positioned vertically in the center of the 
arena. Each subject was observed for 30 min in the empty arena. The novel object was then 
introduced, and observation continued for another 30 min. For time course analysis, total 
observation time was partitioned into 6 bins of 10 min. The same measures were calculated as 
in the emergence test, with three concentric zones defined as follows: a 5 cm wide wall zone, 
a circular exploration zone of 16 cm diameter around the arena center where the object was 
introduced, and a transition zone in between. For relevant measures, we extracted object 
related components by extrapolating object unrelated components from the surrounding 
transition zone and subtracting them from the raw values measured in the exploration zone. 
This method brought corrected measures close to zero in absence of the object. 
 
6.2.4 Light-dark (L/D) test 
Mice were placed into the 30x20 cm area of a Perspex L–D box that was illuminated with an 
average of 700 lux. A dark compartment of 15x20 cm was attached opposite to the releasing 
site with an opening facing the center of the illuminated area (Fig. 10A). Movements were 
tracked in the illuminated area over a 5-min trial. Anxiety was measured by the latency to 
enter and the time spent in the dark compartment. Exploration was defined by the number of 
rearings in the illuminated part, and the percentage of visited tiles/total of 36 tiles (5x3.3 cm) 
entered with all four paws. 
 
 
150 cm
exploration zone
intermediate zone
home zone
Open fied arena
A B
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6.2.5 Elevated zero maze 
The zero maze consisted of a gray plastic annular runway of 5.5 cm width with an outer 
diameter of 46 cm located 40 cm above ground level. Two opposing 90 °C sectors were 
protected by inner and outer walls of gray polyvinyl-chloride (10 or 16 cm high) (Fig. 10B). 
Animals were released in one of the protected sectors and observed for 10 min. For time 
course analysis, this time was partitioned into two bins of 5 min. To complement video 
tracking, head dipping movements were recorded using the keyboard event-recorder function 
of the tracking system. Motion states were defined as in the other tests with progression 
thresholds adapted to the more strongly confined movements: speed threshold 4 cm/s, 
distance threshold 3 cm, deceleration threshold 8 cm/s. Three zones were defined as follows: 
a transition zone comprising four 30° segments at the ends of the protection walls separated 
by the two 50° wide protected and the two 70° wide unprotected exploration zones. With 
these boundaries, the system detected entries to the unprotected sector only when the animal 
moved into it with all four paws. Head dips that occurred while the animal was registered to 
the transition zone with all or part of its body between the protection walls were classified as 
protected dips, all others as unprotected dips.  
 
Figure 10. Apparatus of the light-dark (A) and O-maze (B) tests.  Based on the natural preference of the 
mice for dark protected areas, the anxiety state of the mice was determined by the time spent in protected versus 
unprotected areas. 
 
6.3 Learning and memory behavior 
 
6.3.1 Conditioned taste aversion test 
Water-deprived mice were housed in single cages and allowed access to water only two times 
a day: for 20 min in the morning and for 10 min in the afternoon, with a 4 h interval between 
sessions on 4 consecutive days. The fluid intake was determined by weighing the tubes before 
and after the tests. On the conditioning day, water in the morning session was replaced by a 
0.5% saccharin (saccharin sodium salt hydrate; Fluka Chemie, Buchs, Switzerland) solution 
which acted as the conditioned stimulus. Forty min after drinking the saccharin solution, the 
mice were injected ip with a nausea-inducing solution (0.14 M LiCl solution, 2 % body 
weight) as the unconditioned stimulus (Fig. 11). The initial consumption of saccharin was 
defined as the amount of saccharin drank during the conditioning day divided by the mouse 
weight. 48 h after conditioning, the degree of conditioned aversion was determined in the first 
A B
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choice test. The mice were simultaneously presented with two bottles and allowed to drink for 
20 min. One bottle contained a 0.5% saccharin solution and the other contained water. The 
aversion coefficient was defined as the amount of saccharin consumption divided by the total 
fluid intake. To test the degree of CTA extinction, six to seven choice tests, distributed over a 
period of 30 days, were initially carried out. For the analysis of the NEP deficient mice, 
forced extinctions were further performed during the 34th and the 42nd day of the test and 
choice tests on day 35, 43 and 44. Finally, to test for possible changes of an unconditioned, 
intrinsic aversion, the mice were given a choice to drink either a bitter tasting quinine (Fluka 
Chemie, Buchs, Switzerland) solution (0.02%) or water. 
 
 
Figure 11. Conditioned taste aversion procedure. On the conditioning day, water-deprived mice were allowed 
to drink a saccharin solution before injection of LiCl, a nausea-inducing agent. Two days later, the first choice 
test between saccharin and water solution took place and the percentage of saccharin consumption calculated.  
  
6.3.2 Morris water maze 
Spatial learning and memory were assessed in a Morris water maze task [482] adapted for 
mice. In brief, the testing was done under 12 lux diffuse light in a circular arena made of 
white polypropylene (diameter 150 cm, wall height 50 cm), filled with water (made opaque 
by the addition of milk) to a height of 16 cm and maintained at 24–26 °C (Fig. 12). Extra-
maze visual cues around the room remained in fixed positions throughout the experiment and 
a 14 × 14 cm target platform of white wire mesh was placed 0.5 cm below the water surface 
in the NW, NE, SE or SW quadrant at 35 cm from the wall. Each mouse was first trained for 
2 days with 6 trials per day to find a visible platform located at different positions for each 
trial (12 trials, 120 s for each). Then, the platform was hidden at a constant position for 4 days 
with 6 trials per day separated by 30 to 60 min intervals and lasting maximally 120 s. This 
acquisition phase was followed by a probe trial of 60 s where the platform was removed and 
the spatial retention of the mice was assessed.  
Swimming animals were tracked using a Noldus EthoVision 3.0 video-tracking system 
(www.noldus.com) at 576 × 768 pixel spatial resolution and 4.167 Hz sampling frequency. 
Raw XY coordinates were transferred to custom-developed public domain software Wintrack 
[483] (www.dpwolfer.ch/wintrack) for further analysis. The trials were averaged in blocks of 
two trials and different measures were calculated to assess acquisition and spatial selectivity 
including escape latency, percentage of time in the goal or opposite quadrant and proximity to 
the platform. 
 
 
Figure 12: Morris water maze arena. The mice are 
inserted in the water maze at different positions (red dots) 
and use external visual clues to find a visible or hidden 
platform (scare). Latencies of the mice to reach the platform 
and their ability to remember the platform position allow 
investigation of the mouse spatial learning and memory. 
X
water
deprivation
saccharin
solution
LiCl choice
test ?      ?
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6.3.3 Puzzle box 
This paradigm is adapted from a burrowing task developed in rats [484]. The apparatus is a 
73 cm long, 28 cm wide and 27.5 cm high box, divided by a removable barrier into a small 
dark goal box (14 cm long) containing sawdust and cardboard shapes and a large brightly lit 
(1,000 lux by two spot lamps) start box (58 cm long). There is a 4 cm wide, 2 cm deep and 15 
cm long underpass in the centre of the barrier (Fig. 13). The mice were tested during 3 
consecutive days for their ability to enter in the dark protected area through an open door or 
an underpass (training session), the same entrance blocked by either sawdust (burrowing 
puzzle) or a T-shaped cardboard plug (plug puzzle). The mice performed 3 trials per day with 
an intertrial interval of about 1 min. For each trial, the mouse was placed in the start box 
facing the wall opposite to the goal box and the latencies to enter the protected area was 
measured with a maximum of 3 min. Mice were allowed about 20 s in the goal box and 
moved to their home cage. During the first day, the mice were trained to enter the goal box 
through an open door (trial one) then through an underpass (trial 2 and 3). During the second 
day, the underpass giving access to the goal box was accessible during the first trial and filled 
with sawdust during the second and third trial. On day three, the goal box was accessible 
through the underpass for the first trial and blocked by a 2 g cardboard object during the 
second and third trial. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Puzzle box apparatus. (A) Schematic 
drawing showing its dimensions seen from top and in a 
vertical cross section at the burrow. (B) Different 
barriers can be inserted in order to change the entry 
demands. The course procedure uses a barrier with door 
(left) for the first adaptation trial and a full barrier 
without door to force mouse through underpass of box 
during subsequent training trials. 
 
 
6.3.4 Y-maze 
To determine spontaneous alternation behavior (measure of spatial working memory), the 
mice were tested in a Y-maze with 40 cm long, 10 cm wide and 20 cm high arms (Fig. 14). 
Each mouse received one trial during which it was placed at the end of one of the three arms 
and allowed to explore the maze for 5 min. Alternations and total numbers of arm entries 
were recorded. Spontaneous alternation, expressed as percentage, refers to the ratio of arm 
choices differing from the previous two choices, to the total number of arm entries. Arm entry 
was considered to be completed when the hind paws of the mouse had been completely 
placed in the arm. 
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Figure 14. Y-maze paradigm. To test spontaneous alternation 
behavior, mice were placed at the end of one of the three arms and 
allowed to explore the maze for 5 min. Alternation was recorded. 
 
 
 
 
 
6.3.5 Eight arm radial maze 
10 WT and 12 NEP mice of the 7 months cohort were tested in this working memory 
paradigm. The maze, consisting of 8 arms of grey poly-vinyl chloride (7x38 cm) with clear 
Perspex sidewalls (5 cm high) extended from an octagonal centre platform (diameter 18.5 cm, 
distance platform centre to end of arm 47 cm), was placed 38 cm above the floor (Fig. 15) in 
a dimly lit room (four 40W bulbs, 12 lux) rich in extramaze cues. Small cereal pellets (ca. 6 
mg) were placed as baits in small metal cups (diameter 3 cm, 1 cm deep) located at the end of 
the arms, such that the mouse could not see them without completely entering the arm. A 
reversed box of clear Perspex served to confine the mouse on the centre platform before each 
test session. The body weight of the mice was gradually reduced to and maintained at 85% of 
their free-feeding body weight by allowing them to eat a premeasured amount of chow each 
day. Water was available at libidum. Mice began with two habituation sessions during which 
they were accustomed to collecting pellets that were distributed all over the maze. For each 
training trial, all arms were baited with a single pellet. For 10 days each mouse performed one 
trial per day lasting maximally 10 min or until the animal had collected all pellets. The ability 
of the mice to remember which pellets they have already removed is quantified by counting 
the number of pellets they remove during their first 8 choices and the number of reentry 
errors. 
 
 
 
 
 
 
 
 
 
 
Figure 15. Eight arm radial maze. Each arm is 
baited with a single food pellet. Mice are inserted in 
the middle and allowed to visit the arms. The working 
memory of the mice is determined based on their 
ability to remember the arms already visited and to 
remove the food pellets in the most efficient way.  
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6.3.6 Fear conditioning test 
The conditioning chamber consisted of a gray opaque box (16.5x25 cm) with a grid floor 
through which electric shocks could be delivered (0.15 mA) as the unconditioned stimulus 
(US). The chamber was placed into a dimly lit sound-attenuating box with a speaker on top 
delivering a 92 dB/2,000 Hz tone as the conditioned stimulus (CS). To quantify freezing as 
the conditioned reaction, a grid of photobeams (1x1 cm) detected the inactivity of the mice, 
which was defined as no photobeam breaks for at least 2 s. During the conditioning session, a 
1 min adaptation period in the box was followed by three identical conditioning trials, each 
trial consisting of 30 s CS presentation, with the US being applied during the last 2 s of the 
CS, separated by an intertrial interval of 30 s. 24 h after the conditioning session, retrieval 
tests for context conditioning and, 2 h later, for conditioning to tone were carried out by 
recording freezing as mentioned above. To evaluate context conditioning, mice were placed 
for 2 min in the conditioning chamber. To evaluate conditioning to tone, the physical 
characteristics of the chamber were changed (shape, light, smell, and bedding material). Each 
mouse was then placed for 2 min into this new chamber, and the CS was presented (Fig. 16). 
 
 
Figure 16. Schematic representation of the fear conditioning protocol. (A) During conditioning, a 60 s 
adaptation period was followed by three conditioning trials consisting of 30 s shock with the tone being applied 
during the last 2 s, separated by 30 s intertrial intervals of 30 s. Freezing time was used to evaluate the fear 
conditioning. (B) The next day, conditioning to context was assessed by bringing the mouse in the conditioning 
chamber. Tone conditioning was performed in a totally different and the tone presented.  
 
6.4. Motor and sensory function 
 
6.4.1 Rotarod 
The accelerating rotarod 7650 (Ugo-Basile) for mice was used. Five subjects were tested 
concurrently and placed on the rotating drum at a baseline speed of 4 rpm (Fig. 17). During 
the 5 min observation period speed increased linearly to 40 rpm. Mice were given 5 trials 
with an intertrial interval of 30 min. To distinguish dyscoordination and fatigue, mice were 
also given 5 trials of 5 min with the drum rotating at a constant low speed permitting all mice 
to maintain their balance. 
 
 
B: Context + tone testing (24 h after conditioning)
Context conditioning (120 s) Altered context
(60 s)
Tone conditioning
(60 s tone)
2 h
A: Conditioning (4min) US (2 s) US (2 s) US (2 s)
CS (30 s) CS (30 s)CS (30 s)ITI (30s) ITI (30 s)ITI (30 s)baseline (60s)
ITI = Inter trial interval
US: Unconditioned stimulus = shock
CS: conditioned stimulus = tone
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Figure 17. The accelerating rotarod. The 
mice are placed on a rotating drum at the 
lowest speed. The rod is then switched to 
acceleration mode and the time on the rod 
is recorded for 5 min maximum. 
 
 
6.4.2 Hotplate 
The animals were placed in a transparent cylinder of 20 cm diameter and 30 cm hight, on a 
hot plate, equilibrated at 52 °C 30 min before testing (Fig. 18). The latency of the first 
appearance of signs of discomfort (lifting and licking a paw, hopping, or jumping) was 
recorded and terminated the trial.  
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Hotplate. The mouse is placed on a 52°C plate and the 
latency for the first appearance of signs of discomfort is recorded. 
 
 
6.5 Video tracking 
 
During exploration tests, animals were video-tracked with an electronic imaging system 
(EthoVision 3.0, Noldus Information Technology) at a frequency of 4.2 Hz and a spatial 
resolution of 256x256 pixels. For each sample, the system recorded xy positions, object area, 
and the status of defined event recorder keys on the keyboard. Raw data were then transferred 
to public domain software Wintrack 2.4 for further analysis, www.dpwolfer.ch/wintrack 
[483].  
 
7) Statistical analysis 
 
Student’s t-tests were performed comparing in vitro effect of Aβ on luciferase activity 
triggered by neprilysin promoters. 
Other biochemical data were analyzed by non-parametric Mann-Whitney U tests when only 
comparing two groups or one way ANOVA.  
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Behavioral data were collected by investigators unaware of the genotype of the mice and 
between-group comparisons were analyzed using a one way analysis of variance (ANOVA) 
or a two way ANOVA and repeated measures with time or observation included as a within-
subject factor when appropriate. Computations were done using Statview 5.0 
(www.statview.com). Significant main effects of genotype were further analyzed post hoc 
with Games/Howell test for the CTA and Fisher’s PLSD for the others. Significance of 
correlations was determined using Fisher’s r to z test. A p-value of <0.05 was considered as 
being significant and data are presented in all graphs as means ± standard error. 
 
  
77
III) RESULTS 
 
1) Consequences of neprilysin deficiency in mice  
 
1.1 AD-like amyloidosis in NEP deficient mice 
 
We determined at an age of 18 months, the brain levels of murine Aβ of mice with targeted 
deletion of one (NEP+/-) or both NEP alleles (NEP-/-) and compared them to the 
corresponding levels of the WT littermates. A dose dependent neprilysin enzymatic activity 
was first confirmed in NEP deficient mice for both or one NEP alleles compared to WT 
littermates (Fig. 1A). The addition of a neprilysin inhibitor, thiorphan, allowed the 
determination of specific neprilysin activity. Neprilysin activity was significantly reduced by 
thiorphan in WT and NEP+/- mice brains (p=0.004 and p=0.007, respectively) but did not 
change in NEP-/- mice brains confirming that no active neprilysin was present in the brain of 
NEP-/- mice (Fig. 1A). 
As a consequence of decreased neprilysin activity, quantification of total brain murine Aβ 
levels showed a significant two fold increase in the NEP+/- and NEP-/- mice when compared 
to their age-matched WT littermates, with similar levels between NEP-/- and NEP+/- mice (1-
way ANOVA genotype p<0.0004; NEP-/- versus WT p<0.0005, NEP+/- versus WT 
p<0.0044, NEP-/- versus NEP+/- ns) (Fig.1B). 
We next analyzed whether high levels of Aβ in the NEP deficient brains may be caused by 
the presence of higher levels of APP protein. Western blotting with an antibody recognizing 
murine APP revealed no changes in the amount of full length APP in frontal brains of the 
NEP deficient mice (Fig. 1C). 
To further investigate if increase of murine Aβ levels could lead to plaque formation, one of 
histological AD hallmark, brain paraffin sections were stained with the anti-murine Aβ 
antibody 4G8. At 18 months of age, numerous amyloid-like deposits were found in the 
hippocampus of all NEP mutant mice (Fig. 1E,F, G, arrows) whereas these deposits were 
found in much lesser numbers only in some of the WT littermates (Fig. 1D). Further 
investigation by electron microscopy confirmed the presence of electron dense deposits (Fig. 
2A, circled) surrounded by a membrane in enlarged nerve fibers of aged NEP-/- mice but not 
in aged-matched WT littermates. 
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High resolution electron microscopy revealed the fibrillar structure of these amyloid-like 
fibrillar deposits. Careful examination of 25 such fibrils revealed an average diameter of 10-
12 nm and a length of approximately 100 nm (Fig. 2B, 2C, arrows). Moreover, loosely 
compacted degenerating myelin sheets (Fig. 2A, D, open arrows) were present in both close 
vicinity to electron dense deposits (Fig. 2A, circled) and in no obvious proximity to such 
deposits (Fig. 2D) in hippocampi of the aged NEP-/- mice. Taken together, these data indicate 
that insufficient NEP expression can lead to biochemical and morphological alterations 
reminiscent of AD-amyloidosis in mice. 
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Figure 1. NEP depletion caused AD-like amyloidosis. (A) Neprilysin enzymatic assay with or without the 
specific inhibitor of neprilysin, thiorphan confirmed the absence of neprilysin activity in NEP-/- mice and the 
dose dependent activity in NEP+/- and WT mice. (B) Total brain murine Aβ levels were significantly increased 
in NEP+/- and NEP-/- compared to their WT littermates. (C) Western blot analysis of frontal brain showed no 
alteration of full length APP protein levels in NEP deficient mice compared to their WT controls. β-actin was 
used as a loading control. Numerous deposits recognized by the murine Aβ specific antibody 4G8 (arrows) were 
found in hippocampus of aged NEP+/- (E) and NEP-/- mice (F) whereas these immunoreactive structures were 
only occasionally found in the WT mice (D). 
 
 
Figure 2. Electron microscopy analysis (A) Transmission electron microscopy of brains of aged NEP-/- mice 
revealed the presence of electron dense deposits (circled by dashed line) within enlarged axons. (B, C) At higher 
WT NEP-/-NEP+/-
D E F
G
0.5 µm 100 nm
25 nm 1 µm
A B
C D
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magnifications these deposits exhibited a fibril like structure with an average diameter of 10-12 nm and a length 
of approximately 100 nm (black arrows). (D) Un-compacted, degenerating myelin sheets (arrow heads, also in 
A) were found in hippocampi of NEP-/- mice on electron microscopy level.  
 
1.2 Learning impairment of NEP deficient mice in CTA  
 
The three groups (10 NEP-/-, 7 NEP+/-, 8 WT, age 93.8 ± 0.8 weeks) were analyzed for their 
associative memory in the conditioned taste aversion test. NEP-/- and NEP+/- mice did not 
significantly differ from their WT littermates in body weight (Fig. 3B) and amount of water 
consumed during adaptation (p=0.80 and 0.88), respectively. However, NEP-/- mice drank 
slightly but not significantly more of the saccharin solution during conditioning than WT 
mice with the data of the NEP+/- mice lying in between (p=0.078). Mice of all three 
genotypes drank similar amount of saccharin during the conditioning day and developed a 
strong aversion against saccharin after a single conditioning trial. The memory of the aversive 
taste was measured up to 44 days following the saccharin-LiCl pairing (Fig. 3A). All mice 
avoided saccharin without extinction across the repeated choice sessions and retained 
constant aversion to saccharin for at least 29 days. The average saccharin intake during the 
first choice tests and at day 8 and 9 was significantly higher in both NEP+/- and NEP-/- mice 
compared to WT littermates (2-way ANOVA: genotype p<0.0469, day ns, interaction ns; -/- 
versus WT p<0.0457, +/- versus WT p<0.0223; -/- versus +/- ns) indicating that NEP+/- and 
NEP-/- mice were impaired in taste aversion. A subset of animals (6 NEP-/-, 6 NEP+/-, 3 
WT) performed further choice tests after two forced extinction trials with only saccharin 
available at days 34 and 42 for 2 h. The aversion against saccharin was significantly weaker 
in NEP-/- and NEP+/- mice than in WT littermates during the following repeated choice tests 
(genotype p<0.0231; post-hoc Games/Howell) with no difference between the NEP+/- and 
the NEP-/- mice (Fig. 3A). In contrast to the conditioned aversion, all groups showed similar 
spontaneous quinine aversion (p=0.937) (Fig. 3C), suggesting that taste sensitivity was not 
altered. 
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Figure 3. Aged NEP deficient mice showed impaired learning in the CTA. (A) Percentage of saccharin 
consumption is depicted for 9 choice tests over a 44 days period. All animals acquired a strong conditioned taste 
aversion but NEP+/- and NEP-/- mice drank significantly more saccharin during the first choice test compared to 
their WT littermates and present a significant learning deficit. Memory was not affected by the genotype prior to 
forced extinction (arrows) but NEP deficient mice presented a significant decreased aversion against saccharin 
compared to WT littermates after forced extinction. (B) The body weight of the mice was similar between the 
three groups. (C) No genotype effect was observed in avoidance of a bitter tasting quinine solution. (D) Hot 
plate analysis showed similar pain sensistivity for all three groups. Values are ± SEM. 
 
 
2) Determination of an in vitro model to reproduce and investigate the 
pathway(s) involved in the Aβ-related increase of neprilysin transcription 
in vivo 
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2.1 Determination of the Aβ1-42 incubation time and concentration required 
 
Because of high neprilysin expression in kidney, the role of Aβ1-42 in neprilysin transcription 
was first investigated in human embryonic kidney 293T cells. 
After transfection for 5 h with plasmid expressing firefly luciferase under the control of one 
of the three neprilysin promoters PN1, PN2 and PN3, the transcriptional activity of the three 
promoters and their regulation by different incubation time with 5 µM aggregated Aβ1-42 or 
PBS were analyzed (Fig. 4). All three promoters were activate and produced luciferase 
proteins as early as 17 hours after transfection (5 hours of transfection followed by 12 hours 
incubation with fresh medium containing Aβ1-42). Luciferase activity constantly increased 
during the first 48 h of incubation (Fig. 4) and the increase of luciferase activity under the 
control of the PN2 promoter still doubled between 48 and 72 h (not shown), suggesting a high 
stability of luciferase and a slower degradation than production of luciferase. Once 
normalized with the protein concentration of the lysed cells, PN2 promoter presented the 
highest level of activation followed by the PN3 and PN1 promoters. A significant 25% 
increase of luciferase activity under the control of the PN3 promoter was found after 24 h of 
Aβ1-42 incubation (t-test, p=0.0144) and activity of the PN1 promoter was 38% increased after 
48 h of Aβ1-42 incubation (t-test, p=0.0009). However, 48 h incubation led to overgrowth of 
the 293T cells and to a potential toxicity of the medium.  
 
Figure 4. Time point analysis of neprilysin promoters activity after Aβ incubation. 293T cells, transfected 
with plasmid expressing firefly luciferase under the control of one of the three promoters of neprilysin, PN1, 
PN2 and PN3, were incubated with 5 µM aggregated Aβ1-42 during 12, 24 and 48 h. Luciferase activity was 
normalized with the protein concentration of the cell lysate. Luciferase activity driven by the promoter PN3 and 
PN1 was significantly increased after 24 h and 48 h Aβ incubation, respectively. *: p≤0.05, ***: p≤0.0001. 
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To determine the best incubation time and concentration of Aβ1-42, a time course analysis was 
further performed on the promoter PN2 activity with PBS, 5 µM or 15 µM of aggregated Aβ1-
42 during 12, 24 or 38 h incubation time (Fig. 5A). Incubation during 24 h with 15 µM Aβ1-42 
induced a significant 50% increase luciferase activity (t-test, p=0.0003), while other time 
points and concentration did not significantly change the promoter activity (p≥0.1). Such 
incubation with 15 µM aggregated Aβ1-42 (Fig. 5C) did not modify the trypan blue staining of 
the cells compared to cells treated with same amount of PBS (Fig. 5B), suggesting the 
absence of obvious cytotoxicity after 24 h. Incubation with 15 µM Aβ1-42 during 24 h 
appeared to be the best parameters in our model. 
 
Figure 5. Time point and Aβ1-42 concentration determination. (A) 24 h of incubation with 15 µM Aβ1-42 
significantly increased luciferase activity and therefore the activation of the neprilysin promoter PN2. ***: 
p≤0.0001. Trypan blue staining of 293T cells transfected with PN2 and incubated with either PBS (B) or 15 µM 
Aβ1-42 (C) for 24 h did not show signs of cytotoxicity. 
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2.2 Aβ1-42 did not regulate neprilysin expression in HEK 293T cells  
 
The effect of 15 µM Aβ1-42 on the activation of PN1, 2 and 3 was investigated in 293T cells. 
However, the results were not constantly reproducible (Fig. 6). Two experiments testing the 
effect of 24 h incubation with 15 µM Aβ1-42 or PBS on the regulation of neprilysin promoters’ 
activation were done simultaneously using similar material and methods. The first experiment 
showed a significant increase of the luciferase activity and therefore promoter activation for 
all three promoters with 55% (p=0.016), 43% (p=0.003) and 60% (p=0.0005) increases for 
PN1, PN2 and PN3-related activity, respectively (Fig. 6A). This Aβ1-42-related increase of 
neprilysin promoter activation was not reproduced in the second experiment (Fig. 6B).  
 
 
Figure 6. Inconsistency in Aβ-related increase of neprilysin promoter activation. Two experiments were 
performed at the same time and show a significant (A) and a non-significant (B) effect of 24 h incubation with 
15 µM Aβ1-42 on the activity of the three neprilysin promoters, PN1, PN2 and PN3. *: p≤0.05, **: p≤0.001, ***: 
p≤0.0001. 
 
We further tested the effect of 24 h incubation with 15 µM aggregated Aβ1-42, Aβ42-1 or PBS 
as a control on neprilysin promoter activity. Again, Aβ incubation did not significantly 
increased the activity of any of the promoter (Fig. 7) and even decreased significantly the 
luciferase activity after incubation with 15 µM Aβ42-1 compared to PBS incubation (t-test 
p≤0.0001). 
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Figure 7. Aβ incubation did not increase the activation of any of the three neprilysin promoters. After 
transfection with plasmids expressing luciferase under the control of one of the three neprilysin promoters, PN1, 
PN2 or PN3, 293T cells were incubated during 24 h with PBS, Aβ1-42 or Aβ42-1. 24 h incubation with 5 µM and 
15 µM Aβ1-42 did not increase the luciferase activity controlled by any of the three neprilysin promoters. ***: 
p≤0.0001. 
 
To eliminate the potential variability due to transfection efficiency, we used the newly-
released dual luciferase assay system, which allowed the normalization of the firefly 
luciferase activity controlled by the neprilysin promoters with the activity produced by 
another plasmid transfected at the same time which expressed the renilla luciferase. The 
efficiency of the new kit was tested and showed that the luciferase activity detected was lower 
than the original luciferase assay kit. However, because of specific buffers used in the dual 
luciferase assay system, the renilla luciferase activity did not cross-react with the firefly 
luciferase activity and allowed a more accurate normalization of the results than protein 
concentration. 24 h incubation with 15 µM Aβ1-42 on 293T cells did not increase neprilysin 
promoter activation when the new kit was employed (Fig. 8). 
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Figure 8. Absence of Aβ effect on neprilysin promoter activation in 293T cells. After 24 h incubation, The 
new dual luciferase assay system was used to investigate the effect of Aβ1-42 on the activation of the neprilysin 
promoters PN1, PN2 and PN3, which control the expression of firefly luciferase. Firefly luciferase activity was 
normalized by renilla luciferase activity and Aβ did not modify the activation of any of the three neprilysin 
promoter.  
 
2.3 Aβ1-42 did not regulate neprilysin expression in undifferentiated SH-SY5Y 
cells 
 
Brain injection of Aβ1-42 increased neprilysin protein levels in neurons as determined by 
immunohistochemistry approach [406], suggesting that the observed increase of transcription 
may be mainly present in neurons. Therefore, we tested whether Aβ could affect neprilysin 
expression in SH-SY5Y cells which can be differentiated into neurons. 
SH-SY5Y cells transfected with a plasmid expressing firefly luciferase under the control of 
any of the three neprilysin promoters showed a much lower level of luciferase activity 
compared to 293T cells. These low levels of luciferase activity were not detectable with the 
dual luciferase reporter assay system. 
24 h incubation with 15 µM Aβ1-42 did not alter the luciferase activity produced by the 
activation of the three neprilysin promoters (Fig. 9). Undifferentiated SH-SY5Y cells did not 
reproduce the Aβ1-42-related increase of neprilysin transcription observed in vivo. 
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Figure 9. Effect of Aβ1-42 on neprilysin promoters’ activity in SH-SY5Y cells. After transfection with a 
plasmid expressing firefly luciferase under the control of one of the three neprilysin promoters, PN1, PN2 and 
PN3, 24 h incubation with Aβ1-42 did not increase neprilysin promoters’ activity in undifferentiated SH-SY5Y 
cells. 
 
2.4 Differentiation of the SH-SY5Y cells induced increase of neprilysin 
expression 
 
To assess the effect of Aβ1-42 on differentiated SH-SY5Y cells, we first analyzed the effect of 
RA, the first SH-SY5Y differentiating agent, on the activity of the three promoters. Treatment 
with 10 µM RA for 24 and 72 h significantly increased the luciferase activity, indicating an 
increased activation of PN1, PN2 and PN3 promoters by RA. We observed a 6.2, 3.5 and 3.7 
fold increase after 24 h and 23, 16 and 13 fold increase after 72 h when compared to sister 
cultures without RA incubation (all p<0.003) (Fig. 10). The luciferase activity was 
normalized by the protein concentration of the cell lysate. The high increase of luciferase 
activity after RA incubation and the potential related variability between wells caused by 
differentiation of the SH-SY5Y cells within 5 days suggested that this protocol was not 
suitable to study the potential small effect of Aβ1-42 on the neprilysin promoters’ activity. 
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Figure 10. all trans retinoic acid (RA) increased neprilysin promoter activity in SH-SY5Y cells. 24 h and 
72 h incubation with the differentiating agent, RA, induced high increases of the firefly luciferase activity 
controlled by any of the three neprilysin promoters, PN1, PN2 and PN3. **: p≤0.001, ***: p≤0.0001. 
 
2.5 No involvement of a microglia diffusible factor in Aβ1-42 mediated 
neprilysin expression in vitro 
 
To test the involvement of a potential diffusible factor from the microglia, a human microglia 
cell line, MIC cells [476], were incubated with 15 µM Aβ1-42 or PBS for 48h. The medium 
containing the factors secreted by the MIC cells was then removed, diluted twice with pre-
warmed 293T cells medium. On parallel, 293T cells were grown for 48h and their medium 
treated similarly. 293T cells transiently transfected with a plasmid containing one of the 
neprilysin promoter expressing firefly luciferase were then incubated with the 1:1 diluted 
medium of either the treated MIC cells or the 293T cells. No difference in the luciferase 
activity was observed between the 293T cells which received the 293T cell medium and 
medium from the Aβ-treated and untreated MIC cells (Fig. 11). 
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Figure 11. MIC medium from MIC cells treated or not with 15 µM Aβ did not affect neprilysin promoter 
activation in 293T cells. MIC cells were incubated with PBS or 15 µM Aβ1-42 during 48 h and  50% of the 
medium from 293T cells, which were previously transfected with a plasmid expressing luciferase under the 
control of one of the three neprilysin promoter PN1, PN2 and PN3, was replaced by MIC conditioned medium. 
To control for the effect of the MIC medium on neprilysin transcription, the medium from non-treated 293T 
cells was also tested. The medium did not affect the neprilysin promoter activation. 
 
2.6 Aβ1-42 induced increased brain neprilysin protein level 
 
Due to the lack of effect in vitro, a group of aged SweAPP mice was either not injected (n=4) 
or intracranialy injected with 1 µl 350 µM stock concentration fibrillar Aβ1-42 (n=5) or Aβ42-1 
(n=6) to investigate which neprilysin promoter was activated in vivo. 20 weeks after injection, 
brain neprilysin protein and mRNA levels were investigated by Western blot and RT-PCR 
analysis, respectively. Uninjected and Aβ42-1 injected mice exhibited low levels of neprilysin 
protein in brain homogenates (not shown). In contrast, mice injected with Aβ1-42 exhibited a 
marked elevation of neprilysin levels (Fig. 12A), reproducing our previous data [406]. 
 
2.7 No variation of brain neprilysin mRNA 20 weeks after Aβ1-42 injection 
 
To determine if the increase of neprilysin levels observed was associated with increased 
transcription, total mRNA from the same mouse brains was purified, the RNA integrity 
confirmed and neprilysin mRNA levels quantified with specific primers recognizing total 
neprilysin mRNA by RT-PCR. With a normalized abundance of 1.0 ± 0.15, 1.8 ± 0.24 and 
1.0 ± 0.47 for non-injected, Aβ42-1 and Aβ1-42 injected groups, the level of total neprilysin 
mRNA was not significantly changed when comparing the Aβ1-42 injected group to the 
uninjected or the Aβ42-1 injected control groups (Fig. 12B). 
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To further investigate if Aβ injection could specifically act on one of the three major 
neprilysin promoters, RT-PCR on the samples from injected mice was performed using 
specific primers for transcripted but non-coding exon 1, 2 and 3. Similarly, with normalized 
abundance of 1.0 ± 0.48 and 0.61 ± 0.05 for exon 1, 1.0 ± 0.60 and 0.87 ± 0.26 for exon 2 and 
1.0 ± 0.27 and 1.89 ± 0.79 for exon 3, levels of Aβ42-1 and Aβ1-42 neprilysin mRNA were 
similar (Fig. 12C). Therefore, no variation of neprilysin mRNA levels was observed when 
comparing the Aβ1-42 and Aβ42-1 injected group in spite of a clear overexpression of the 
neprilysin protein level. All primers were tested in absence of DNA for potential artifacts due 
to dimerization. No background signal was detected. Primers and quencher sequences were 
also blasted against the entire mouse genome for potential homologies with other murine 
cDNA sequences. Their specificity was confirmed. The specificity of the sequence and lack 
of homology was confirmed by blasting the primer sequences against the mouse genome 
(http://www.ncbi.nlm.nih.gov/genome/seq/MmBlast.html) 
 
 
Figure 12. Brain Aβ1-42 injection increased neprilysin protein levels without altering mRNA levels in aged 
SwAPP mice. (A) Western blot analysis for neprilysin of the brain homogenates, 20 weeks after intracranial Aβ 
injection. Neprilysin levels were increased in mice injected with Aβ1-42 compared to Aβ42-1. (B) RNA prepared 
from frontal mouse brain 20 weeks after Aβ1-42 or Aβ42-1 injection or non-injected was analyzed by semi-
quantitative RT-PCR for expression of neprilysin. The values represent relative mRNA abundance and were 
normalized to β-actin with the mRNA level in the brain of non-injected mice used as reference. Aβ1-42 injection 
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did not affect neprilysin mRNA level when compared to the two other treatments. (C) Use of primers for the 
three non-coding exons specific for the activity of the three neprilysin promoters confirmed that Aβ injection did 
not affect neprilysin mRNA levels. All The abundance of the 3 transcripts in the Aβ42-1 injected group is used as 
reference with a relative mRNA abundance of 1. All values were normalized with relative levels of PBGD 
mRNA and values are ± SEM. 
 
2.8 The specific Aβ1-42-related increase of neprilysin level is not associated with 
difference in levels of important inflammation-related factors 
 
To investigate the potential role of inflammation-related soluble factors involved in the 
increase of neprilysin mRNA and protein levels observed 20 weeks after injection of Aβ1-42 
compared to Aβ42-1 or PBS, brain homogenate from young WT mice which received an 
intracranial injection of Aβ1-42 (n=2) or Aβ42-1 (n=2) and showed an Aβ1-42-specific increase 
of neprilysin mRNA and protein level and increase of uPA activity were analyzed on a mouse 
array. It allowed comparing the effect of the treatment on 24 angiogenesis factors. Positive 
control spots confirmed that the arrays worked correctly, in a similar way through the 4 arrays 
used and allowed normalizing the signal intensity of the spots of interest. Similarly, negative 
control spots and blank spots confirmed that the signals observed for the factors analyzed 
were not artifacts due to unspecific binding of the brain homogenates and antibody solution. 
Two samples per group do not allow statistical analysis but the brain homogenates from mice 
which received intracranial injection of Aβ1-42 treatment and showed 20 weeks later its 
associated increase of neprilysin level and uPA activity contained similar levels of the factors 
analyzed when compared to brain homogenates from mice treated with Aβ42-1 (Fig. 13A). In 
particular signal intensity of IL-1α, IL-1β, IL-6, IFNγ and TNFα, which are all associated 
with inflammation and were linked to neprilysin in vitro [245, 256] were similar. This 
suggests that the Aβ1-42-specific increase of neprilysin mRNA, protein level and increase of 
uPA activity did not involve were the action of one of these factors. 
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Figure 13. The Aβ1-42-specific increase of neprilysin protein level and increase of uPA activity were not 
associated with variation of inflammatory pathways. (A) Mouse array showing no difference in the signal 
intensity for the factors analyzed between mice which received Aβ1-42 or Aβ42-1. White rectangles represented the 
localization of the positive, negative control and blank spots confirming that the array detection system 
functioned and the spots observed were not due to background levels. Beige, red, pink, green and blue rectangles 
represented the localization of the IFNγ, IL-1α, IL-1β, IL-6 and TNFα, respectively. (B) Localization and name 
of the factors analyzed. The colored names are similar to the rectangles used in (A). 
 
 
3) RA as a potential neprilysin transcription activator in vitro 
 
3.1 RA activated neprilysin transcription in 293T cells 
 
The role of RA on neprilysin transcription was further assessed on 293T cells which did not 
show signs of differentiation or decreased proliferation during RA incubation. When 
compared to cells incubated with the RA solvent, DMSO, 24 h incubation with 10 µM RA 
significantly increased the luciferase activity driven by the neprilysin promoters PN1, PN2  
and PN3 to 80% (p<0.0001), 125 (p<0.001) and 155% (p<0.013), respectively (Fig. 14). 
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Figure 14. Effect of all trans retinoic acid (RA) on neprilysin promoter activity in 293T cells. 293T cells 
transiently transfected with a plasmid expressing luciferase under the control of the neprilysin promoter PN1, 
PN2 or PN3 were incubated with RA during 24 h. RA significantly increased the luciferase activity driven by all 
three neprilysin promoters when compared to the control RA solvent. *: p≤0.05, **: p≤0.001. 
 
3.2 Identification of minimal NEP promoter PN1 responsive to RA 
 
To narrow the promoter fragment involved in the RA-related increase of promoter activity 
plasmids expressing the firefly luciferase under the control of PN1 or two fragments of 900 
and 400 base pairs were cotransfected with the control plasmid expressing renilla luciferase 
(Fig. 15A). While 24 h incubation with RA still significantly increased the normalized 
luciferase activity with 40, 24 and 12% increase for PN1, 900 and 400 amino acids promoter 
fragments, renilla luciferase activities were unchanged (Fig. 15B). This suggested that the 
observed RA-related increase of firefly luciferase activity was driven by the neprilysin 
promoter PN1 with the necessary regulatory sequences of the PN1 promoter lying within the 
first 400 nucleotides upstream of the exon 1. The absence of RA effect on renilla luciferase 
activity also suggested that RA incubation did not affect renilla luciferase activity, which can 
be used for normalization. 
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Figure 15. The first upstream 400 base pairs of the PN1 neprilysin promoter are suffisant for the RA-
related increase of neprilysin promoter activity. (A) Representation of PN1 promoter and its deletion 
fragments formed by the 900 and 400 upstream base pairs (B) 24 h RA incubation of 293T cells significantly 
increased firefly luciferase activity driven by the neprilysin promoter PN1 or its 900 and 400 base pairs 
fragments without affecting the renilla activity in transfected 293T cells. *: p≤0.05, **: p≤0.001. 
 
3.3 RA increased neprilysin protein levels in 293T cells 
 
Western blot analysis of 293T cells treated with 10 µM RA or its solvent DMSO for 24 and 
48 h showed an increase of neprilysin protein level after retinoic acid treatment (Fig. 16). 
Because RA incubation could also affect β-actin levels, the samples were normalized with 
their protein concentration. This data suggest that the RA effect observed on neprilysin 
transcription level in 293T cells also leads to increased protein levels in vitro. 
 
Figure 16. RA increased neprilysin protein level in 293T cells. 293T cells were incubated for 24 and 48 h 
with 10 µM RA or its solvent, DMSO. Western blot analysis with the antibody 56C6 recognizing human and 
murine neprilysin showed an increase of neprilysin level after RA incubation. 
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3.4 RA did not upregulate brain neprilysin level in vivo 
 
To investigate the role of RA on neprilysin levels in vivo, WT mice were chronically treated 
with RA or a control treatment. After 5 days treatment with 3 µg RA, 125 µg RA or control 
treatment, brain neprilysin levels were quantified by Western blot analysis. RA did not alter 
the level of neprilysin protein after the single (not shown) or the chronic injection treatments 
(Fig. 17). 
 
 
Figure 17. Chronic treatment (5 days) with all trans retinoic acid (RA) did not increase brain neprilysin 
levels in vivo. Western blot analysis for murine neprilysin showed similar neprilysin protein level independent 
of the treatment. 
 
 
4) Activation of the plasminogen system by Aβ1-42  
 
4.1 Intracranial injection of Aβ1-42 increased brain plasmin activity in vivo 
 
Intracranial injection of Aβ1-42 was found to increase brain neprilysin protein level and 
activity in mice leading to a decrease of Aβ levels and prevention of amyloid plaque 
formation [406]. To investigate if other Aβ-degrading pathways could have also been 
involved, we assessed plasmin activity in the same brain homogenates that have elevated 
neprilysin levels, 12 weeks post injection [406]. The brain homogenates from mice which 
were injected with Aβ1-42 showed a significant 5 ± 0.7 fold increase plasmin activity when 
compared to PBS (1.0 ± 0.3) and Aβ42-1 (1.0 ± 0.3) injected mice (p≤0.001 for both) (Fig. 
18A). 
 
4.2 Aβ1-42–related increased brain plasmin activity in vivo is associated with 
increased uPA activity 
 
control RA (3µg/day) RA (125µg/day)control
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Since plasminogen can be activited into plasmin by two specific plasminogen activators, tPA 
and uPA, their enzymatic activity was investigated in the same brain homogenates from the 
Aβ1-42 and Aβ42-1 injected mice. The injection did not affect the level of tPA activity. 
However, uPA activity was highly increased in brain homogenates of Aβ1-42 injected mice 
compared to Aβ42-1 control mice (Fig. 18B). This specific Aβ1-42-related increase of uPA 
activity was further confirmed in two independent groups of mice 20 weeks after similar 
intracranial injection of PBS, Aβ1-42 or Aβ42-1 (Fig. 22A, B). This suggests that the increase of 
plasmin activity is due to an increased activation of uPA and does not involve tPA. 
 
 
Figure 18. Aβ1-42 activated the plasminogen system in vivo. (A) Plasmin activity was initially measured at 
intervalles of three min. 12 weeks after intracranial injection of Aβ1-42, Aβ42-1 or PBS, Aβ1-42 significantly 
increased brain plasmin activity compared to its controls. Linear curves represent the average values over the 1 h 
period. (B) Zymography of the same samples showed that Aβ1-42-related increase of plasmin activity was 
associated with increased uPA but no variation of tPA activity when compared to Aβ1-42 injected or a non-
injected (WT) mice. Values are average ± SEM. 
 
4.3 Brain localization of uPA activity after Aβ1-42 injection 
 
Mice (n=10) received an intracranial injection of Aβ1-42 and zymography on slide was 
performed 12 weeks post injection on cryostat sections. Since the zymography allows the 
detection of tpA and uPA, the addition into the gel of amiloride, an uPA inhibitor, allowed the 
localization of tPA and by subtraction localization of uPA activity. The activitites of tPA and 
uPA were located in the meningeal cell layer (white arrows) surrounding the brain and in the 
hippocampus. Zymography after the addition of amiloride to the gel layer suggested that uPA 
activity was highly present in the meningeal epithelium cells but also present in the neurons 
of the CA1 region of the hippocampus and the dentate gyrus (black arrows) (Fig. 19A, B).  
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Figure. 19. uPA localization after Aβ1-42 injection. 12 weeks after Aβ1-42 injection, zymography on brain slide 
with (B) or without an uPA inhibitor (A), amiloride, showed uPA activity in the meningeal epithelium located 
around the brain (white arrows) but also CA1 and dentate gyrus of the hippocampus (black arrows). 
 
4.4 Aβ injection did not change mRNA levels of the plasminogen activators 
 
To determine whether Aβ1-42 affected transcription of the plasminogen activators, mRNA 
levels of uPA, its receptor uPAR and tPA were quantified 20 weeks after Aβ1-42 or Aβ42-1 
intracranial injection by RT-PCR in the brain of mice and normalized to β-actin expression 
levels. Aβ injection did not affect the mRNA levels of uPA, uPAR or tPA (Fig. 20). 
Therefore, the Aβ1-42-related increase of uPA activity is not due to increased uPA mRNA 
levels. 
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Figure 20. Aβ1-42 injection did not affect mRNA levels of uPA, uPA receptor and tPA. 20 weeks after 
intracranial injection of Aβ1-42 or Aβ42-1, the relative abundance of brain mRNA levels for uPA, uPA receptor 
(uPAR) and tPA were unchanged. Values are ± SEM and were normalized with the reference gene β-actin. 
 
4.5 UPA deficiency did not alter murine Aβ levels 
 
To investigate in Aβ1-42 injected mice the potential role of increased uPA activity in the 
observed decrease of Aβ levels and subsequent prevention of plaque formation, total murine 
Aβ levels were quantified in the frontal brain area of 9.6 ± 0.25 months old uPA KO mice 
(n=11) and their aged matched WT littermates (n=11, 9.6 ± 0.8 months old) (Fig. 21). 12.8 ± 
2.0 ng/g wet tissue and 13.4 ± 1.2 ng/g wet tissue were found in uPA KO and WT mouse 
brains, respectively, demonstrating that brain total Aβ levels were not affected by uPA 
deficiency. This suggests that uPA is not a rate limiting enzyme in Aβ degradation in vivo. 
 
Figure 21. Total murine Aβ quantification. Frontal brains from 12 months old uPA KO mice (n=11) and WT 
littermates (n=11) showed no difference in the amount of total murine Aβ quantified by ELISA. 
 
0
5
10
15
murine Aβ
ng
/g
 w
et
 ti
ss
ue
 
WT
uPA KO
total murine Aβ
ng
/g
 w
et
 ti
ss
ue
 
  
99
4.6 Neprilysin protein levels and uPA activity correlated after Aβ injection in 
vivo 
 
Intracranial Aβ1-42 injection increased neprilysin protein levels and uPA activity in a similar 
manner. 20 weeks after PBS or Aβ injection, brain neprilysin protein level and uPA activity 
were only increased in the Aβ1-42 injected mice. Furthermore, Aβ1-42 injected mice exhibiting 
a low increase of neprilysin level also displayed lower level of uPA activity (Fig. 22A) and 
samples with high levels of neprilysin exhibited high uPA activity (Fig. 22B). Spearman’s 
correlation analysis between neprilysin protein level and uPA activity in the second group of 
mice injected with Aβ1-42 (n=5) confirmed a significant correlation between both (p=0.037). 
 
 
Figure 22. Correlation between neprilysin protein level and uPA activity induced by Aβ1-42 in vivo. 20 
weeks after Aβ1-42 or Aβ42-1 injection, two independent groups (A) and (B) showed a similar increase of brain 
uPA activity on zymography and neprilysin protein level on Western blot. Aβ1-42 induced increase of neprilysin 
protein level significantly correlated with uPA activity (p=0.037).  
 
4.7 No correlation between Aβ1-42-related increase of uPA activity and 
neprilysin level in vitro 
 
4.7.1 Aβ1-42 activated both plasminogen activators in vitro 
To study the potential link between Aβ1-42-related increase of neprilysin protein level and 
uPA activity observed in vivo, SH-SY5Y and MIC cells were incubated during 2 days with 
PBS or 10 µM of aggregated Aβ1-42 and tPA and uPA activity were further analyzed by 
zymography. Aβ1-42 treatment was associated with an increase of tPA and uPA activity in SH-
SY5Y cells (Fig. 23A) and led to an increase of uPA activity in the MIC cells without 
detection of tPA activity (Fig. 23B).  
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To investigate the specific role of Aβ1-42, SH-SY5Y cells (Fig. 23C) and primary neuronal 
cultures (Fig. 23D, E) were also incubated with PBS, 10 µM of aggregated Aβ1-42 or 
aggregated Aβ42-1 for 2 and 5 days, respectively. Aβ1-42 incubation increased uPA and tPA 
activity in both systems when compared to cultures treated with PBS. However, the uPA and 
tPA activity of the Aβ42-1 treated cells were also increased when compared to PBS treated 
cultures but was lower than Aβ1-42 treated cells. Similarly, an increase of tPA-tPA inhibitor 
complexes was found in both cell systems and increased levels of uPA-uPA inhibitor 
appeared after Aβ incubation in primary neuronal culture (Fig. 23E). These results suggest 
that Aβ1-42 can activate the plasminogen system via a general mechanism present in different 
cell types. However, the effect is not specific to Aβ1-42 and may be due in part to the 
aggregation state of the protein. 
 
 
Figure 23. Aβ activated the plasminogen activators in vitro. SH-SY5Y cells (A, C), MIC cells (B) and 
primary neuronal cultures (D,E) were incubated with 10 µM Aβ1-42, Aβ42-1 or PBS during 2 for the cell lines and 
5 days for the neuronal culture. Aβ1-42 incubation increased cell tPA and uPA activity when compared to PBS 
treated cultures. Aβ42-1 also increased uPA and tPA activity compared to PBS treated cells but with a less extend 
than Aβ1-42. tPA and uPA complexed with inhibitors (PAI) were also increased after Aβ treatment (D,E). 
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4.7.2 Aβ1-42 does not increase neprilysin protein level in vitro 
Effect of Aβ incubation on neprilysin levels was investigated in MIC cells which exhibited a 
high increase of uPA activity but no tPA activity after Aβ1-42 incubation, being therefore a 
potential model to the in vivo specific Aβ1-42-related increase of uPA activity. The effect of 
Aβ on neprilysin level was also investigated in primary neuronal culture, since the increase 
neprilysin protein levels in Aβ1-42 injected mice was localized in neurons [406]. 
Western blot analysis showed no alteration of neprilysin levels after Aβ1-42 and Aβ42-1 
treatment compared to PBS treated MIC cells (Fig. 24A) and primary neuronal culture (Fig. 
24B). β-actin staining was used as a loading control. Therefore, the observed Aβ1-42-related 
increase of uPA or tPA activity in these two cell models did not lead to increase of neprilysin 
protein levels. These in vitro models did not reproduce the effect observed in vivo after 
intracranial Aβ injection. These data either suggest the absence of a direct link between uPA 
activity and neprilysin levels in Aβ injected mice or indicate that these in vitro systems are 
not good models for the in vivo situation. 
 
Figure 24. Aβ incubation did not increase neprilysin protein level in vitro. Western blot analysis showed no 
difference in neprilysin levels after 2 days incubation on MIC cells (A) and 5 days incubation on primary 
neurons (B) with 10 µM Aβ1-42, 10 µM Aβ42-1 or PBS. 
 
4.8 Neprilysin overexpression increased plasminogen activators activity in vivo 
 
To investigate if the Aβ1-42 specific increase of neprilysin protein level and activity could be 
responsible for the observed increase of uPA activity, we analyzed by zymography the 
plasminogen activators’ activity in the cortex and hippocampus of transgenic mice 
overexpressing neprilysin in neurons (NEP mice; n=4) compared to WT littermates (n=4). An 
increase of both tPA and uPA activity was observed in the cortex and hippocampus of the 
transgenic mice overexpressing neprilysin at the age of 18 months when compared to WT 
littermates (Fig. 25). While these data suggest a link between neprilysin overexpression and 
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increase of plasminogen activators activity, the presence of increased tPA activity imply that 
the pathways involved in the NEP mice may be different than the one involved in the brain of 
mice 12 weeks after intracranial injection of Aβ1-42 where only an increase of uPA activity 
was observed. 
 
 
Figure 25. Transgenic neprilysin overexpression increased plasminogen activators activity in the brain. 
Zymography analysis showed an increase of tPA and uPA activity in the cortex and hippocampus (hipp.) of NEP 
mice (n=4) compared to WT littermates (n=4). TPA and uPA were also loaded as positive controls. 
 
 
5) Evaluation of intracranial injection of recombinant adeno-associated 
virus (rAAV) to overexpress neprilysin in vivo 
 
5.1 Intracranial injection of rAAV efficiently transfect neurons 
 
To investigate the efficiency of rAAV to transfect cells in a large area in vivo, 2.5 108 intact 
rAAV particles expressing EGFP under the control of the CMV or the PDGF promoter were 
injected in a volume of 2 µl in the hippocampus and striatum of WT mice. 
One week after injection of rAAV expressing EGFP under the control of the CMV promoter, 
a strong EGFP fluorescence was observed mainly localized in the striatum (green) (Fig. 26A). 
Staining for activated astrocytes with the GFAP antibody (red) showed a lack of 
colocalization with EGFP fluorescence suggesting that the transfected cells were mainly 
neurons. Four weeks after injection of rAAV expressing EGFP under the control of the PDGF 
promoter, EGFP fluorescence was observed in neurons of the dentate gyrus (Fig. 26B) and 
the striatum (not shown). Injection of rAAV led to a localized overexpression of EGFP 
around the injection sites. Therefore, rAAV injection appears to be a good tool for 
hippocampal overexpression of neprilysin. However, the areas of the brain transduced by 
these injections were restricted. 
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Figure 26. EGFP fluorescence in brain cells transfected via intracranial injection of rAAV. Mice were 
injected at the hippocampal and striatum levels with rAAV expressing EGFP under the control of the CMV (A) 
or the PDGF promoter (B) and analyzed one week and one month after, respectively. The lack of EGFP 
fluorescence colocalization with a GFAP staining suggested a neuronal transfection by rAAV.  
 
 
6) Biochemical analysis of NEPxJ20 mice  
 
6.1 Transgenic overexpression of neprilysin in the NEP mice 
 
We have generated 10 transgenic lines of mice expressing human neprilysin in brain neurons 
under the control of the PrP regulatory sequences. Transmission to their progeny was 
confirmed by PCR in 8 lines. Localization of the brain neprilysin overexpression was 
investigated by immunohistochemistry and NEP mice exhibited neuronal staining in different 
areas of the brain including the thalamus, striatum (not shown) and frontal cortex (Fig. 27A). 
Due to inconsistency in the neprilysin staining, comparison of neprilysin levels and selection 
of the best line were achieved by Western blot analysis. All lines tested exhibited significant 
increases of neprilysin protein levels in the cortex, hippocampus, subcortical area and 
cerebellum, compared to WT littermates (Fig. 27B), with line 1 and 5 expressing the higher 
and the lower level of neprilysin, respectively. Line 1, also named NEP, was further analyzed. 
Neprilysin overexpression resulted in a significant 34 ± 1.5 (mean ± SEM) fold increase of 
neprilysin activity (Mann–Whitney U test, p≤0.021) in the frontal brain area of NEP (n=4) 
mice compared to WT controls (n=4) (Fig. 27C). 
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NEP males were further mated with J20 females, overexpressing in neurons the AD-causing 
human mutated APP and their progeny analyzed. Similar high levels of neprilysin protein 
were found in different areas of the brain, including frontal brain, hippocampus, amygdala 
and subcortical areas overexpression in NEPxJ20 mice when compared to J20 mice (Fig. 
27D).  
To determine if the neprilysin overexpression triggered by the PrP promoter led to neprilysin 
overexpression elsewhere than the brain, neprilysin protein levels were also quantified in the 
kidney, heart and liver of NEP mice. Western blot analysis for HA and neprilysin (Fig. 27E) 
confirmed the expression of the construct in these three peripherical organs and showed an 
increase of neprilysin protein levels in NEP mice compared to WT littermates. 
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Figure 27. Characterization of the NEP transgenic mice. (A) Frontal brain area of NEP and WT mice 
showing neprilysin staining in mice overexpressing neprilysin. (B) Western blot analysis of the neprilysin 
transgene in different areas of the brain with the 56C6 antibody showed a high elevation of neprilysin protein 
levels in different neprilysin overexpressing lines. (C) Neprilysin activity analyzed in the frontal brain area of 
NEP mice was 34 ± 1.5 fold higher than in WT littermates (*: p=0.0021; n=4 per group). Values represent the 
mean ± SEM. (D) Similar high neprilysin levels in different brain areas of the NEP transgenic mice (NEP) 
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compared to WT littermates. The membrane was further probed with β-actin antibody as a loading control. Sub. 
Area: subcortical area, Hipp: hippocampus. The protein molecular weights are represented in kilodaltons (kD). 
(E) HA and neprilysin staining confirmed the presence and the increased levels of neprilysin protein in 
peripherical organs of NEP mice compared to WT littermates. 
 
6.2 Neprilysin overexpression decreased Aβ levels without altering the APP 
processing in vivo 
 
To investigate if overexpression of neprilysin would lead to a decrease of Aβ levels without 
alteration of APP processing, NEP mice were crossbred with J20 mice which express the AD-
causing mutated human APP and as a processing product, Aβ. The levels of Aβ, full length 
APP and its CTF were analyzed in different brain areas of NEPxJ20 and NEP mice. Western 
blot analysis showed a decrease of Aβ levels in brain areas including cortex (Fig. 28A, C), 
amygdala (Fig. 28B, C), hippocampus and subcortical areas (Fig. 28C) and no alteration of 
APP levels or its CTF in NEPxJ20 double transgenic as compared to J20 mice (Fig. 28A, B), 
emphasizing that removal of Aβ by a neprilysin-dependent mechanism would not interfere 
with processing and physiological functions of APP. 
The effect of neprilysin overexpression on triton-soluble and SDS-soluble Aβ levels was 
further determined in frontal brains of NEPxJ20 and J20 mice, sequentially extracted with 
triton and SDS containing buffers. Western blot analysis confirmed the decrease of Aβ levels 
in NEPxJ20 mice compared to J20 littermates and the lack of APP processing alteration in 
both fractions (Fig. 29A). 
Overexpression of neprilysin resulted in significant 71% and 72% reductions in brain 
concentrations of triton soluble Aβ42 and Aβ40, respectively (both p<0.001) (Fig. 29B), as 
determined by specific ELISA systems. Similarly, brain levels of SDS soluble Aβ42 and Aβ40 
were also significantly decreased by 72% and 50%, respectively (both p<0.001) (Fig. 29B). 
After extraction of SDS-soluble Aβ, no FA extractable Aβ was detected by ELISA in the 
brain tissue of the J20 and NEPxJ20 mice.  
To analyze the efficiency of neprilysin to prevent the formation of Aβ42 and Aβ40 in the two 
fractions, the ratio Aβ40/Aβ42 of the triton and the SDS fractions was calculated for the 
NEPxJ20 and J20 mice (Fig. 29C). In the triton fraction, NEPxJ20 and J20 mice displayed 
similar ratios Aβ40/Aβ42 with 1.86 ± 0.09 and 1.91 ± 0.06 (mean ± SEM), respectively, 
illustrating the similar degradation of triton-soluble Aβ40 and Aβ42 by neprilysin in NEPxJ20 
mice. In the SDS fraction, the ratio of Aβ40/Aβ42 in J20 mice, with 1.48 ± 0.07 (mean ± 
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SEM), was significantly lower than in the triton fraction (Mann–Whitney U test, p≤0.002) 
suggesting an increased propensity of Aβ42 versus Aβ40 to be present in this fraction. The 
NEPxJ20 mice displayed a ratio of 2.72 ± 0.21 (mean ± SEM) in the SDS fraction, which is 
significantly higher than the J20 mice (Mann–Whitney U test, p≤0.002). This is due to the 
decreased efficiency of neprilysin to prevent the formation of SDS-soluble Aβ40 versus Aβ42. 
 
 
Figure 28. Neuronal neprilysin overexpression decreased brain Aβ levels in the NEPxJ20 mice without 
affecting the APP processing. Western blot analysis of neprilysin, full length APP (flAPP), APP C-terminal 
fragments (CTFα and CTFβ) and Aβ in the cortex (A), the amygdala (B) of NEPxJ20 and J20 mice. While no 
change of full length APP or its CTF were observed in NEPxJ20 mice compared to J20 mice, Aβ levels were 
decreased in NEPxJ20 mice compared to J20 mice. β-actin was used as a loading control and the cortex of a WT 
mouse (WT) shows specificity of the 6E10 antibody recognizing human APP, CTFβ and Aβ. (C) Representative 
Western blot analysis of neprilysin, Aβ and β-actin levels in the cortex, the hippocampus (hipp.), the subcortical 
area (sub. area) and the amygdala of NEPxJ20 and J20 mice. Overexpression of neprilysin led to reduced levels 
of Aβ in all areas.The protein molecular weights are represented in kilodaltons (kD). 
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Figure 29. Neuronal neprilysin overexpression decreased brain Aβ40 and Aβ42 levels in the NEPxJ20 mice 
without affecting the APP processing. (A) Representative Western blot analysis of neprilysin, full length APP 
(flAPP), APP C-terminal fragments (CTF) and Aβ in the sequentially extracted triton and SDS fractions from 
the frontal brain of NEPxJ20 mice compared to J20 littermates. No changes of full length APP or its CTF were 
observed in NEPxJ20 mice compared to J20 mice. In contrast, Aβ levels were reduced in NEPxJ20 mice. (B) 
Triton and SDS soluble Aβ40 and Aβ42 levels were significantly reduced in 9 months old NEPxJ20 mice when 
compared to their J20 littermates. (C) Ratio of the triton soluble and SDS soluble Aβ40/42 in J20 and NEPxJ20 
mice showed similar Aβ ratios in the triton fraction but an increased ratio in the SDS fraction of the NEPxJ20 
mice compared to the J20 mice. In J20 mice, the ratio also significantly decreased in the SDS fraction compared 
to the triton fraction. However, the ratio of the SDS fraction was decreased in J20 mice and increased in 
NEPxJ20 mice compared to their respective triton-soluble Aβ ratios. Values represent the mean ± SEM. (**: 
p<0.01, ***: p<0.001).  
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6.3 Neprilysin overexpression decreased Aβ levels in aged mouse brains 
 
Effects of neprilysin overexpression on Aβ levels and APP processing were confirmed in the 
15 months cohort following behavioral analysis. After sequential extraction of tris soluble 
Aβ, triton soluble Aβ, SDS soluble Aβ and FA soluble Aβ, Western blot analysis confirmed 
the decrease of Aβ levels in tris, triton and SDS fraction of the NEPxJ20 mice compared to 
their control J20 littermates (Fig. 30A). No FA soluble Aβ was detected. 
Semi quantification by Western blot suggested that most of the Aβ was present in the SDS 
and the tris fraction rather than in the triton fraction (Fig. 30B). 
 
 
Figure 30. Neprilysin prevented Aβ formation in 18 months old NEPxJ20 mice. (A) Western blot analysis of 
Aβ levels in sequentially extracted tris, triton and SDS soluble Aβ from frontal brain of NEPxJ20 and J20 mice. 
(B) Western blot comparison of the Aβ levels in the three fractions. 
 
6.4 Absence of amyloid pathology in the J20 mice 
 
Following the behavioral studies, brains were analyzed by an immunohistological approach. 
No amyloid plaques were found in the J20 or the NEPxJ20 mice at 11 and 18 months of age. 
These data are in agreement with the absence of FA soluble Aβ species by ELISA or Western 
blot approaches (not shown). Similarly, the number of activated astrocytes (Fig. 31A) and 
microglia (Fig. 31B) did not differ between all four groups analyzed at the age of 11 months.  
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Figure 31. No difference in gliosis in 11 months old NEP, J20, NEPxJ20 and WT mice. Brain sections 
stained for GFAP (A) and IBA-I (B), antibodies recognizing activated astrocytes and microglia, respectively, 
showed similar pattern of expression in all four groups tested.  
 
6.5 Unchanged levels of substance P, met-enkephalin and somatostatin  
 
To investigate the effect of neprilysin and APP overexpressions on the level of other known 
substrates of neprilysin, substance P, met-enkephalin and somatostatin levels were first 
analyzed in the frontal cortex (9 WT, 8 NEP, 8 J20 and 8 NEPxJ20) and the hippocampus (8 
WT, 7 NEP, 7 J20 and 7 NEPxJ20). Their levels were further investigated in the bigger 
frontal brain area (9 WT, 13 NEP, 22 J20 and 15 NEPxJ20). 
Genotype did not significantly affect the levels of substance P in the frontal cortex (p=0.130), 
hippocampus (p=0.521) and frontal brain areas (p=0.546) (Fig. 32A, B and C). Met-
enkephalin levels were also not affected by genotype in the three areas tested (frontal brain: 
p=0.375, hippocampus: p=0.524, frontal brain: p=0.069) (Fig. 32A, B and C). Similarly, 
levels of somatostatin were not significantly changed in the frontal cortex (p=0.614), 
hippocampus (p=0.429) and frontal brain areas (p=0.374) (Fig. 32A, B and C). 
To assess the role of neprilysin on the levels of these three substrates in other organs, kidney 
and heart from NEP (n=10 and 8, respectively) and WT littermates (n=8 and 10, respectively) 
were also analyzed. Neprilysin levels were increased in these two organs (Fig. 27E). 
Substance P levels were undetectable in both organs and therefore not quantifiable. In the 
kidney, levels of met-enkephalin and somatostatin were not affected by the overexpression of 
neprilysin (met-enkephalin: p=0.657 and somatostatin: p=0.374) (Fig. 32D). In the heart, a 
WT
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similar absence of effect due to neprilysin overexpression was present (met-enkephalin: 
p=0.534 and somatostatin: p=0.248) (Fig.32E). No significant differences in the levels of 
substance P, met-enkephalin and somatostatin were found between the 4 groups in all three 
brain areas and two peripherical organs analyzed, suggesting that Aβ is a better brain 
substrate for neprilysin in vivo and that overexpression of neprilysin is unlikely to interfere 
with the physiological functions of these other neuropeptides. 
 
 
Figure 32. Substance P, met-enkephalin and somatostatin quantification in WT, NEP, J20 and NEPxJ20 
mice. In the frontal cortex (cortex), hippocampus (hipp.) and frontal brain area (frontal), genotype did not affect 
the levels of substance P (A), met-enkephalin (B) and somatostatin (C). In the peripherical organs, kidney and 
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heart, levels of met-enkephalin (D) and somatostatin (E) were similar in NEP mice and WT littermates. In all 
graphs, mean ± SEM are shown. 
 
 
7) Behavioral analysis of NEPxJ20 mice 
 
7.1 Body weight, motor and sensory function 
 
7.1.1 Transgene affected body weight 
NEP and J20 mice of the 7 months and the 15 months cohorts exhibited a decrease of body 
weight which was constantly significant in double transgenic NEPxJ20 mice. At 4.5 months 
of age, the first group of mice composed only of the male progeny (17 WT, 16 NEP, 17 J20 
and 13 NEPxJ20) was weighted on the conditioning day of the CTA. Body weight of the mice 
varied significantly between groups (genotype x body weight p<0.0001; Fig. 33A). WT mice 
(27.8 ± 0.7 g) were significantly heavier than NEP (23.8 ± 0.5 g) and NEPxJ20 mice (23.2 ± 
0.8 g) (p<0.001 for each) while body weight of the J20 mice (25.6 ± 0.5 g) did not 
significantly differ from control littermates (mean ± SEM) (Fig. 33A). 
The females of the second cohort (n=11 for each, age: 15.0 months) were also weighted prior 
to behavioral testing. Genotype also affected body weight (p<0.008) with the WT mice (29.6 
± 0.86 g) being significantly heavier than the J20 (25.5 ± 0.59 g) (p<0.004) and the NEPxJ20 
mice (25.4 ± 0.77 g) (p<0.003). The body weight of the NEP mice (27.5 ± 1.34 g) did not 
significantly differ from any of the groups (Fig. 33B). 
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Figure 33. Weight reduction linked to the transgenes. (A) Body weight of the NEP and NEPxJ20 mice of the 
first analyzed group was significantly smaller at 4.5 months of age. (B) Alteration of body weight was also 
observed in the second group at 15 months of age with significant decrease of the J20 and NEPxJ20 mice body 
weight compared to WT littermates. The values represent the mean ± SEM. **: p<0.01, ***: p<0.001. 
 
7.1.2 Normal motor functions in NEP mice 
To test whether neprilysin expression and the observed decrease of body weight affected 
locomotor coordination, the rotarod paradigm was performed on the male NEP and WT mice 
of the first group (WT: n=14, NEP: n=13, age: 47.0 ± 0.2 weeks). This test did not provide 
any evidence of motor impairment in any of the two groups since average performance and 
learning rates of the two groups were similar (repeated ANOVA: genotype ns, time p<0.0001, 
interaction ns) (Fig. 34A). 
 
7.1.3 No difference in pain sensitivity of NEP mice 
We determined the average latency of the NEP (n=13) and WT (n=14) mice which had also 
performed the fear conditioning test, to react on a 55°C hotplate (age: 47.0 ± 0.2 weeks). We 
did not find any significant difference in the latency of the two groups to lick their paws as 
the sign of discomfort (factorial ANOVA: genotype ns) (Fig. 34B). Similar results were 
obtained when analyzing the 15 months old cohort (16 WT, 15 NEP, 16 J20 and 14 NEPxJ20, 
age: 16.5 months ± 0.2 weeks). The latency of the mice to lick their paws was not affected by 
genotype. 
 
 
Figure 34. NEP mice were indistinguishable from controls with respect to motor coordination and pain 
sensitivity. (A). Average performance and learning rates of the NEP and WT mice from the 7 months old cohort 
on the accelerating Rotarod were indistinguishable. (B) NEP and WT mice showed the same average latency to 
lick their paws when placed on a 55°C hotplate. (C) Similar absence of genotype effect is observed on the 
A 15 months cohort
0
5
10
15
20
25
la
te
nc
y
to
 li
ck
(s
)
genotype
nsla
te
nc
y 
to
 li
ck
 (s
)
0
5
10
15
20
25
30
genotype
ns
tim
e 
to
 fa
ll 
(s
)
5 trials
40
60
80
100
120
140
160
180
200
genotype
ns
7 months cohort7 months cohort
WT
J20
NEP
NEPxJ20
B C
la
te
nc
y
to
 li
ck
(s
)
la
te
nc
y
to
 li
ck
(s
)
la
te
nc
y 
to
 li
ck
 (s
)
la
te
nc
y 
to
 li
ck
 (s
)
la
te
nc
y 
to
 li
ck
 (s
)
tim
e 
to
 fa
ll 
(s
)
tim
e 
to
 fa
ll 
(s
)
tim
e 
to
 fa
ll 
(s
)
  
114
latency to lick their paws in the 15 months old cohort. Values represent the mean ± SEM. ns (not significant) is 
mentioned when p>0.1.  
 
7.2 Exploratory behavior and anxiety 
 
7.2.1 Additive effects on locomotion in open field test 
Levels of spontaneous locomotor activity, anxiety-like behavior and exploration were 
assessed in the open field. Genotype strongly affected the locomotion of the 7 months (17 
WT, 15 NEP, 17 J20, 12 NEPxJ20, age: 7.0 months) and the 15 months cohorts (16 WT, 16 
NEP, 16 J20, 16 NEPxJ20, age: 15.6 months). While J20 mice were clearly hyperactive in 
both cohorts, NEP mice exhibited a lack of habituation associated with increased number of 
lingering and progression states only in the 7 months cohort. Neprilysin overexpression did 
not prevent the deficit of the J20 mice and NEPxJ20 mice presented the impairments present 
in both NEP and J20 mice.  
At 7 months of age, genotype affected both amount and time course of locomotor activity 
(repeated ANOVA: genotype p<0.0001, time p<0.0001, interaction p<0.0010) (Fig. 35A). 
While WT mice showed clear habituation over time (partial ANOVA WT: time p<0.0001), 
NEP mice exhibited an abnormal temporal organization of locomotion with a locomotor 
activity similar to the control littermates during the first day but absence of the normal 
decrease of activity usually observed during the second day of the test (repeated ANOVA: 
genotype ns, time p<0.0001, interaction, p<0.0009; partial ANOVA time: WT p<0.0001, 
NEP ns) (Fig. 35A), indicating a lack of habituation from the NEP mice. Independently of the 
presence of the NEP transgene, the J20 transgene increased overall activity without affecting 
time course (partial repeated ANOVA J20 versus WT: genotype p<0.0011, time p<0.0001 
interaction ns; NEPxJ20 versus NEP: genotype p<0.0014, time p<0.0001 interaction ns). The 
NEP transgene also abolished habituation in presence of the J20 transgene and slightly 
increased overall activity (partial repeated ANOVA NEP versus WT: genotype ns, time 
p<0.0001 interaction p<0.0006; NEPxJ20 versus J20: genotype p<0.0206, time p<0.0013, 
interaction p<0.0141) (Fig. 35A).  
Analysis of the acceleration and velocity progression confirmed the presence of an abnormal 
locomotion for both transgenes (acceleration: genotype p<0.0001, J20 versus WT p<0.0182, 
NEP versus WT p<0.0001, NEPxJ20 versus NEP ns and NEPxJ20 versus J20 p<0.0189; 
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velocity progression: genotype p<0.0001, J20 versus WT p<0.0002, NEP versus WT 
p<0.0041, NEPxJ20 versus NEP p<0.0089 and NEPxJ20 versus J20 p<0.0269) (not shown). 
In addition, differential analysis of motion states revealed that the frequency of lingering and 
progression but not resting episodes was significantly increased in the NEP mice compared to 
WT controls (repeated ANOVA: genotype p<0.0002, state p<0.0001, interaction p<0.0002; 
partial ANOVA genotype: rest ns, linger p<0.0004, progress p<0.0011) (Fig. 35B). However, 
the time spent in these different states was similar in NEP and WT groups (repeated ANOVA: 
state p<0.0001, interaction ns) (Fig. 35C) indicating that the increased frequency of lingering 
and progression episodes was compensated by their shorter duration. Therefore, both 
transgenes led to specific alteration of the locomotor pattern in this task with NEP and J20 
transgenes associated with a lack of habituation and hyperlocomotion, respectively. Both 
related impairments were found in the NEPxJ20 mice. The parameters related to anxiety-like 
behavior were not affected by genotype. A similar preference for the wall zone over the 
center field with values clearly below chance level, confirmed that the open field center was 
aversive (1-sample t-test: 7 months p<0.0001, 15 months p<0.0001) (Fig. 35E). Despite a 
graphical trend suggesting that the J20 transgene slightly increased center time, there was 
only a borderline but non significant effect of genotype (repeated ANOVA: genotype ns, zone 
p<0.0001, interaction ns; time in center field genotype p<0.0692) (Fig. 35E). 
 
Analysis of the 15 months cohort showed changes reminiscent of those seen in the 7 months 
cohort (Fig. 35D). However, many effects were weaker. Genotype affected overall level of 
activity without significantly changing its time course (repeated ANOVA: genotype 
p<0.0001, time p<0.0001, interaction ns). As in the younger cohort, WT mice showed 
significant habituation over time (partial ANOVA WT: time p<0.0008). The J20 transgene 
increased overall activity independently of the presence of the NEP transgene (partial 
repeated ANOVA J20 versus WT: p<0.0013, time p<0.0002 interaction ns; NEPxJ20 versus 
NEP: genotype p<0.0005, time p<0.0166, interaction ns) (Fig. 35D). In contrast to younger 
animals, the NEP transgene had no significant effect anymore (partial repeated ANOVA NEP 
versus WT: ns, time p<0.0001 interaction p<0.0657; NEPxJ20 versus J20: genotype ns, time 
p<0.0917 interaction ns). Genotype did not alter the preference for the wall zone versus the 
center field (1-sample t-test: p<0.0001) and the percentage of time spent in the center field 
(repeated ANOVA: genotype ns, zone p<0.0001, interaction ns; time in center field genotype 
ns) (Fig. 35F). 
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Figure 35. Additive effects of both transgenes in the open field. (A) In the 7 months cohort, J20 mice showed 
a clear overall hyperactivity and the NEP mice a significant lack of habituation during the second day of testing. 
Both impairments were found in the NEPxJ20 mice. (B) The frequency of lingering and progression but not 
resting episodes was increased in NEP mice compared to WT littermates. (C) NEP and WT mice were 
indistinguishable with respect to time spent in each of the three motion states. (D) The 15 months cohort showed 
changes reminiscent of those seen in the 7 months cohort with significant habituation overtime in the WT mice 
and significant hyperlocomotion associated with the J20 transgene. However, effects previously observed in 
NEP mice were not significant anymore. (E, F) The amount of time spent in the center field was below chance 
level and not affected by genotype in both cohorts. . ns (not significant) is mentioned when p>0.1. 
 
7.2.2 Hyperlocomotion in the emergence test and novel object exploration in 7 
months NEP mice  
The emergence test is a free exploration paradigm designed to assess approach or exploratory 
behavior of rodents in an environment that provides a safe refuge. 
Once the J20 and NEPxJ20 mice removed for biochemical analysis, NEP (n=13) and WT 
(n=14) mice of the 7 months cohort were tested in the emergence test at 42.6 ± 0.2 weeks of 
age. NEP mice showed clear signs of hyperlocomotion and a decreased habituation with time 
(repeated ANOVA: genotype p<0.0001, time p<0.0001, interaction p<0.0338; partial 
ANOVA time: WT p<0.0001, NEP p<0.0001) (Fig. 36A). The NEP mice also presented an 
increased frequency of lingering and progression and a decreased number of resting episodes 
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reminiscent of the open field test (repeated ANOVA: genotype p<0.0001, state p<0.0001, 
interaction p<0.0001; partial ANOVA genotype: rest p<0.0006, linger p<0.0001, progress 
p<0.0001) (Fig. 36B). The time spent during these periods was also significantly changed 
with increased duration of the lingering and progression periods and a decreased of the 
resting periods (repeated ANOVA: state p<0.0001, interaction genotype-state p<0.0001; 
partial ANOVA genotype: rest p<0.0001, linger p<0.0359, progress p<0.0001) (Fig. 36C). 
Time in the home box, usually considered a measure of anxiety, was similar in NEP and WT 
mice (Fig. 36D). However, NEP mice spent significantly more time in the center field 
(p<0.0353), visited a larger percentage of the arena (p<0.0334) and showed a non significant 
reduced center field avoidance (repeated ANOVA: genotype ns, zone p<0.0001, interaction 
p<0.0935) (Fig. 36E) compared to their control littermates. 
 
 
Figure 36. NEP mice were overall clearly hyperactive in the emergence test. (A) NEP mice were more 
active and habituated less during the 30 min session. (B). The frequency of lingering and progression episodes 
was increased in NEP mice, whereas resting episodes were less numerous. (C) Time spent with progressive 
locomotion and to a lesser degree time spent lingering was increased in NEP mice, at the expense of resting time 
which was strongly diminished. (D) Both groups spent a similar small amount of time inside the home box. (E) 
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Both groups strongly preferred the zone around the home box over the center field. The strength of center field 
avoidance tended to be slightly reduced in NEP mice. Chance levels depended on relative zone area and are 
indicated by a dotted line. Values represent the mean ± SEM. ns (not significant) is mentioned when p>0.1. 
 
The novel object test is another free exploration paradigm that exposes the animals to a novel 
stimulus in a familiar arena and inflicts an approach avoidance conflict. Before and after 
introduction of the novel object into the arena NEP mice showed hyperlocomotion (repeated 
ANOVA: genotype p<0.0001, time p<0.0001, interaction p<0.0179) (Fig. 37A) reminiscent 
of the emergence test with similar temporal disorganization of the locomotion. The frequency 
of resting episodes was unchanged but lingering and progression episodes were significantly 
increased in the NEP mice (repeated ANOVA: genotype p<0.0005, state p<0.0001, 
interaction p<0.0001; partial ANOVA genotype: rest ns, linger p<0.0004, progress p<0.0001) 
(not shown). The percent of time in motion state was also modified: they spent less time 
resting and increased amount of time lingering and progressing (repeated ANOVA: state 
p<0.0001, interaction genotype-state p<0.0001; partial ANOVA genotype: rest p<0.0005, 
linger p<0.0026, progress p<0.0002) (not shown). The NEP mice responded to the 
introduction of the novel object by an increase of general activity (Fig. 37A). However, 
despite the marked group differences in general locomotion, interest in the new object was 
indistinguishable between the NEP and WT mice, which presented a similar horizontal 
(repeated ANOVA: genotype ns, time p<0.0001, interaction ns) (Fig. 37B) and vertical 
(repeated ANOVA: genotype ns, time p<0.0002, interaction ns) (Fig. 37C) activity toward the 
new object. 
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Figure 37. NEP mice are hyperactive but present a normal exploratory activity toward the novel object. 
(A) NEP mice were hyperactive and unlike WT mice, responded to the introduction of the novel object by an 
increase of general activity. (B) Horizontal exploratory activity toward the novel object was significant and 
indistinguishable between groups despite the marked group differences in general locomotion. (C) Similarly, 
NEP and WT mice did not differ with respect to estimated vertical activity toward the object. Values represent 
the mean ± SEM. ns (not significant) is mentioned when p>0.1.  
 
7.2.3 NEP did not prevent J20-related hyperlocomotion in emergence test and 
novel object exploration at 15 months of age. 
To assess the effect of age on this NEP-related hyperlocomotion, the 15 months cohort (16 
WT, 15 NEP, 16 J20, 14 NEPxJ20) was also tested in the emergence paradigm (age 16.1 
months). NEP mice exhibited a normal locomotion at 15 months of age in the emergence and 
object exploration paradigm but showed a lack of interest when the novel object was 
presented. J20 mice exhibited again, during both paradigms, a clear hyperlocomotion, which 
was not prevented by neprilysin overexpression. Exploration of the novel object was not 
affected in mice with the J20 transgene. 
Genotype affected overall level of activity without influencing habituation over time 
(repeated ANOVA genotype p<0.0001, time p<0.0001, interaction ns) (Fig. 38A). The J20 
transgene increased locomotor activity independently of the presence of the NEP transgene 
(partial ANOVA J20 versus WT: genotype p<0.0107; NEPxJ20 versus NEP: genotype 
p<0.0062). The NEP transgene, by contrast, had no effect on locomotor activity and did not 
prevent the J20-related hyperlocomotion (partial ANOVA NEP versus WT: genotype ns; 
NEPxJ20 versus J20: genotype ns) (Fig. 38A). Effects on measures of anxiety were only 
borderline with small, non cumulative attenuating effects of both transgenes on center 
avoidance (genotype p<0.0443, NEP versus WT p<0.0175, J20 versus WT p<0.0394) and no 
effect of genotype on percentage of time spent in the box (not shown). These data support that 
NEP transgene does not affect locomotion but also does not prevent the hyperlocomotion 
associated with the J20 transgene. 
In the object exploration test, genotype affected both overall level and time course of activity 
(repeated ANOVA genotype p<0.0001, time p<0.0001, interaction p<0.0242) (Fig. 38B). As 
in the emergence test, the J20 transgene was associated with a general increase of locomotor 
activity independently of the presence of the NEP transgene (partial ANOVA J20 versus WT: 
genotype p<0.001, time p<0.0001, interaction ns; NEPxJ20 versus NEP: genotype p<0.0001, 
time p<0.0749, interaction ns) (Fig. 38B). The NEP transgene affected the time course of 
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activity in absence of the J20 transgene but not in its presence (partial ANOVA NEP versus 
WT: genotype ns, time p<0.0001, interaction p<0.0155; NEPxJ20 versus J20: genotype ns, 
time p<0.0012, interaction ns) (Fig. 38B). NEP mice were the only group responding to the 
introduction of the object with an increase of general locomotor activity. Genotype affected 
exploration parameters such as the horizontal exploratory activity (repeated ANOVA 
genotype p<0.0107, time p<0.0001, interaction p<0.0035) (Fig. 38C) and vertical movements 
toward the object (repeated ANOVA genotype p<0.0103, time p<0.0001, interaction 
p<0.0006) (Fig. 38D). All groups except NEP mice showed a significant exploratory response 
toward the object (partial ANOVA WT: time p<0.0001; J20: time p<0.0001; NEPxJ20: time 
p<0.0094; NEP: time ns). The NEP transgene reduced object exploration significantly in 
absence of the J20 transgene, but not in its presence (partial ANOVA NEP versus WT: 
genotype p<0.0038, time p<0.0019, interaction p<0.0002; NEPxJ20 versus J20: genotype ns, 
time p<0.0001, interaction ns). The J20 transgene had no effect on object exploration in 
absence of the NEP transgene but significantly improved object exploration in NEP 
transgenic animals (partial ANOVA J20 versus WT: genotype ns, time p<0.0001, interaction 
ns; NEPxJ20 versus NEP genotype p<0.0247, time p<0.0333, interaction p<0.0277). Analysis 
of estimated vertical movements toward the object confirmed the results obtained by 
analyzing horizontal exploratory activity (repeated ANOVA genotype p<0.0103, time 
p<0.0001, interaction p<0.0006). The four groups showed locomotion similar to the 
emergence test but NEP mice spent less time toward the object. 
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Figure 38. Emergence test and object exploration in the 15 months cohort. (A) Emergence test showed a 
clear hyperlocomotion associated with the J20 transgene, while habituation was not affected by genotype. The 
distance moved by NEP and WT mice was similar, but neprilysin overexpression did not prevent the J20-related 
hyperlocomotion. (B) Novel object exploration paradigm presented prior to insertion of the object a similar 
locomotion effect of the different transgene reminiscent of the emergence test.  Insertion of the novel object 
induced increase of locomotion only in the NEP mice. (C) All groups except NEP mice showed a significant 
exploratory response toward the object. This lack of exploration was prevented by the presence of the J20 
transgene. (D) Vertical movements toward the object confirmed the lack of object exploration from the NEP 
mice. Values represent the mean ± SEM. 
 
7.2.4 Both transgenes are associated with decreased anxiety-like measures in 
elevated zero Maze 
The elevated zero maze is a standard test to analyze anxiety-related behavior by measuring 
the avoidance of the unsheltered open sectors. The 7 months cohort (16 WT, 15 NEP; 17 J20, 
12 NEPxJ20, age 7.0 months) showed no genotype effect on the total distance moved, 
suggesting that locomotion was not affected. Percentage entries to the open sectors were 
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clearly below chance for all groups, confirming their aversive nature (1-sample t-tests: WT 
p<0.0001, NEP p<0.0001, J20 p<0.0001, NEPxJ20 p<0.0001) (Fig. 39A). The avoidance of 
open sectors was significantly affected by genotype with both transgenes increasing the time 
spent in the open sectors (genotype: p<0.0122, NEP versus WT p<0.0034, J20 versus WT 
p<0.0067) without showing an additive effect in NEPxJ20 mice (Fig. 39A). 
The number of protected and unprotected head dips were affected by genotype with J20 
transgene leading to a significant increase of head dips (genotype p<0.0009, J20 versus WT 
p<0.0016, NEP versus WT ns, NEPxJ20 versus NEP p<0.0181, NEPxJ20 versus J20 ns) 
((Fig. 39C). At 7 months, J20 mice were less reluctant to enter the open sectors and showed 
more head dips than WT mice. The NEP transgene was associated with similar significant 
changes, but the effects of the two transgenes were not additive. Therefore, both transgenes 
induced decreased anxiety in the elevated zero maze paradigm. 
In the 15 months cohort (16 WT, 16 NEP; 16 J20, 15 NEPxJ20, age 15.8 months), open 
sectors were clearly avoided by all groups (1-sample t-tests: WT p<0.0001, NEP p<0.0001, 
J20 p<0.0001, NEPxJ20 p<0.0001) (Fig. 39B). Genotype effects showed a trend in the same 
direction as in the 7 months cohort but were much weaker and statistically only borderline: 
despite a graphical trend suggesting reduced open sector avoidance in NEPxJ20 mice, there 
was no significant effect of genotype on open sector avoidance (ANOVA genotype ns) (Fig. 
39B). Genotype still significantly affected the number of head dips (genotype p<0.0300) with 
NEPxJ20 mice making more head dips compared to the NEP mice (Fig. 39D). 
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Figure 39. Both transgenes decrease anxiety parameters in the O-maze. (A) In the 7 months cohort, both 
transgenes significantly increased the percentage (%) of open sector entries compared to WT littermates. (B) In 
the 15 months cohort, genotype did not affect the percentage of open sector entries , in spite of a trend. (C) total 
number of head dips was significantly increased by J20 transgene, while NEP transgene did not have any effect 
by itself and did not prevent the effect of the J20 transgene. (D) Only NEPxJ20 mice presented a significant 
increase of head dips when compared to NEP mice. Values represent the mean ± SEM. **: p<0.01. 
 
7.2.5 NEP and J20 transgenes decreased anxiety-related measures in the light-
dark (L/D) test only when both present 
Similar to the elevated zero maze, this test allows the assessment of unconditioned anxiety 
related parameters such as the time spent in a protected area. 10 months old mice mixed for 
gender (31 WT, 28 NEP, 31 J20 and 26 NEPxJ20) were tested in this paradigm.  
NEP and J20 mice did not show significant decrease of anxiety-like parameters when 
compared to WT mice. However, NEPxJ20 mice, which entered less quickly and spent less 
time in the dark area than the other groups, exhibited a clear decrease of anxiety-like 
parameters. 
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A separate 2-way ANOVA with factors genotype and gender revealed no significant 
genotype-gender interactions. Genotype significantly affected the measures of anxiety such as 
the latency to enter in the dark area (p<0.0217) (Fig. 40A) and the time spent in the dark area 
(p<0.0001) (Fig. 40B). NEPxJ20 mice took significantly more time to enter for the first time 
in the dark compartment than the other groups which did not differ in this respect (NEPxJ20 
versus NEP p<0.0365, NEPxJ20 versus J20 p<0.0136, NEP and J20 versus WT ns) (Fig. 
40A). In agreement with the preference of the mice for dark protected area, WT mice spent 
more time in the dark area than the opened area. In contrast, both single transgenic groups 
were not significantly different from controls, but neither preferred nor avoided the dark 
compartment and only NEPxJ20 mice significantly avoided the dark area (one sample t-test 
against 50%: WT p<0.0158, NEP ns, J20 ns, NEPxJ20 p<0.0001) (Fig. 40B). In spite of a 
graphical trend, NEP and J20 mice did not spent significantly less time in the dark area and 
only the presence of both transgenes led to a significant decrease (genotype p<0.0001, NEP 
versus WT ns, J20 versus WT p<0.0838, NEPxJ20 versus NEP p<0.0002, NEPxJ20 versus 
J20 p<0.0009) (Fig. 40B). Moreover, locomotion and count of stereotypic movement like 
circular running and edge jumping were also modified by genotype (p<0.0025 and p<0.0001, 
respectively). While the NEPxJ20 mice presented a borderline non significant increase of 
locomotion compared to J20 littermates (p<0.0708) and a significant increase compared to 
NEP littermates (p<0.0002) (Fig. 40C), they also presented a significant increase of 
stereotypic movements compared to NEP (p<0.0001) and J20 littermates (p<0.0001) (not 
shown). 
These data suggest that both transgenes lead in the L/D paradigm to a non significant 
decreased anxiety, which becomes significant in the NEPxJ20 mice and therefore present 
boosting effects. This decreased anxiety was associated with hyperlocomotion. 
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Figure 40. Presence of both transgenes led to decrease of anxiety-like measures and abnormal locomotion 
in the L/D test. (A) NEPxJ20 mice took significantly longer to enter the dark compartment for the first time 
than the other groups which did not differ in this respect. (B) While WT mice spent significantly more time in 
the dark compartment than chance level, NEP and J20 mice spent less amount of time in the dark box but the 
effect was only significant when both transgenes were present. (C) The J20 transgene increased locomotion in 
the lit compartment, but this was only significant in presence of the NEP transgene. Values represent the mean ± 
SEM. *: p<0.05; *: p<0.001. 
 
7.3 Learning and memory behavior 
 
7.3.1 Neprilysin overexpression did not prevent the memory deficit of the J20 
mice in the CTA test 
To investigate the potential effect of neprilysin overexpression on hipocampally-independent 
associative learning and memory, the mice of the 7 months cohort were tested in the CTA (17 
WT, 16 NEP, 17 J20 and 13 NEPxJ20, age: 4.5 ± 0.2 months). While NEP mice learned and 
remembered the association like WT mice, J20 mice exhibited an impaired memory of the 
association. This deficit was not prevented by neprilysin overexpression. 
All groups drank comparable amounts of water during the adaptation and conditioning but 
genotype affected the amount of saccharin drunk during the conditioning (genotype p<0.021; 
Fig. 41A). While all groups drank a similar amount of saccharin when compared to WT mice, 
NEP mice drank significantly less saccharin than J20 (genotype p<0.007) and NEPxJ20 mice 
(genotype p<0.038). 48 hours after conditioning, genotype strongly affected the strength of 
the conditioned aversion (p<0.0002) and the speed of its extinction (genotype x days 
p<0.0006; Fig. 41C). Whereas WT and NEP mice displayed an equally strong aversion 
against saccharin, J20 as well as NEPxJ20 mice showed a weaker conditioned aversion in the 
following choice tests with no difference between the two latter groups. When the avoidance 
of an intrinsically aversive bitter quinine solution was measured, no difference between the 
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four mice groups could be detected (p<0.31) (Fig. 41B), confirming that taste sensitivity was 
not altered. 
 
 
Figure 41. Neprilysin overexpression did not prevent J20 memory deficit in the conditioned taste aversion 
test. (A) NEP mice drank significantly less of the saccharin solution (CS) than J20 and NEPxJ20 but did not 
differ from WT mice during conditioning. (B) In spite a graphic trend, consumption of a bitter quinine solution 
was not affected by genotype. (C) The aversion coefficient, defined as the percentage of saccharin consumption 
divided by the total fluid intake, is depicted over 7 choice tests for the WT, NEP, J20 and NEPxJ20 mice. Both, 
J20 as well as NEPxJ20 mice displayed a similar diminished conditioned aversion against saccharin compared to 
NEP and WT mice. Performance of NEP mice was indifferent from their WT littermates. (*: p<0.05; **: 
p<0.01). Values represent the mean ± SEM 
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7.3.2 Neprilysin overexpression prevented the spatial memory deficit of the J20 
mice in the Morris water maze test 
To assess the effects of neprilysin overexpression in spatial learning and memory and its 
ability to prevent the Aβ-related cognitive deficits, the 7 months cohort (16 WT, 17 J20, 10 
NEPxJ20, 15 NEP, age: 7.0 months) was tested in the Morris water maze paradigm. Whereas 
NEP mice behaved similarly to WT mice, J20 mice exhibited impairments in spatial measures 
while looking for the hidden platform and showed significant memory deficit. This deficit 
was prevented by neprilysin overexpression.  
During the visible and hidden platform learning trials, mice of all groups learned to find the 
platform (Fig. 42A). Learning rate and overall performance during localization of the visible 
platform, as measured by the escape latency, was not significantly affected by genotype 
(repeated ANOVA visible platform: genotype ns, time p<0.0001, interaction ns). In the place 
navigation task, there was a non significant trend contributed by J20 and NEPxJ20 mice 
which performed similarly and took slightly longer time than the other groups when 
localizing the hidden platform (repeated ANOVA hidden platform: genotype p<0.0571, time 
p<0.0001, interaction ns) (Fig. 42A). By contrast, the genotype effect on spatial measures that 
are more directly related to memory and cognition was significant and demonstrated a clear 
beneficial effect of the NEP transgene: during the hidden platform trials, genotype affected 
the percentage of time spent in the goal quadrant when compared to adjacent quadrants 
(genotype p<0.0008) and goal proximity (genotype p<0.0130) (Table 1). This effect was 
specifically attributable to the J20 mice which spent significantly less time in the goal 
quadrant (p<0.0003) and swam further from the target (p<0.0087) as compared to WT 
littermates. These effects were not observed in the NEPxJ20 mice that performed normally as 
compared to the WT or NEP single transgenic littermates, suggesting a behaviorally-relevant 
therapeutic effect of overexpressing the NEP transgene. 
During the probe trial, all groups showed a significant preference for the target quadrant 
compared to adjacent quadrants (repeated ANOVA place: WT p<0.0001, NEP p<0.0001, J20 
p<0.0084, NEPxJ20 p<0.0023) but the strength of the preference for the target quadrant was 
significantly affected by genotype (repeated ANOVA: place p<0.0001, interaction place-
genotype p<0.0257) (Table 1, Fig. 42B)). Specifically, the J20 transgene was associated with 
reduced preference for the target quadrant only in absence of the NEP transgene but not in its 
presence (partial repeated ANOVA interaction place - genotype: J20 versus WT p<0.0231, 
NEPxJ20 versus NEP ns) (Table 1, Fig. 42B). The NEP transgene had no effect in absence of 
the J20 transgene but improved target preference of J20 transgenic mice (partial repeated 
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ANOVA interaction place - genotype: NEP versus WT ns, NEPxJ20 versus J20 p<0.0458) 
(Table 1, Fig. 42B). The proximity measure (average distance to target) confirmed the results 
of quadrant time analysis. There was a significant overall genotype effect (factorial ANOVA 
genotype p<0.0131) with partial comparisons indicating that the J20 transgene was associated 
with poor proximity scores only in absence of the NEP transgene but not in its presence (J20 
versus WT p<0.0163, NEPxJ20 versus NEP ns) (Table 1, Fig. 42C). The NEP transgene had 
no effect in absence of the J20 transgene but significantly improved proximity scores of J20 
transgenic mice (NEP versus WT ns, NEPxJ20 versus J20 p<0.0369) (Table 1, Fig. 42C). 
Together, these data provide evidence that the transgenic expression of neuronal neprilysin 
alone had no effect on performance in this spatial memory task but could prevent the memory 
deficit of the J20 mice. 
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Figure 42. Neprilysin overexpression prevented spatial memory deficits of the J20 mice in the Morris 
water maze. (A) Mean escape latency of WT, NEP, J20 and NEPxJ20 mice to find a visible and a hidden 
platform. All groups learned to locate the visible and the hidden platform position through the trials and 
genotype did not significantly affect the learning rate or the overall performance. (B) Mean percent time spent in 
target and adjacent quadrants during the probe trial. All groups showed a significant preference for the target 
quadrant compared to adjacent quadrants. Genotype significantly affected the preference for the target quadrant. 
J20 mice spent significantly less time in the goal quadrant compared to WT littermates. There was no difference 
observed between NEP and WT mice and neprilysin transgene prevented the spatial deficit of J20 transgenic 
mice. (C) Mean distance to the platform localization during the probe trial. Genotype significantly affected the 
proximity to the target during the probe trial. The J20 mice swam further to the platform localization when 
compared to WT littermates. In contrast NEPxJ20 swam at the same average distance to the target as NEP and 
WT mice and performed significantly better than the J20 mice. (*: p<0.05). Values represent the mean ± SEM. 
 
 
Table 1. Spatial selectivity during the Morris water maze paradigm. Main effects of genotype are shown 
first, followed by partial genotype comparisons. For partial comparisons, vertical arrows indicate the direction of 
the effect. The J20 mice were impaired in spatial selectivity during the place navigation and the probe trial. In 
the presence of NEP transgene, this effect became non-significant during the place navigation and was 
significantly rescued during the probe trial. P values are only shown if <0.1 or mentioned ns (not significant).  
 
The 15 months old cohort (15 WT, 16 NEP, 15 J20, and 14 NEPxJ20) showed better 
performance during cue navigation than the 7 months cohort and performed similarly in the 
place navigation task, again showing significant learning in both protocols. Neither learning 
rate nor overall performance measured by escape latency were affected by genotype (repeated 
ANOVA cued: genotype ns, time p<0.0001, interaction ns; place navigation: genotype ns, 
time p<0.0001, interaction ns) (Fig. 43A). In contrast to the 7 months cohort, the genotype 
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had no effect on spatial measures such as the percentage of time in goal quadrant (p<0.0959) 
or proximity to the platform (ns, not shown). 
During the probe trial, preference for the target quadrant was strong overall and highly 
significant but no longer affected by genotype (repeated ANOVA place p<0.0001, interaction 
place-genotype ns) (Fig. 43B). In spite of a graphic tendency, neither the percentage of time 
spent in the goal quadrant (Fig. 43B) nor the proximity to the platform was affected by 
genotype (ns for both). Spatial selectivity of WT animals in this cohort was virtually identical 
to the younger animals. These data suggest that the impairment observed in the J20 mice of 
the 7 months cohort was weak and disappeared with age. 
 
 
Figure 43. The 15 months cohort was not impaired in the Morris water maze paradigm. (A) Mean 
escape latency of WT, NEP, J20 and NEPxJ20 mice to find a visible and a hidden platform. All groups 
learned to locate the visible and the hidden platform position through the trials and genotype did not 
significantly affect the learning rate or the overall performance. (B) Mean percent time spent in target 
and adjacent quadrants during the probe trial. All groups showed a significant preference for the target 
quadrant compared to adjacent quadrants. Genotype did not significantly affect the preference for the 
target quadrant. 
 
7.3.3 Similar performance in the Y maze paradigm 
To assess the effects of neprilysin overexpression in spatial working memory and its ability to 
prevent the potential Aβ-related cognitive deficits, the 15 months cohort (16 WT, 14 NEP, 15 
J20 and 13 NEPxJ20, age: 17.5 months) was tested in the Y maze paradigm. The percentage 
of spontaneous alternation did not differ between genotypes (Fig. 44) and was above the 22% 
chance level [485]. Neither neprilysin nor mutated APP overexpression affected the working 
memory of the mice. 
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Figure 44. Spatial working memory is not affected by genotype in the Y maze paradigm. Percentage of 
spontaneous alternation was similar in all groups tested. 
 
7.3.4 NEP mice showed intact cognitive abilities in the puzzle box paradigm 
To further analyze the effect of neprilysin overexpression on general cognitive abilities, we 
tested the NEP (n=15) and WT (n=17) mice from the 7 months cohort (age 40.9 ± 0.4 weeks 
= 9.6 months) in the motivational driven puzzle box task. During training with an open door 
as well as in the burrowing and plug puzzles, the two groups showed a highly significant 
decrease of escape latencies with no significant effect of genotype on overall performance or 
learning rate (repeated ANOVA training: genotype ns, trial p<0.0001, interaction ns; 
burrowing puzzle: genotype ns, trial p<0.0001; plug puzzle: genotype ns, trial p<0.0001) (Fig. 
45).  
 
Figure 44. NEP mice show intact cognitive abilities in the puzzle box paradigm. Performance of NEP and 
WT mice was indistinguishable during escape training (T) with an open underpass, when the underpass was 
buried (B) in sawdust, and when a plug (P) had to be removed to free the underpass. Both groups learned 
similarly the tasks and spent less time during the second trial of the cognitive tasks. Values represent the mean ± 
SEM. 
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7.3.5 Borderline working memory deficit in NEP mice in 8-arm radial maze 
NEP mice (n=12) were slightly impaired in a working memory procedure on the 8-arm radial 
maze when compared to WT littermates (n=10) (age 44.6 ± 0.2 weeks) but presented strong 
hyperactivity. The total of reentry errors declined over the 10 days of training with a 
significant learning and similar rates for both groups, but NEP mice tended to make more 
errors than control littermates (repeated ANOVA: genotype p<0.0575, time p<0.0001, 
interaction ns) (Fig. 46A). NEP mice also differed from WT mice in the number of correct 
arm choices before the occurrence of the first error and show that despite slightly reduced 
average performance (repeated ANOVA: genotype p<0.0494, time p<0.0001, interaction ns) 
(Fig. 46B), NEP mice learned at similar rate as WT and reached a performance level well 
above chance (22%). NEP mice also presented a strong locomotor hyperactivity. The NEP 
mice spent less time to remove all the pellets than WT mice (p<0.0005) (Fig. 46C) and 
traveled a longer distance (p<0.0309) while completing the task at an higher speed 
(p<0.0066) when compared to WT controls (not shown). Therefore, the borderline effect on 
working memory may be in part due to the NEP mice hyperlocomotion. 
 
 
NEP
WT
co
rr
ec
t i
n 
fir
st
 8
 (x
)
B
5
5.5
6
6.5
7
7.5
8
chance
genotype
p<0.0494
Day 1-2 3-4 5-6 7-8 9-10
re
en
try
 e
rr
or
s (
x)
A
Day 1-2 3-4 5-6 7-8 9-10
0
1
2
3
4
5
6
7
8
genotype
p<0.0575
7 months cohort
0
50
100
150
200
250
300
350
tim
e 
(s
)
genotype
p<0.0005
Day 1-2 3-4 5-6 7-8 9-10
C
co
rr
ec
t i
n 
fir
st
 8
 (x
)
co
rr
ec
t i
n 
fir
st
 8
 (x
)
re
en
try
 e
rr
or
s (
x)
re
en
try
 e
rr
or
s (
x)
tim
e 
(s
)
  
133
Figure 46. Slight impairment of the NEP mice in the eight-arm radial maze. (A) According to number of 
reentry errors, NEP and WT learned significantly and at indistinguishable rates, but mutants showed a borderline 
reduction of overall performance. (B) Correct choices in first 8 plotted against time show that despite slightly 
reduced average performance, NEP mice learn at similar rate as WT mice and reach a performance level well 
above chance. (C) NEP mice were hyperactive and needed less time to remove all the pellets when compared to 
WT mice. Values represent the mean ± SEM.  
 
7.3.6 Altered fear conditioning in NEP mice 
To assess associative learning, NEP (n=13) and WT (n=14) mice of the 7 months cohort (age 
44.6 ± 0.2 weeks), were used in the auditory fear conditioning test and showed that NEP mice 
were impaired in contextual fear conditioning. The percentage of freezing during the 
conditioning session as well as the retrieval sessions for conditioning to context or tone was 
recorded. During the conditioning session, WT mice showed a high level of freezing 
compared to pre-training freezing percentage (Fig. 47A). However, NEP mice exhibited a 
higher percentage of freezing during the pre-training session (Fig. 47A), which may be due to 
a decreased distance moved (factorial ANOVA: genotype p<0.0017) (Fig. 47B), and a lack of 
training effect with no significant increase of percentage of freezing time (repeated ANOVA: 
genotype ns, training p<0.0002, interaction p<0.0099; partial ANOVA training: WT 
p<0.0005, NEP ns) (Fig. 47A). To further investigate the impairment of the NEP mice in fear 
conditioning, a context and a tone conditioning analysis were performed 24 hours after the 
training. During the retrieval test for context conditioning, similar results persisted (repeated 
ANOVA: genotype ns, training p<0.0001, interaction p<0.0267; partial ANOVA training: 
WT p<0.0005, NEP p<0.0925) (Fig. 47C). However, in spite of a weak effect, both groups 
reacted significantly to the tone (repeated ANOVA: genotype ns, training p<0.0006, 
interaction ns) (Fig. 47D). These data suggest that NEP mice were impaired in contextual fear 
conditioning. 
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Figure 47. NEP mice were impaired in contextual fear conditioning. (A) WT mice showed little pre-training 
freezing and a clear training response when observed in the conditioning chamber immediately after training. 
NEP mice froze more before training and lacked a significant training effect. (B) NEP mice moved a 
significantly shorter distance during pre-training baseline recording. (C) Both training effect in WT and 
impairment of NEP mice persisted during a retest 24 h after training. (D) Freezing responses to the tone after 24 
h were similarly weak in both groups despite a clearly observable reaction to the tone in most animals. Values 
represent the mean ± SEM. ns (not significant) is mentioned when p>0.1. 
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IV) DISCUSSION 
 
1) In vivo effect of neprilysin deficiency 
 
The analysis of NEP KO mice showed that neprilysin deficiency led to elevated Aβ levels and 
deposition of amyloid-like deposits in the brain accompanied by neurodegeneration and 
behavioral deficits. Western blotting with anti-APP antibodies revealed no changes in the 
amount of full length APP in neprilysin deleted mice. This data is confirmed by previous 
findings that neprilysin hydrolyzes Aβ without affecting APP metabolism [303] and that 
newborn and adult NEP-/- mice are normal, suggesting that the enzyme is not necessary for 
embryonic development, presumably due to the redundancy of the enzyme activity [314]. 
Taken together these results suggest that neprilysin upregulation as a therapeutic intervention 
would not affect APP processing and would probably not interfere with any yet unknown 
physiological functions of APP. 
Total brain Aβ concentrations of NEP KO mice were twofold higher than the corresponding 
levels of WT littermates. A 1.5-fold increase in brain Aβ content of mice carrying a familial 
AD-causing presenilin 1 gene mutation leads to AD-like pathology in mice [486-488]. Thus, 
the increase in Aβ caused by neprilysin deficiency in our study was comparable to that caused 
by presenilin mutations. Interestingly, neprilysin deficiency seemed not to affect the levels of 
other NEP substrates; the enkephalin levels in brains NEP KO mice were reported to be 
normal [489], indicating that neprilysin paucity is compensated by other mechanisms in the 
case of enkephalin metabolism [488]. Similarly, neprilysin deficiency did not seem to alter 
the levels of somatostatin, cholecystokinin and substance P in the hippocampal formation and 
cerebral cortex (Iwata and Saido, unpublished observations). The fact that NEP KO and 
NEP+/- mice exhibited similar brain Aβ concentrations strengths the hypothesis that a partial 
reduction of NEP activity, which could be caused by aging [396, 397], will promote Aβ 
deposition in the brain [488]. These data are in concert with a report describing the selective 
reduction of neprilysin expression in brains with sporadic AD, particularly in high plaque 
regions such as hippocampus and temporal gyrus [490]. Moreover, we found that neprilysin 
depletion compromised the neuronal integrity as we found signs of neurodegenerartion in 
hippocampi of aged NEP KO mice. These findings are supported by the report of an 
impairment of hippocampal long-term potentiation (LTP) in NEP KO APP transgenic mice 
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(Haung, S.M. et al. Ann. Meeting of Soc. for Neurosci. San Diego, CA. Program no. 220.5 
(2004)) and that soluble Aβ impairs hippocampal LTP in rats in vivo [133, 491]. Similarly, 
accumulation of Aβ in brains of transgenic mice expressing AD-related APP and presenilin 
mutations caused massive neuronal loss in the hippocampus [492-494], reconfirming that 
high Aβ levels are toxic to neurons in vivo. 
Most current transgenic models of amyloid pathology that exhibit high brain Aβ levels and 
behavioral deficits, overexpress AD-causing human APP [495-497]. Therefore, the observed 
pathology and behavioral impairments in those models can, at least partially, be attributed to 
high levels of APP transgene and its processing products. In contrast to those studies, 
utilizing mice with unphysiologically high transgenic expression of AD-causing mutated 
forms of human APP, we employed mice with normal APP levels. The 4G8 positive amyloid 
deposits found in neprilysin deficient brains differed from the amyloid plaques exhibited by 
most AD mouse models overexpressing human AD, probably because in the neprilysin 
deficient mouse brains the murine Aβ, which is accumulated, is much less amyloidogenic 
than the human Aβ. Taken together, our results show that neurodegeneration and behavioral 
deficiencies can be caused by sole accumulation of Aβ in the brains. The presence of stained 
murine Aβ plaques and the association with intraneuronal fibrillar structure strongly suggest 
that neprilysin deletion leads to murine Aβ fibrillization and plaque formation. We can not 
exclude the theorical possibility that neprilysin deletion could lead to the fibrillization of 
another another substrate of neprilysin which will be immunolocalized with Aβ in these 
brains. Nevertheless, none of the other substrate of neprilysin is known to fibrillize in vivo. 
The confirmation of Aβ as the main component of these fibrillar structures will have to be 
confirmed by immunoelectron microscopy. 
To test the hypothesis whether high brain Aβ levels are detrimental to neuronal function in 
vivo, the effects of Aβ accumulation in the brains were tested by subjecting the mice to CTA, 
an associative learning paradigm. Neprilysin deficient mice exhibited a significant two fold 
increase in brain Aβ levels and were significantly impaired in CTA, a measure for cognitive 
performance [498]. These data are in accord with a report showing that aged TgCRND8 mice, 
overexpressing the KM670/671 and the V717F mutations of human APP in neurons, are 
impaired in CTA learning and memory performance [499]. In addition, AD patients exhibit 
impairments at all levels of gustatory information processing. Significant losses in the ability 
to detect the taste of glutamic acid and to recognize olfactory stimuli were found in demented 
AD patients when compared with age-matched controls [500-502]. 
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The impairment of CTA in NEP KO and NEP+/- mice, exhibiting high levels of brain Aβ, 
stresses the specificity of the observed effects. These differences could not be caused by a 
reduction in neophobia, increased inborn preference for the sweet saccharin solution or 
reduced inborn aversion for an aversively (bitter) tasting solution, because no genotype 
differences could be found with respect to all these three traits. Lesions of the basolateral 
nuclei of the amygdala (BLA) have a general effect on the response to novel stimuli by 
decreasing neophobia [503]. A large body of literature supports among other areas [504], an 
important involvement of the amygdala in CTA [504-507] . More specifically, the central and 
basolateral nuclei of the amygdala are respectively involved in the acquisition and extinction 
of the CTA [508]. The BLA were also proposed to modulate memory consolidation via 
projections to brain regions involved in consolidating lasting memory, including the 
hippocampus, caudate nucleus, nucleus basalis and cortex [509]. Accumulation of Aβ in the 
amygdala and the subsequent disruption of the pathways involved in CTA could be 
responsible for the decreased learning and memory observed in NEP KO and NEP+/- mice 
during CTA. Because Aβ is increased in various areas of NEP deficient brains including 
amygdala and hippocampus [488], it is conceivable that Aβ accumulation may be responsible 
for the observed behavioral changes in these mice. It is possible that other substrates of 
neprilysin, whose levels may be modified, can act on the brain areas implicated in learning 
and memory of the CTA, or decrease the LiCl-induced nausea. Among them, substance P, 
whose level was increased in the colon of NEP KO mice [351], is a nociceptor [510-512] 
which is also thought to play a key role in emetic responses [513, 514]. While substance P is 
localized within both the vagal afferent nerve fibres and brainstem emetic circuitry [515-517] 
its intravenous injection induces nausea and vomiting [518]. Therefore, antagonists of the 
substance P/neurokinin 1 receptor are now used to prevent and delay chemotherapy-induced 
nausea and vomiting [513]. The potential increase of substance P levels in mice due to 
decreased neprilysin activity would be expected to increase LiCl-induced nausea and strength 
the CTA. On the contrary, a decreased CTA is observed in NEP KO and NEP+/- mice. These 
data suggest that alteration of substance P levels was not involved in learning and memory of 
the CTA and that the impairment of neprilysin deficient mice observed in CTA is a sensitive 
measure of altered neuronal function in brain areas involved in CTA [504] in response to 
accumulation of endogenous murine Aβ in these brains. 
It is well known that Aβ production is intracellular [519, 520] and its intraneuronal 
accumulation may precede plaque formation in AD brains as well as in a transgenic mouse 
model of AD [519, 521, 522], suggesting that sole accumulation of Aβ in brains impairs 
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neuronal function. Because we did not find any amyloid-like deposits in the amygdala of 
these mice, we hypothesize that Aβ accumulation in brain nuclei without the obvious 
induction of amyloid deposits may influence their functioning and induce cognitive deficits 
associated with AD. Indeed, soluble oligomers of Aβ were shown to induce cognitive deficits 
and were proposed to be one of the major toxic Aβ species in vivo [134, 226, 491]. 
This is, to our knowledge, the first study identifying murine Aβ plaque-like structures in 
mouse brains. In addition, our study shows that insufficient removal of Aβ from the brain, 
even without increasing physiological levels of APP, led to chronic accumulation of Aβ, to 
signs of neurodegeneration and to behavioral abnormalities. Our data support the idea that 
decrease of neprilysin level observed with aging [396, 397] and in vulnerable brain areas of 
AD patients [391, 392] may contribute to the AD pathology and strenght that brain specific 
elevation of neprilysin levels may prove to be useful in anti-Aβ therapies. 
 
2) Aβ-related increase of neprilysin level  
 
It was found in our laboratory that injection of synthetic fibrillar Aβ1-42 into mouse brains, but 
not PBS or synthetic fibrillar Aβ42-1, caused sustained increases in brain levels of neprilysin 
from 3 to at least of 20 weeks after injection [406]. These increases were associated with a 
dramatic reduction in brain tissue levels of Aβ, as well as prevention of amyloid plaque 
formation and reduced astrogliosos in a mouse model of amyloidosis 20 weeks after injection 
[406]. The mechanism that linked Aβ1-42 to increased NEP level is unknown. The data 
favored the possibility of a transcriptional activation of NEP gene expression in response to 
injections, and a sustained stimulation of this mechanism by highly insoluble Aβ1-42 
aggregates, ensuring a long-term elevation of NEP protein levels in the brain. This scenario is 
supported by the fact that the synthetic Aβ aggregates injected into mouse brains were 
remarkably stable over 20 weeks following the injection and seem to be resistant to the 
clearing mechanism triggered, constantly causing the induction of the unknown signal for the 
NEP upregulation. This is consistent with other studies showing that aggregated Aβ is still 
detected at the injection site months after the injection [523-527] and may constitute local 
reservoirs of smaller and biologically active polymers and oligomers of Aβ which may be 
released and associate with brain cells, including vessels [527]. In contrast, intracranial 
injected soluble Aβ species are quickly cleared from the brain within minutes [317, 528], 
possibly via degradation [317] and receptor-mediated transport through ventricle and choroid 
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plexus cells [529, 530]. Furthermore, neprilysin mRNA was significantly increased by Aβ1-42 
injection but not PBS or Aβ42-1, 20 weeks after injection [406]. Neprilysin is the major rate 
limiting Aβ-degrading enzyme (reviewed in [230]). While lots of evidences, including our 
own data, show that decrease of neprilysin mRNA and protein may contribute to AD 
pathology by promoting Aβ accumulation [229, 317, 391, 392, 396], neprilysin 
overexpression was shown by others and by us to prevent Aβ accumulation, its associated 
cytopathology and Aβ-related memory deficits [403, 405, 531]. 
Substance P and somatostatin, two substrates of neprilysin, were found to regulate neprilysin 
activity in vitro [532-534]. Based on their mode of action, it was hypothesized that this feed 
back loop regulation involved activation of G-protein-coupled receptors [387, 532]. Lack of 
somatostatin in the brain of somatostatin deficient mice was further associated with a 
decrease of neprilysin activity in vivo [532]. As a major substrate of neprilysin, the observed 
Aβ1-42-related increase of neprilysin protein may involve a similar feedback loop via one of 
the numerous potential Aβ receptors and activated mechanisms (reviewed in [119, 535]). 
Determination of the pathway responsible for the Aβ-related upregulation of neprilysin 
mRNA and protein level could be of major interest for AD therapy and may involve few side 
effects since this pathway would be naturally activated by Aβ accumulation in vivo. 
 
To investigate the transcriptional regulation of neprilysin and the Aβ1-42-related upregulation 
of neprilysin expression observed in vivo, we attempted to establish an in vitro model, which 
would allow the biochemical analysis of the pathways and transcription factors involved. 
Because of high neprilysin expression in the kidney [240], the effect of aggregated Aβ on 
neprilysin transcription was first analyzed in a human embryonic kidney cell line (293T 
cells). Since immunohistochemical detection of neprilysin protein illustrated a neuronal 
localization in vivo, the human neuroblastoma SH-SY5Y cells, which can be differentiated 
into neurons, were also tested. 
We took advantage of the high sensitivity of the luciferase assay system to measure the effect 
of Aβ on the activity of the three neprilysin promoters. The cells were transfected with a 
plasmid expressing firefly luciferase under the control of one of the three promoters of 
neprilysin (pN1, pN2 or pN3) and the effects of aggregated synthetic Aβ1-42 or Aβ42-1 
incubation on the luciferase activity which corresponds to the neprilysin promoter activity 
was analyzed. The luciferase activity was initially normalized by the protein concentration of 
the sample analyzed and non consistent results were obtained. We postulated that small 
variability caused by differences in transfection efficiencies between wells could have caused 
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or hidden the Aβ-related effects observed. Therefore, we used a new protocol which involved 
simultaneous transfection of a control plasmid expressing renilla luciferase under the control 
of the constitutively active pRLTK promoter, with the plasmid expressing firefly luciferase 
under the control of the neprilysin promoters. Normalization of the firefly luciferase activity 
with the renilla luciferase activity took the transfection efficiency of each well into account. 
Stable transfection of the cell lines was not performed due to an observed increase stability of 
the luciferase protein over time, which could have hidden the potential small Aβ-related 
increase of neprilysin promoter activation.  
To find out whether addition of aggregated Aβ1-42 activates neprilysin promoters in vitro and 
determine the optimal parameters, different concentrations of aggregated Aβ1-42 and Aβ42-1 
and different time points, which did not compromise the viability of the cells, were tested. In 
spite of initial small irreproducible Aβ-related increase of neprilysin promoter activities 
which could have been due to variability of the normalization that did not take into account 
transfection efficiency, Aβ1-42 incubation did not affect neprilysin promoter activity in 293T 
and undifferentiated SH-SY5Y cells when compared to Aβ42-1 and PBS treated cultures. 
Therefore, these cellular systems did not allow further investigation of the potential 
transcription factors involved. Analysis of Aβ1-42 effect on neprilysin transcription activity in 
differentiated SH-SY5Y cells was also discarded due to the many fold increases of all three 
neprilysin promoters’ activities after RA incubation , the first agent used to differentiate SH-
SY5Y cells. Our data, therefore, suggest that these two cell lines are not good models for 
studying the Aβ-related increased neprilysin transcription observed in vivo. 
Based on the in vivo data showing that biochemically induced upregulation of neprilysin by 
intracranial injection of aggregated Aβ1-42 was not only found in the vicinity of the injection 
site but also in the contralateral hemisphere, we hypothesized that the Aβ1-42-related increase 
of neprilysin mRNA and protein levels could involve a diffusible factor activated by the 
injection of Aβ. Aβ is known to trigger inflammation by activation of microglia and 
astrocytes cells leading to secretion of various diffusible factors, including cytokines such as 
IL-1β, IL-6 or TNFα [119, 536, 537] mainly involving the microglia cells. Intracranial 
injection of aggregated Aβ and its long term deposit around the injection site was shown by 
several other groups to have similar effects in vivo [523-525, 538]. One week after 
intracranial injection of Aβ1-42, Aβ42-1 and PBS, a four fold increase of neprilysin mRNA 
associated with an increase of protein levels was observed when compared to non-injected 
control mice [406]. Damage of the brain tissue, disruption of the blood brain barrier and 
consequences which followed including microglia and astrocytes activation may have 
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activated neprilysin transcription and increased its protein levels. Among the diffusible 
factors released by activated microglia, cytokines such as IL-1α, IL-1β, IL-6 or TNFα were 
already shown to increase neprilysin transcription and protein levels in different cell culture 
models via pathways involving cAMP signaling pathway [245, 256] in addition to increasing 
glucocorticoid-induced transcriptional activity [539, 540]. 
We first investigated the potential involvement of a microglia diffusible factor in vitro. We 
measured the activity of the neprilysin promoters in 293T cells after incubation with 
conditioned medium of a microglia cell line previously cultured in presence or absence of 
Aβ1-42, or conditioned medium from 293T cells cultured in absence of Aβ1-42. No effect on 
neprilysin transcription was observed, suggesting that the cytokines secreted by the microglia 
cell line, during normal conditions and under Aβ stress, did not affect neprilysin transcription 
in a kidney cell line. We could not, however, study whether 293T cell line express the 
necessary receptors and pathways to mediate the effect of the microglia-derived factors. To 
confirm the absence of role from these cytokines, we further analyzed their levels in vivo, 20 
weeks after injection in the brain of WT mice, when Aβ1-42 specifically induced an increase of 
neprilysin mRNA and protein levels. No difference in a cytokine array including IL-1α, IL-
1β, IL-6 and TNFα were observed when comparing Aβ1-42 and Aβ42-1 injected mice. This 
does not exclude the potential role of these factors in the non-specific Aβ increase of 
neprilysin level one week after injection but suggests that they are not involved in the Aβ1-42 
specific effects observed after longer post-injection time. 
To focus our search of an in vitro model we decided to determine the promoter(s) involved in 
the upregulation of neprilysin observed after Aβ1-42 injection in vivo. New groups of mice 
were injected with Aβ1-42, Aβ42-1 or PBS and brain neprilysin mRNA and protein levels were 
analyzed 20 weeks after injection. A specific Aβ1-42-related increase of neprilysin protein 
level was observed. However, total neprilysin mRNA levels were not changed in the brain of 
Aβ1-42 injected mice when compared to PBS and Aβ42-1 injected groups. 
Since each one of the three neprilysin promoters lead to the transcription of a specific but 
non-coding exon, the activity of the three promoters was investigated by RT-PCR using 
specific primers recognizing each of the three non-coding exons. Similar to the total 
neprilysin mRNA level, we did not find any variation of mRNA levels specific for the 
activity of the three promoters of neprilysin when comparing the Aβ1-42 and Aβ42-1 injected 
group in spite of a clear Aβ1-42-related upregulation of the neprilysin protein level. These data 
suggest that the upregulation of neprilysin protein level associated with intracranial injection 
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of fibrillar Aβ1-42 does not require an increase of neprilysin transcription. Furthermore, careful 
analysis of the 20 weeks post injection groups, which previously illustrated the Aβ1-42 specific 
increase of neprilysin mRNA, suggests that the increase of mRNA does not correlate with the 
increase of protein level. Indeed, while similar increase of mRNA levels were observed in the 
4 mice of the original Aβ1-42 treated group, only 2 showed a clear increase of neprilysin 
protein level [406]. Considering the precedent results, we extrapolated that two pathways may 
be responsible for the Aβ1-42-related increase of neprilysin protein level: The first one 
implicates increased activation of neprilysin promoters, leading to an increase of mRNA and 
protein levels. Specific parameters such as incubation time, macromolecular identity of the 
injected aggregates and unknown diffusible factors are involved. The second pathway  
appears to be independent of neprilysin promoter activation and may be due to an increased 
stability of the neprilysin protein. 
 
3) All trans retinoic acid and neprilysin transcription 
 
In this work, RA incubation was used to differentiate the SH-SY5Y cells into neurons. 
Unexpectively, this treatment enhanced the activity of all three neprilysin promoters.  
RA treatment of SH-SY5Y cells was previously shown to increase transcription of important 
proteins involved in APP processing including APP [153, 541-544], presenilin [545] and 
ADAM10 [546]. A recent study reported that such a treatment also increased APP and APLPs 
protein levels with increased release of sAPPα, no effect on C99 levels and increased levels 
of AICD [543]. They suggested that RA shifted the APP processing in favor of the α-
secretase pathway and therefore could be beneficial in AD therapy. Interestingly, AICD from 
APP-like proteins (APP, APLP1, and APLP2), whose protein levels are increased after RA 
incubation of SH-SY5Y cells, were shown to transactivate neprilysin promoters leading to an 
increase of protein and activity levels in vitro and in vivo [547]. The use of APLP KO SH-
SY5Y cells or incubation with presenilin inhibitors could confirm the potential role of AICDs 
in the observed increase of neprilysin transcription. 
All three neprilysin promoters were highly activated by RA. While promoter 3 of neprilysin 
present three potential binding sites for retinoic acid receptors, neprilysin promoters 1 and 2 
do not contain such potential binding sites for transcription factors related to retinoic acid like 
retinoic acid receptors or retinoid X receptors. Therefore, we could not speculate that the 
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increase of neprilysin transcription was due to direct effect of RA or activation of other 
transcriptional pathways activated by RA rather than the differentiation process. 
The effect of RA incubation was confirmed in 293T cells which are not known to be 
differentiated by RA and presented no variation in cell proliferation rate and cell morphology 
during RA incubation. Again, all three neprilysin promoters were activated by RA incubation. 
Moreover, RA incubation also led to an increase of endogenous neprilysin protein level, 
providing the evidence for the specific activation of neprilysin promoters by RA in these 
culture systems. 
Retinoic acid isomers were also shown to protect hippocampal neurons from oxidative 
damage [548] and Aβ-induced neurodegeneration [549], inhibiting the Aβ aggregation and 
destabilizing preformed Aβ fibrils [550]. From our in vitro data showing that RA increases 
neprilysin transcription and protein levels, we extrapolate that the neuroprotective effect of 
RA observed against Aβ toxicity may also be in part due to increased neprilysin protein levels 
which would lead to Aβ degradation [401, 551]. 
Previous studies have shown the importance of retinoid signalling in the adult brain and it has 
been hypothesized, based on genetic and dietary data, that defective retinoid transport and 
function may contribute to LOAD [552]. Dietary deficiency of vitamin A in rodents affected 
LTP, synaptic plasticity [553, 554] and induced reversible learning and memory impairments 
[555-557], all reversed by addition of retinoids in the diet. 
The role of vitamin A in the pathology of AD, however, remains unclear. Retinoids levels 
appeared similar in normal and AD brain in spite of increased synthesis in the hippocampus 
[558]. Conversely, plasma levels were depleted in AD patients and subjects with mild 
cognitive impairment [559-561]. Vitamin A deficiency also caused deposition of Aβ in the 
brain of WT rats [562]. 
To determine if RA could also increase neprilysin protein level in vivo and therefore be a 
potential therapeutic approach for AD, we chronically treated the mice with RA during 5 
days. However, the brain level of neprilysin protein was not affected by this treatment. 
The concentration of RA is actively regulated at the blood brain barrier in vivo [563] and 
injection of similar RA concentrations were shown to restore decreased retinoid receptor 
levels in the brain of aging mice and to alleviate their memory deficit [555]. Possible 
explanations for the lack of effects on neprilysin protein level in vivo include the permeability 
of the blood brain barrier to RA and reequilibration of its brain level limiting its action. 
We have also implanted subcutaneously RA tablettes releasing a constant RA level every day 
during 3 weeks in WT and transgenic mouse models of amyloidosis. Effect of RA on 
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neprilysin level and APP processing including Aβ production is currently under investigation. 
Due to its general function as a gene regulator, RA was found to regulate directly and 
indirectly hundreds of genes [564, 565] and therefore, its overexpression may lead to various 
side effects. However, RA and analogs have been used systemically in therapies against 
cancers [566-568] and acne [569, 570] and low and high consumption of vitamin A reached 
via specific diet, allow to apprehend the potential side effects [571-573]. Due to the 
involvement of the retinoid signalling pathways in regulating synaptic plasticity and 
associated learning and memory behaviors, increase of retinoid levels easily reachable via a 
proper diet, may be a promissing approach against the pathophysiology of AD. 
 
4) Aβ activated the plasminogen system in vitro and in vivo 
 
Since intracranial injection of synthetic fibrillar Aβ1-42 caused a sustained increase of the 
major Aβ degrading enzyme, neprilysin [230], we hypothesized that this effect could have 
been a part of a general feedback loop and that this injection could have also triggered the 
activation of other pathways known to degrade Aβ. We further speculated that these pathways 
could also contribute to Aβ removal from the brain and the observed prevention of amyloid 
plaque and the associated cytopathology.  
Brain tissue levels of IDE, ACE and the metalloprotease 3.4.24.15, which were all shown to 
be involved in Aβ degradation, were previously found unchanged in response to Aβ1-42 
injections [406]. However, when the activity of plasmin, another Aβ degrading enzyme [422, 
447], was analyzed, a 5 fold increased activity was found 20 weeks post-injection in the brain 
of mice which received the Aβ1-42 injection when compared to PBS and Aβ42-1 injected mice. 
Plasmin deficiency led to increased time necessary for removal of intracranial injected Aβ1-42 
and pathological consequences [422]. The increase of plasmin activity can therefore be 
responsible, in part, for the observed Aβ degradation. To investigate the pathway involved in 
the activation of plasmin, the activity of its two known activators, uPA and tPA was 
determined. While tPA activity remained unchanged, uPA activity was highly increased in 
the brain of mice 12 and 20 weeks after Aβ1-42 injection but almost absent in the brain of mice 
which received other treatments. These data strongly suggest that uPA was responsible for the 
observed Aβ1-42-related increase of plasmin activity.  
After Aβ1-42 injection, uPA activity was mainly localized in the cell layers of the meninges 
but also detectable in neurons of the hippocampal CA1 region and dentate gyrus. Our in vivo 
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data are in agreement with previous studies showing that Aβ can stimulate the expression of 
uPA and its receptor with increase of uPA activity in human cerebrovascular smooth muscle 
cells [449]. Increase of uPA activity and the following activation of plasminogen further 
inhibited Aβ neurotoxicity and fibrillogenesis in vitro [450]. While the Aβ activated pathway 
leading to increase of uPA activity is unknown, cytokines including IL-1α, IL-1β, TNFα and 
other factors such as bFGF, IFNγ, IGF-I and IGF-II were shown to modulate uPA expression 
and protein level of uPA and uPAR in different in vitro systems [574-580]. Aβ is known to 
increase transcription and protein levels of some of these factors including IL-1, TNFα [537, 
581, 582]. However, no variation in the levels of bFGF, IFNγ, IL-1α, TNFα or IGF-II were 
observed in the brain homogenates of the mice which received Aβ1-42 and Aβ42-1 injections 
and therefore, the role of these factors should be excluded. In coherence with this, the mRNA 
levels of uPA, uPAR and tPA were not affected in treated brains. Taken together these data 
suggest that the observed increase of uPA activity was not due to an increased transcription of 
uPA and may involve an increased stability of the protein and/or decreased levels of uPA 
inhibitors. However, since plasminogen activator inhibitors (PAI) inhibit similarly uPA and 
tPA activity, the absence of variation in tPA activity suggests that decreased levels of PAI are 
unlikely to be involved in the observed increase of uPA activity. 
In spite of contradictory studies, uPA has been associated with LOAD [454, 455] and its 
decreased activity could lead to the decreased plasmin activity observed in AD patients [451, 
453] and therefore create an imbalance in brain Aβ levels in favor of its production. 
Furthermore, uPA can lead to degradation of Aβ via activation of plasminogen [450] and can 
activate many intracellular pathways via binding to its receptor [442, 443]. We decided to 
investigate uPA as a potential candidate promoting Aβ degradation. Published uPA transgenic 
mice [583, 584] unfortunately lost their brain uPA overexpression due to unknown factors 
with increasing generation, hampering the evaluation of uPA overexpression effect on Aβ 
level in vivo. On the other hand, we found that in uPA KO mice, the brain levels of murine 
Aβ were unchanged compared to brain from mice with a similar background as confirmed by 
a recent study [454]. It suggests that uPA is not by itself an important Aβ-degrading enzyme 
in vivo. 
Interestingly, uPA activity closely correlated with neprilysin protein levels after Aβ1-42 
injection. No direct link between these two proteins was ever published. However, these 
proteins play an opposite role in cancer development and cell migration and their 
transcription is activated by similar cytokines in vitro [245, 256, 576, 577]. 20 weeks after 
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injection, Aβ1-42 did not affect the levels of these cytokines and the transcription of uPA, 
uPAR and neprilysin in the brain of the mice when compared to Aβ42-1 injected mice, 
suggesting that the increase of uPA activity and neprilysin level were not due to increased 
transcription and did not involve the factors analyzed. We then hypothesized that uPA 
activity and neprilysin protein level may be directly linked via increased protein stability. 
Since the lack of mice overexpressing uPA in the brain did not allow us to investigate if 
upregulation of neprilysin protein level could be due to the increased uPA activity, we first 
tried to reproduce the results in vitro. Aβ1-42 strongly increased uPA activities in SH-SY5Y 
cells, MIC cells and primary neuronal cultures. However, tPA activity was also increased 
suggesting that incubation with aggregated Aβ1-42 resulted in a general activation of the 
plasminogen system in vitro. Interestingly, Aβ1-42 incubation increased plasminogen 
activators activity in all in vitro models tested suggesting that the pathway involved was 
broadly present. 
Since tPA can be activated by direct contact with aggregated Aβ, we also analyzed the effect 
of Aβ42-1 ,which is a non physiological protein and aggregates less easily than Aβ1-42. Aβ42-1 
incubation also increased with less extend uPA and tPA activity. This suggests that the Aβ1-
42-related increase of plasminogen activators activity may be due, in part, to the aggregation 
state of aggregated Aβ. Indeed, it is possible that binding of Aβ, or Aβ1-42, to tPA leads to 
plasminogen activation and plasmin generation which is known to cleave and activate among 
others uPA [585]. Aβ1-42-related increase of uPA activity in absence of tPA activity in MIC 
cultures suggests that increased uPA activity is not a consequence of unspecific tPA-
plasminogen pathway activation. However, whether or not a sub-threshold activation of tPA 
takes place in these cells and would lead to increase uPA activity should be confirmed using 
tPA KO cell lines. 
To determine if the increase of neprilysin protein level in vivo could be due to the Aβ-related 
increase of uPA activity, neprilysin protein levels were quantified after Aβ treatment in MIC 
cells which lacked detectable tPA activity and primary neuronal cultures since Aβ-related 
increase of neprilysin protein level was observed in neurons. Levels of neprilysin were 
unchanged by the treatment and therefore did not correlate with the Aβ1-42-related increase of 
uPA activity. We concluded that increase of uPA activity observed was not responsible for 
the increased levels of neprilysin in vitro. A direct link between uPA activity and neprilysin 
protein level could be confirmed by investigation of brain uPA activity and neprilysin protein 
level after intracranial Aβ1-42 injection in uPA KO mice and NEP KO mice compared to WT 
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littermates. The brain localization of the uPA activity and the potential neuronal 
colocalization with neprilysin could be investigated in the Aβ1-42 injected WT mice. 
To assess if increased uPA activity could be due to the increased neprilysin protein level and 
activity, plasminogen activators’ activities were analyzed in the brain of NEP mice 
overexpressing neprilysin in brain neurons and presenting an increase of brain neprilysin 
activity. Both uPA and tPA activities were increased in frontal cortex and hippocampus of the 
NEP mice when compared to WT littermates. Therefore, transgenic overexpression of 
neprilysin in neurons induces increase of plasminogen activators activity. These data suggest 
in two unrelated in vivo systems that an elevation of neprilysin protein and activity increases 
uPA activity. Plasmin activity has to be determined in the brain of NEP mice and WT 
controls to establish a link between neprilysin and the activation of the plasminogen system in 
vivo. Indeed, the increase of tPA activity observed in the brain of NEP mice can also be 
explained by the the neprilysin induced increase of uPA activity and subsequent plasmin 
activation. Differences in adaptation mechanisms may also explain the difference observed in 
tPA activity between our two in vivo systems exhibiting a neuronal neprilysin upregulation 
after Aβ1-42 injection or lifelong transgenic overexpression. 
Neprilysin and uPA/uPAR complex are known to have opposite effects on cell migration and 
proliferation. While neprilysin prevent them by inhibiting the Akt and FAK pathways [373, 
586, 587], uPA/uPAR complexes activate them [443, 588-590]. Neprilysin can act on cell 
migration via different pathways (reviewed in [586]): Neprilysin degrades neuropeptides such 
as bombesin endothelin-1 or bradykinins, which can activate, after binding to their receptors, 
Src phosphorylation leading to direct association and activation of FAK [372, 373], normaly 
resulting in cell migration. Binding to their receptors can also stimulate the phosphorylation 
and activation of growth factor receptors such as EGFR and IGFR [591-593] which bind and 
activate the PI3 kinase resulting in Akt and FAK signalling activation. Neprilysin also 
indirectly associates with the regulatory subunit p85 of the PI3 kinase through lyn kinase, 
thus inhibiting the interaction of the PI3 kinase with integrin and FAK. Neprilysin was finally 
shown to bind to ezrin/radixin/moesin (ERM) proteins limiting the interaction of this complex 
with CD44 and the subsequent cell mobility activation. On the contrary, the uPA/uPAR 
complex also contains the lyn kinase [594, 595] and activates the PI3 kinase which induce 
Akt and FAK activation leading to cell proliferation and migration. The intracellular 
signalling pathway induced by the uPA/uPAR complex can also be modulated by binding and 
activation of EGFR, IGFR, integrin or CD44 [443, 595-598]. 
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The neuronal overexpression of neprilysin in the NEP mice may result in PI3 kinase 
inhibition. It was shown in endothelial cells that inhibition of PI3 kinase could lead to an 
increased FGF-2-mediated uPA production [599]. It is conceivable that, if in the brain, PI3 
kinase activation level is regulated, its inhibition via high levels of neprilysin could lead to 
activation of pathways such as the uPA/uPAR complex which may counteract neprilysin 
effects. Decreased availability of proteins such as lyn kinase may also prolong the life of the 
uPA/uPAR complex prior to internalization and degradation with decreased activation of the 
intracellular signalling pathways but increased uPA activity. 
Transgenic overexpression of neprilysin may also result in decreased levels of other enzymes 
competing for similar substrates. For example, the protein levels of IDE, another Aβ 
degrading enzyme, were decreased in the brain of a transgenic mouse overexpressing 
neprilysin in neurons [405]. IDE also degrades insulin and TGFα [600-603], two activators of 
uPA or uPA/uPAR signalling in vitro [604, 605]. Inhibition of ACE by a similar regulation or 
by increased level of neprilysin cleavage products, such as substance P (1-6) [606] or 
angiotensin (1-7) [607], can also lead to increased levels of bradykinin [608, 609] which was 
shown to decrease expression and protein levels of PAI with subsequent increase of 
plasminogen activators activity [610]. However, brain levels of substance P, enkephalin and 
somatostatin are unchanged in our NEP mice and in NEP KO brains (Iwata and Saido, 
unpublished data). All together, these data suggest that either these neuropeptides are not 
good neprilysin substrates or that the levels of these neuropeptides are tightly regulated with 
neprilysin dependant degradation being prevented or compensated by increased synthesis in 
vivo. Tachykinin levels are regulated in part by the kallikrein-kinin System which can release 
tachykinins by cleavage of precursors (reviewed in [611]). Interestingly, kallikreins were also 
shown to cleave pro-uPA [439, 441] and to inhibit PAI functions [612]. Activation of such a 
pathway may also explain the increase of uPA and tPA activity in NEP mice. It will be 
interesting to investigate the physiological relevance of these different pathways in the 
neprilysin-related increase of plasminogen activators activities observed in vivo. 
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5) Neprilysin as a potential therapeutical approach in AD 
5.1 Biochemical analysis of the mice  
 
During this thesis, transgenic mice with neuronal expression of neprilysin (NEP mice) were 
generated and analyzed. We found that the transgenic neprilysin overexpression in mouse 
brains was associated with increased neprilysin activity and reduced levels of total Aβ and 
both Aβ1-40 and Aβ1-42 when our NEP mice were bred with J20 mice, a mouse model for 
amyloidosis which overexpressed mutated AD-causing APP in neurons. Furthermore, no 
alteration of APP levels or its CTF was found in the NEPxJ20 double transgenic as compared 
to J20 mice, emphasizing that removal of Aβ by a NEP-dependent mechanism would not 
interfere with processing and physiological function of APP. These data strengths similar 
observations including ours using genetic deletion [229], viral [403, 531] and transgenic 
neprilysin overexpression [405] which confirmed neprilysin as a major rate limiting Aβ-
degrading enzyme [230] and showed that its overexpression could decrease Aβ levels, 
prevent plaque formation and its associated glial activation without modification of APP level 
[303, 405]. 
Degree of astrocytes or microglia activation was not affected by neprilysin or mutated APP 
overexpression, confirming our previous data that glial activation depends mostly on amyloid 
plaque pathology in AD mouse models [613, 614]. 
Sequential extraction of Aβ and use of specific ELISA systems recognizing Aβ40 and Aβ42 
showed that neprilysin acted differentially on Aβ species depending on their aggregation 
state: While triton soluble Aβ species presented a similar 70% decrease for Aβ42 and Aβ40 
levels, SDS soluble Aβ species levels were differently affected by neprilysin overexpression. 
Neprilysin overexpression prevented more efficiently the aggregation of Aβ42 species rather 
than Aβ40 species in the SDS fraction with 70% and 50% decrease, respectively. 
Our finding that neprilysin overexpression prevented the formation of Aβ42 in a similar 
manner in the triton and the SDS fraction is consistent with the concept of equilibrium 
between the different aggregation states of Aβ. Consistent with our data suggesting a 
decreased efficiency of Aβ40 hydrolysis by neprilysin compared to Aβ42 species, levels of 
Aβ40 species were less decreased than Aβ42 species in another neprilysin overexpressing 
mouse model [405]. Infusion of the neprilysin inhibitor, thiorphan, similarly increased brain 
Aβ42 levels without affecting Aβ40 levels [317] and somatostatin deficient mice which present 
a reduced neprilysin activity also had a 50% increase of Aβ42 levels without variation of Aβ40 
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levels [532]. However, since the triton soluble Aβ40 and Aβ42 species were similarly 
decreased by neprilysin overexpression and only the formation of aggregated SDS soluble 
Aβ40 was less efficiently prevented compared to Aβ42 species, we speculate that neprilysin 
degrade similarly soluble Aβ40 and Aβ42 species but that aggregation of Aβ present in the 
SDS fraction protected better Aβ40 than Aβ42 from neprilysin degradation. 
Different studies suggested that oligomers of Aβ, rather than monomers, may be the real 
culprit in the pathology of AD [134, 226, 615]. The fact that neprilysin degrades mostly Aβ 
monomers and dimers [405] raised the question about the efficiency of neprilysin 
overexpression in AD therapy. However, Marr and colleagues [402] showed, using a 
lentivirus overexpressing neprilysin, that neprilysin overexpression in the brain could induce 
the degradation of aggregated Aβ including amyloid plaques, confirming in vitro data where 
neprilysin degraded both monomers and oligomers of Aβ1-40 and Aβ1-42 [331, 388]. Our data 
suggest that equilibrium exists between the different aggregation state of Aβ and that 
neprilysin can decrease the level of Aβ species independently on their aggregation state. 
Neprilysin overexpression was shown to prevent Aβ accumulation and to degrade high levels 
of Aβ. Moreover, murine Aβ levels were also found decreased in neprilysin overexpressing 
mice suggesting that neprilysin has a physiological role in degrading Aβ and may decrease 
Aβ levels also in non pathological conditions [405].  
The levels of substance P, enkephalin and somatostatin are reported to be generally decreased 
in the brain of AD patients [616-619] but also present an increased immunoreactivity 
associated with amyloid plaques in the brain of AD patients and mouse model of amyloidosis 
[620-625]. Neprilysin was shown to exhibit similar affinity for Aβ and for some of its other 
known substrates present in the brain such as substance P or enkephalin [294, 331]. 
Therefore, we determined the effect of neprilysin overexpression on substance P, enkephalin 
and somatostatin levels, three important brain neuropeptides shown to be degraded by 
neprilysin in vitro [279, 293, 300, 302] in our mouse models. The levels of substance P, 
enkephalin and somatostatin were not affected by overexpression of neprilysin and mutated 
APP. The absence of variation in our J20 mice can be explained by the weak pathology 
observed in our mice with absence of plaque formation, associated glia activation and 
neurodegeneration which are usually present in AD brains. Since murine Aβ levels were also 
found decreased in neprilysin overexpressing mice [405], our data suggest that Aβ is a better 
brain substrate for neprilysin than substance P, enkephalin or somatostatin in vivo and that 
overexpression of neprilysin would not interfere with the physiological functions of these 
neuropeptides. This is also coherent with data obtained in neprilysin deficient mice, which 
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present increased levels of Aβ ([229] and our data) without alteration of enkephalin [344] 
substance P or somatostatin levels (Iwata and Saido, unpublished data) in the brain. It is 
nevertheless possible that neprilysin overexpression led to non detectable decreased levels of 
these neuropeptides and microdialysis analysis will allow a better determination of neprilysin 
effect on these substrates and their functions. 
Furthermore, Aβ levels in AD brains are 103-104 fold higher than those in normal brains 
without Aβ plaque pathology [626, 627] and neprilysin is able to degrade large amount of Aβ 
in vivo [317, 531]. Our data suggest that neprilysin preferentially degrades Aβ without 
altering the level of its other substrates and therefore put forward the hypothesis that 
neprilysin overexpression present a valid therapeutic approach against Aβ with little impact, 
if any, on APP procesing and the functions of its other substrates in the brain.  
 
5.2 Behavioral consequences of neuronal neprilysin overexpression and 
potential prevention of Aβ-related behavioral deficits 
 
Progressive cognitive impairment is one of the first and major symptoms in AD [6]. Multiple 
transgenic mice mainly overexpressing mutated APP were generated that reproduced both the 
amyloid deposition and progressive memory loss (reviewed in [628, 629]). Among them, the 
J20 mice, which neuronaly overexpress human APP with the Swedish and Indiana mutations, 
were previously published to present high brain levels of Aβ [70] with learning deficit in the 
Morris water maze paradigm at 7 months of age [69].  
To determine the potential therapeutic effect of neuronal neprilysin overexpression in AD and 
confirm Aβ as the culprit of memory deficits in mouse models of amyloidosis, NEP mice 
overexpressing neprilysin in neurons were crossed with J20 mice and their progeny were 
analyzed in cognitive and non-cognitive tasks. Since AD patients also present behavioral 
impairments unrelated to cognition such as anxiety and depression [7-9, 630], we also 
investigated the behavioral phenotype caused by human mutated APP overexpression, and the 
therapeutic effect of neprilysin overexpression on non-cognitive parameters by using a 
comprehensive test battery covering not only cognitive skills but also exploration, anxiety and 
locomotor activities. A more complete analysis of the NEP mice and WT littermates was 
further performed to evaluate the potential side effects of neprilysin overexpression. 
Genetic background can affect brain APP processing, Aβ deposition in mice [631] and 
behavior performances in WT [632] and APP transgenic mice [633]. Since both transgenes 
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were initially expressed in mice with different backgrounds, NEP males were bred with J20 
females and only the male progeny was initially tested in the 7 months cohort. This approach 
allowed us to decrease the variability induced by sexual dimorphism [634, 635] and aleatory 
transmission of the 2.5% known imprinted genes [632, 636]. The strong transgene effects 
observed through the different behavioral tasks and the high similarity in Aβ levels quantified 
biochemically in J20 and NEPxJ20 mice suggest that variabilities due to background were 
negligeable. A second group of mice balanced with both genders was also analyzed at 15 
months to determine the effects of aging in these mice. 
 
5.2.1 Behavioral analysis of the NEP mice 
Neuronal overexpression of neprilysin was triggered by the Prp promoter which was shown to 
induce high levels of transgene expression in brains and hearts of transgenic mice [637]. This 
promoter led to similar high levels of neprilysin protein in the different brain areas analyzed 
including the hippocampus, cortex, amygdala, cerebellum and subcortical areas. It also led to 
neprilysin expression in the liver, heart and kidney. Since mice devoid of prion protein 
exhibit deficits in exploratory behavior and cognition [638-640], we verified that the presence 
of an extra prion promoter did not affect the levels of the endogenous prion protein. A recent 
study also showed that prion protein could promote Aβ aggregation in vivo [641]. 
Furthermore, since neprilysin has a broad substrate specificity and aggregation of PrPsc shares 
similarities with that of Aβ, endogenous level of prion protein and its potential degradation by 
neprilysin were investigated [642]. The brain level of Prion protein were found similar in 
NEP mice and WT littermates [642], suggesting that behavior changes observed in mice 
carrying the NEP transgene was not due to variation of the prion protein expression. 
Neuronal neprilysin overexpression did not affect the well being of the transgenic mice. 
Despite a decreased body weight observed in the 7 months cohort, longevity (up to 27 
months) and fertility were not altered by neprilysin overexpression. 
Among the different brain system regulating body weight (reviewed in [643]), the 
hypothalamus and the amygdala are two major areas. It is noteworthy that the neuropeptide Y 
(NPY), a sustrate of neprilysin [644, 645], is an established potent stimulator of food intake 
[646-648]. In spite of lack of hyperphagy in NPY KO and NPY1 receptor KO mice, ablation 
in adult mice of hypothalamic neurons that express NPY and agouti-related protein was 
shown to cause rapid starvation [649]. Therefore, potential degradation of NPY by 
overexpression of neprilysin may result in decrease of body weight. 
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NEP transgenic mice of the 7 months cohort behaved abnormally in all exploration tests with 
pattern of changes which strongly depended on the test condition. They were strongly 
hyperactive both in the emergence and object exploration test. In the open field, they were 
more active only on the second day, indicating impaired habituation, which was also evident 
in the emergence test in addition to the general increase of activity. Independently of 
hyperactivity, an altered pattern of locomotion was also observed whenever the arena 
provided enough space for its expression: NEP mice presented shortened more frequent 
locomotor episodes characterized by stronger acceleration, during the open field, emergence 
and object exploration paradigms. Since NEP mice performed similarly to their WT 
littermates on the rotarod, decreased body weight and defect in locomotor coordination were 
not responsible for the abnormal locomotion of the NEP mice. By contrast, no evidence for 
increased activity was found in the light-dark box or the O-maze. Similar defects of 
habituation associated with enhanced locomotor activity have been frequently reported in 
rodents with hippocampal damage (reviewed in [650]). While the presence of an hippocampal 
disruption in the NEP mice is unprobable based on the normal behavior of these mice in the 
hippocampal-dependent Morris water maze, puzzle box or Y maze paradigms, it can not be 
excluded since the NEP mice also presented a contextual learning impairment during fear 
conditioning.  
In addition to locomotor activity, anxiety-related parameters were also changed in NEP mice. 
Open sector avoidance on the O-maze was significantly decreased and dark time in the light-
dark box was reduced, while center field time in the emergence test was slightly increased. In 
the open-field, NEP mice did not spend more time in the center but were significantly less 
attached to their home base. These changes may be interpreted as evidence for reduced 
anxiety. 
Regarding learning and memory, NEP mice performed normally across multiple tasks. In the 
hippocampal-dependent Morris water-maze place navigation task, the learning rate and the 
overall performance as measured by the escape latency was similar in NEP and WT mice. 
Locomotion and ability to use visual and spatial information to find the visible and hidden 
platform were not affected by neprilysin overexpression. 
During the CTA, a hipocampally-independent associative learning and memory task, both 
groups developed a comparable strong taste aversion for saccharin and similar sensitivity to a 
quinine solution, confirming that taste sensitivity was not altered. Neprilysin overexpression 
did not alter the long term memory for taste aversion. It can be concluded that neprilysin 
overxpression did not affect the structures and pathways involved in CTA such as the 
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gustatory neural pathways and among others, the nucleus of the solitary tract, the parabrachial 
nucleus of the pons, the hypothalamus and the amygdala (reviewed in [504]). 
NEP mice behaved indistinguishably from their WT littermates in the puzzle box paradigm, 
which was shown to be sensitive to damage in 41 brain areas in rats [484, 651] and involves 
quick problem-solving tasks [652]. The motivation of both groups to reach the dark protected 
area was similar as shown by the escape latency during the training sessions. When the 
entrance was plugged by sawdust or a T-shaped cardboard, all mice adapted similarly by 
spending more time during the first trial and significantly less time during the second trial. 
Similarly, no impairment was found in spatial working memory as assessed by spontaneous 
alternation behavior in the Y-maze. In the 8 arm radial maze, another working memory 
paradigm, NEP mice showed a borderline reduction of overall performance. However, this 
could be explained by strong locomotor hyperactivity: despite spending on average less time 
on the maze than WT mice, NEP mice traveled a longer distance while completing the task, a 
fact that reflect their hyperactivity in the radial maze. Therefore the observed borderline 
impairment was not due to cognitive deficits but rather involved hyperactivity. 
Finally, NEP mice were impaired in fear conditioning and showed less contextual freezing, 
both immediately following training and after a 24h interval. Because they were less active 
than WT mice during baseline recording this is unlikely to represent a freezing deficit 
possibly present in hyperactive mice. Nociceptive threshold of NEP KO mice was shown to 
be significantly increased compared to control mice in the hotplate paradigm [344]. However, 
our own data contradict this finding showing no difference in pain sensitivity between NEP 
KO and WT mice in the hotplate task. Similarly, the pain sensitivity of the NEP mice tested 
in the hot plate was also unchanged and therefore, is not responsible for the observed deficit 
in fear conditioning. Rather, it may be taken as evidence for a reduced ability to form or 
retrieve an association between context and shock. Freezing to tone after 24h was significant 
and similarly modest in NEP and WT mice confirming the normal ability of the NEP mice to 
perform single association already observed in the CTA test. Since the lack of freezing was 
already observed during training, we could conclude that NEP mice presented a deficit in 
learning the context association in this specific paradigm. 
While conditioning to an auditory stimulus involves projection from the auditory system to 
the lateral nucleus of the amygdala followed by transfert to central nucleus of the amygdala, 
[653], conditioning to the context is more complex and depends on intact hippocampus and 
projection to the basal and accessory basal nuclei of the amygdala which project to the central 
nucleus of the amygdala [653]. Neprilysin was overexpressed in the amygdala but we did not 
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specifically investigate the neprilysin overexpression in the different nuclei of the amygdala. 
Lesion approach and local blockade of protein synthesis showed that the central and 
basolateral nuclei of the amygdala are respectively involved in the acquisition and extinction 
of the CTA [508, 654]. Since NEP mice presented normal learning and memory during CTA, 
the fear conditioning impairment observed in the NEP mice can not be explained by 
disruption of pathways involving these nuclei. Normal learning and memory behavior of the 
NEP mice in the hippocampal-dependent paradigms, such as Morris water maze and the 
puzzle box, also suggest that the pathways involving the hippocampus are not altered. 
However, among the corticohippocampal circuitry taking part in mnemonic functions, 
neurotoxic lesions of perirhinal or postrhinal cortex that were previously shown to impair 
contextual fear conditioning [655, 656] or contextual discrimination [657], caused little or no 
impairment in place learning in the Morris water maze paradigm [658]. Therefore, the 
disturbance of specific cortical areas associated with the hippocampus may be responsible for 
the lack of contextual fear conditioning observed in the NEP mice. 
Brain and peripherical levels of substance P, enkephalin and somatostatin were similar in 
NEP mice and WT control littermates. Therefore, their involvement in the behavior changes 
of the NEP mice should be excluded. It is still possible that small variations localized at the 
synaptic level could not have been detected and further analysis using microdialysis or 
quantification following injection of the radiolabeled neuropeptides could confirm our data. 
Other unidentified substrates of neprilysin may also play a role in the behavioral impairment 
of the NEP mice. Among them, only Aβ levels were found to be decreased in vivo by 
neprilysin overexpression [405]. The behavioral effects due to decrease of murine Aβ level is 
difficult to evaluate because of lack of proper mouse models. Indeed, no behavioral analysis 
of mice overexpressing Aβ-degrading enzyme has yet been published and behavioral 
consequences of Aβ levels decrease by deletion of APP are not dissociable from behavioral 
effects related to the lack of APP itself or its other proteolytic fragments. Interestingly, mice 
with APP deletion exhibited weight loss [62] and decreased activity in the open field [62, 
659] associated with decreased muscular strength [62]. Our data show opposite effects in 
NEP mice and no locomotor impairments as assessed by the rotarod could be found, 
suggesting that decrease of Aβ levels is not responsible for the abnormal locomotion of the 
NEP mice. Because neprilysin was shown to be involved in intracellular signalling pathways 
[373, 586, 587], a potential effect of neprilysin via internal signalling should also be 
considered. Overexpression of an inactive neprilysin mutated in its active site [586, 660] 
could dissociate the behavioral effects of neprilysin overexpression due to its enzymatic 
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activity from intracellular signalling pathway activation. To achieve this aim, similar 
expression pattern and protein levels should be reached to efficiently compare both pathways 
in the transgenic mice. 
We also found an increase in plasminogen activators activity in 18 months old NEP mice. 
Prior to confirmation of such an increase of uPA and tPA activity in the brain of NEP mice at 
a younger age, we can only speculate about the role played by these plasminogen activators in 
the behavioral phenotype of the NEP mice. For example, uPA transgenic mice expressing 
uPA in the hypothalamus, a region implicated in feeding behavior, exhibited reduced food 
consumption and body weight [583]. Therefore, a higher uPA activity could be responsible 
for the decreased body weight observed in the NEP mice. However, the same mice, which 
also presented increased uPA activity in cortical and hippocampal areas, exhibited impaired 
performance in Morris water maze and failed to normally acquire CTA [584]. The normal 
performance of the NEP mice from the 7 months cohort observed in these two paradigms and 
the lack of deficit of the 15 months old cohort in the Morris water maze suggest that the 
endogenous uPA upregulation observed in the NEP mice does not contribute to the behavioral 
changes observed in the NEP mice. A role of uPA in locomotion was proposed in a model 
involving chronic cocaine administration. Using regulatable virus, gene delivery of wild type 
uPA in the nucleus accumbens, the ventral tegmental area or the ventral subiculum increased 
cocaine associated hyperlocomotion. In contrast, delivery of mutated inactive uPA decreased 
it. However, expression of uPA did not affect the basal activity in the absence of drug [661], 
suggesting that increased uPA activity does not affect locomotion in normal conditions.  
Similarly, tPA upregulation could be responsibe for some of the behavior effects observed in 
NEP mice. TPA has been shown to be involved in synaptic plasticity and LTP. Whereas 
genetic or pharmacological inhibition of tPA affects the late phase of LTP [430], treatment 
with tPA facilitates LTP [662]. The effect of tPA deletion on locomotion, habituation of 
object exploration or spatial memory is controversial and led to poor rearing activity, absence 
of habituation, poor contextual fear conditioning but enhanced cue fear conditioning in one 
study [663] and had no effect in a second one [662]. The potential role of tPA in contextual 
fear conditioning was further suggested by Ammassari-Teule et al. confirming that tPA KO 
mice spent less time freezing in the context test but more time freezing during the cue test 
[664]. tPA also plays an important role in amygdala-related processing including fear and 
anxiety [665, 666], both inducing synaptic plasticity in the amygdala [665, 667]. While tPA 
activity was increased in the amygdala by acute restraint stress, disruption of tPA led to lack 
of anxiety in the O-maze paradigm after up to three weeks of daily restraint [668]. Taken 
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together, these data suggest that tPA is involved in many behavioral processes including 
locomotion, anxiety and cognition. However, most of these data were obtained by inhibition 
or deletion of tPA. Since tPA deletion present similar phenotype as in the NEP mice which 
present an upregulation of tPA, we speculate that these impairments are not related to tPA 
upregulation. To our knowledge, tPA overexpressing mice were only investigated in Morris 
water maze paradigm where they improved learning performances [419]. We can not exclude 
that increase and decrease activity of the plasminogen activators may both lead to similar 
behavioral changes but suggest that like for uPA, if tPA deficiency leads to decreased 
anxiety, lack of habituation and impaired contextual fear conditioning it is unlikely that its 
upregulation in NEP mice would lead to similar impairments. 
The behavioral analysis of the 15 months old cohort, balanced for both genders, showed that 
the abnormal locomotion and decreased anxiety observed in the 7 months old cohort 
disappeared with aging. Indeed, NEP mice did not differ anymore from their WT littermates. 
Body weight, locomotion in the open field, emergence and novel object exploration tests did 
not differ between NEP and WT mice. Interestingly, for unknown reasons, NEP mice showed 
lack of interest for the new object inserted during the novel object exploration task. However, 
no other results confirmed this finding. Anxiety-related parameters such as the preference for 
the open sectors and the percentage of open sector entries in the O maze were also 
comparable in NEP and WT mice. Like in the 7 months cohort, aged NEP mice performed 
similarly to WT littermates in the Morris water maze. Interestingly, the 15 months old cohort 
showed better performance to find the visible platform and performed similarly when the 
platform was hidden. We do not have a clear explanation for the age-related improvement in 
finding the visible platform and can only speculate that environmental conditions and age-
related decreased locomotion may play a role. Furthermore, in spite of absence of sex effect, 
the presence of both genders in the 15 months cohort may also increase the variability of the 
performances. 
Transgenic overexpression of neprilysin induced abnormal locomotion and decrease of 
anxiety-like behavior in the 7 months cohort. While the pathways responsible for these 
impairments are still unclear, they disappeared with age, suggesting that these effects were 
small and may be considered negligeable for using neprilysin overexpression therapeuticaly 
in AD. More importantly, neprilysin overexpression did not affect learning and memory in a 
battery of different cognitive tasks at two different ages. Neprilysin overexpression does not 
seem to present strong side effects in mice and can be considered as a potential therapeutic 
approach in AD.  
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5.2.2) Behavioral analysis of the J20 mice 
Our results show that J20 mice of the 7 months old cohort were characterized by a clear 
decrease of body weight, hyperlocomotion, decreased anxiety and memory deficits. 
The absence of similar behavioral effects observed in transgenic mice, whose transgene is 
driven by the PDGF promoter [128, 669] and the other studies showing similar results in 
transgenic mice overexpressing human mutated APP under the control of other neuronal 
promoters [629, 670-672] strongly suggest that the effects observed in the J20 mice are not 
due to impairement of the endogenous PDGF protein but involve APP overexpression. 
The initial concept that brain accumulation of Aβ causes the cognitive dysfunction in vivo has 
been controversially discussed, mostly due to the lack of correlation between β-amyloid 
plaque load and cognitive deficits [37, 130-132]. Furthermore, studies on transgenic mice 
showed that neuronal dysfunctions, including memory deficits, appeared before β-amyloid 
plaque formation [68, 128, 129] and passive antibody transfer could reverse memory deficits 
without reducing β-amyloid plaque in an APP transgenic mouse model [673], suggesting Aβ 
fibril intermediates rather than amyloid plaques as the major cause of neuronal dysfunction 
and cognitive abnormalities. To circumvent the effects exerted by β-amyloid plaques and 
their associated cytopathology on cognition, we have tested the mice at an age prior to β-
amyloid plaque formation. The immunohistochemistry data showed no β-amyloid plaque 
staining along with the absence of insoluble Aβ aggregates in FA extracts. Moreover, the 
degree of astrocytes or microglia activation did not differ between the four groups, 
confirming our previous data that glial activation depends mostly on amyloid plaque 
pathology in AD mouse models [613, 614]. Therefore, the impairments of the J20 mice 
observed in the different paradigms were not related to the β-amyloid plaque formation or to 
an associated inflammatory response. 
We found that body weight of the J20 mice was smaller than their WT littermates as early as 
4.5 months and 15 months of age. This is consistent with studies showing similar findings in 
adults with Down syndrome and in AD patients [674, 675] and may involve dysfunction in 
the hypothalamus which was shown by lesion studies to regulate food intake and body weight 
[643]. 
J20 mice also showed a strong hyperlocomotion across multiple tasks in both ages studied. 
This was particularly evident in the open field where J20 mice exhibited hyperlocomotion at 
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7 months and 15 months of age. Similar effect was present in the emergence test and novel 
object exploration paradigms performed by the 15 months old cohort.  
Tested for anxiety-related parameters, J20 mice exhibited a decrease of anxiety-like behavior 
with a significant higher percentage of opened arm entries and higher number of head dips in 
elevated O-maze corroborated by non significant decrease of time spent in the dark area of 
the light/dark test. At 15 months of age, J20 mice showed a trend toward decrease anxiety-
like responses in the O-maze task but did not reach significancy. 
In addition to amnesia, AD patients exhibit neuropsychiatric symptoms such as apathy, 
associated with depression, dysphoria and social withdrawal [676, 677]. However, agitation, 
restlessness, disinhibition and euphoria are also frequently reported [678]. Our data are 
consistent with the uninhibited nature often observed in late AD patients [679, 680]. 
Disinhibition of exploratory behaviors including decrease of anxiety-like behavior was 
present in rodents with deficits in hippocampal function [681, 682]. Rodents with 
hippocampal lesions also exhibited a significant increase in locomotor activity in a novel 
environment [683], which may be due to a disruption in the ability to gather the spatial 
information necessary to establish an internal representation of the environment [684]. Since 
APP and Aβ were expressed in the hippocampus of the J20 mice, it is possible that the 
hyperlocomotion and decreased anxiety may be due to disruption of the neural pathways of 
the hippocampus. This assumption was further strenghted by the memory impairment 
observed in the Morris water maze paradigm at 7 months of age. Whereas the ability to find a 
visible platform was not affected, J20 mice spent significantly less time in the goal quadrant 
during the place navigation tasks and the probe trial indicating impairment in spatial reference 
memory compared to controls. 
The J20 mice were previously published to present high levels of Aβ with learning deficit in 
the Morris water maze paradigm at 7 months of age [69], detectable amyloid deposits at 8 
months of age [70] associated with glial activation at 14 months of age [405]. Differences in 
behavioral results between laboratories can be caused by many factors including genetic 
background, environmental parameters or experimental procedures [685]. However, the lack 
of plaque detection by immunohistochemical approach at 11 and 18 months of age in our J20 
strongly suggest that the pathology of the J20 mice analyzed in our lab varied from the one 
previously published and therefore may explain the weaker learning deficit of the J20 mice 
observed in the Morris water maze paradigm. 
Interestingly, other brain areas such as perirhinal cortex and amygdala act on the stress factors 
associated with the Morris water maze. Rats with perirhinal cortex and amygdala lesions 
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performed normally on the Morris water task, but showed reduced searching behavior in the 
correct quadrant on the probe trial [686]. Lesion studies [687] and pharmacological inhibition 
of the amygdala [688] were shown to further prevent, certainly via its hippocampal 
projections [689, 690], LTP in the hippocampus and spatial memory in Morris water maze 
[687, 688, 691, 692]. 
The potential disruption of pathways involving amygdala is further strenghted by the 
increased extinction of the CTA observed in the J20 mice already at 4.5 months of age. 
During the CTA paradigm, the J20 mice drank similar amount of saccharin during the 
conditioning day and avoided the bitter kinin solution similarly to the WT littermates showing 
normal taste function. During the first choice test, the amount of saccharin drank did not 
differ from WT littermates suggesting that the mice associated correctly the saccharin taste 
with the LiCl induced nausea. However, the J20 mice drank significantly more saccharin 
during the following choice tests indicating an increased extinction of taste aversion in these 
mice. Reduced neophobia or taste sensitivity can not explain the CTA memory deficit 
observed in the J20 mice. The BLA were shown to be important for extinction but not 
acquisition of CTA [508]. Therefore, it is possible that human APP overexpression and the 
subsequent accumulation of Aβ, present in the amygdala of the J20 mice, specifically 
disrupted the BLA without acting on the other nuclei involved in learning in the CTA such as 
the central nucleus [508]. A similar accelerated extinction of the CTA memory was already 
found in another transgenic model of amyloidosis, which also presented a learning deficit 
[499]. These data are in agreement with the with implicit memory deficits observed in AD 
patients [693, 694].  
Analysis of J20 mice of the 15 months old cohort showed behavioral changes reminiscent of 
those seen in the 7 months cohort. However, many effects were weaker. Despite decreased 
locomotion, the J20 mice still presented a strong hyperlocomotion in the open field paradigm 
when compared to the 7 months old cohort. However, J20 mice did not show anymore signs 
of decreased anxiety-like behavior as assessed by the percentage of open sector entries in the 
elevated O-maze paradigm or memory deficit in the Morris water maze. This weakening of 
the effects previously observed in the 7 months cohort is similar to the ones observed for the 
NEP mice and therefore, may imply factors independent of the transgene expressed such as 
aging, housing conditions, presence of both genders etc. In the case of J20 mice, there is 
absence of amyloid plaque formation in both cohorts. It is also possible that oligomerization 
of Aβ in the 15 months old cohort involved formation of less toxic Aβ intermediates 
compared to the 7 months cohort where higher levels of oligomers, which were shown to 
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induce cognitive deficits [134, 226, 615], is expected. Interestingly, similar decrease of 
pathology with aging was also observed in other mouse models of amyloidosis [695] and 
transgenic mice overexpressing Swedish mutated APP were shown not to be impaired at 26 
months of age despite the presence of high levels of Aβ [696]. 
 
5.2.3 Prevention of Aβ-related behavioral deficits by neuronal neprilysin 
overexpression 
Our data show that overexpression of neprilysin in neurons did not prevent the non-cognitive 
impairments associated with neuronal expression of AD-causing human APP. The lack of 
effect is in part due to similar impairments present in NEP and J20 mice. Indeed, both 
transgenes induced a decrease in body weight and decrease of anxiety-related parameters in 
the O maze and L/D test. Determination of beneficial neprilysin effects on Aβ-related 
behavioral deficits is futher complicated by the numerous pathways activated by both 
transgenes which do not involve Aβ. For example, the behavioral deficits observed in the 
NEP mice can involve the degradation of other substrates [230] and/or activation of 
intracellular signaling pathways [373, 586, 587] which still need to be confirmed in vivo. 
Similarly, the non-cognitive impairments observed in J20 mice may include the involvement 
of APP or its other proteolytic fragments, whose levels were not modified by neprilysin 
overexpression. Furthermore, an additive effect of both transgenes was observed in the L/D 
test where decreased anxiety, determined by the decreased percentage of time spent in the 
dark, became significant only in NEPxJ20 mice further suggesting that the transgenes even 
bosted each other. 
Neprilysin overexpression did not prevent the hyperlocomotion induced by the J20 transgene 
in the open field at 7 months of age and during the emergence and novel object exploration 
paradigms. These data do not allow us to confirm the role of Aβ in the decrease body weight, 
hyperlocomotion and decreased anxiety exhibited by the J20 mice and would rather suggest 
that increased levels of APP or its other proteolytic fragments are responsible for these 
effects. This conclusion is supported by decreased locomotor activity observed in APP 
deficient mice [62, 659]. 
On the cognitive level, our data showed that overexpression of neprilysin in neurons 
prevented the impairment of spatial memory associated with neuronal expression of AD-
causing human APP in the highly used Morris water waze paradigm. While NEP mice 
behaved similarly to WT littermates, J20 and NEPxJ20 mice spent non-significantly more 
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time finding the hidden platform. However, NEPxJ20 mice also needed more time to find the 
visible platform suggesting that other parameters than cognition may have been involved. 
Furthermore, J20 mice also exhibited spatial memory impairments and spent less time in the 
goal quadrant during learning and memory tasks, the later being prevented by neprilysin 
overexpression.  Together with a neprilysin-dependent decrease in brain levels of Aβ1-40 and 
Aβ1-42, these data provide the evidence for the therapeutic potential of neprilysin 
overexpression for AD therapy. Because overexpression of neprilysin did not change levels of 
full length APP or its other proteolytic fragments, these data strongly support a role of Aβ, as 
the pathogenic agent responsible for the cognitive deficits of the J20 mice in the Morris water 
maze.  
Previous studies comparing APP transgenic mice to WT littermates demonstrated cognitive 
deficits linked to the APP transgene but none could provide direct evidence that the observed 
impairments were solely due to high brain levels of Aβ rather than high levels of APP itself or 
its other proteolytic fragments. Several Aβ-lowering therapeutic approaches including BACE 
deficiency or removal of Aβ by immunotherapy rescued cognitive impairments in mouse 
models [697-700] as well as in AD patients [701]. However, inhibition of BACE or γ-
secretase complex also interacts with APP processing. Moreover, immunization against Aβ 
acts through mechanisms that include among others microglia-mediated phagocytosis [702], 
depletion of Aβ peripheric pool of [703] and inhibition of fibrillogenesis and cytotoxic Aβ 
species [704] but also involves inflammatory reactions [705, 706]. 
In J20 mice and other transgenic APP mouse models, hippocampal synaptophysin 
immunoreactivity correlated inversely with Aβ levels but not APP levels, suggesting that Aβ 
rather than APP is involved in synaptotoxicity [70]. However, a similar disruption or decrease 
of synaptophysin immunoreactivity, impaired synaptic plasticity with decreased LTP and 
deficits in cognitive functions were also present in mice lacking APP [707, 708] and mice 
ovexpressing wild type APP also exhibited memory deficits [68], rendering a definite 
conclusion about the role of Aβ in mice overexpressing APP difficult. Using transgenic 
overexpression of an Aβ-degrading enzyme such as neprilysin, we could circumvent that 
problem by specifically targeting Aβ without modification of the APP processing as 
confirmed by Western blot analysis in this study and by others [303, 405]. APP and CTF 
levels were similar in J20 and NEPxJ20 mice but Aβ level was highly reduced in the double 
transgenic mice. These results were confirmed by specific ELISA showing an approximate 
70% decrease of Aβ1-42 and Aβ1-40 levels. Transgenic mice with neuronal overexpression of 
neprilysin behaved similarly to their control littermates in all cognitive tasks performed. 
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Therefore, it is likely that the beneficial effect of neprilysin overexpression seen in the 
NEPxJ20 mice in the Morris water maze was due to the ability of neprilysin to degrade the 
APP-transgene derived Aβ. Taken together, these data stress the specificity of the observed 
effects showing that in contrast to deficient performance of the J20 mice, the improved 
memory performance of the NEPxJ20 mice in the Morris water maze was caused by removal 
of Aβ from the brain. 
Our data also suggest that, in J20 mice, CTA, a learning and memory paradigm involving the 
amygdala [504], could be a sensitive paradigm to measure early cognitive deficits in 
transgenic APP mouse models [499]. However, in spite of a high level of neprilysin and 
decreased Aβ level in the amygdala of the NEPxJ20 compared to J20 mice, neprilysin 
overexpression did not prevent the memory deficit of the J20 mice in the CTA test. This 
result can be explained by the possibility that areas and pathways involved in CTA retention 
[504, 709] are more sensitive to Aβ insult and that the decrease of Aβ levels observed in the 
amygdala of the NEPxJ20 mice was not sufficient to prevent the memory deficit. Another 
explanation may include the involvement of APP or its other proteolytic fragments, whose 
levels are not modified by neprilysin overexpression. Indeed, APP is involved in multiple 
functions, including learning and memory [67 for review] and cognitive impairments are 
present in mice overexpressing [68] or lacking APP [707, 708].  
Furthermore, sAPP was shown to be neurotrophic [95] and neuroprotective [74, 99]. 
Intracerebroventricular injection of sAPPα further enhanced memory and blocked induced 
learning deficits in mice [102]. In addition, a chronic overexpression of sAPP could also 
affect the pathways involved in CTA. For example, sAPPα selectively suppress N-methyl-D-
aspartate receptor (NMDAR) current without affecting currents induced by α-amino-3-
hydroxy-5-methylisoxazole-4-propionate (AMPA) or kainate receptors in hippocampal 
neurons [106] and modulates the properties required for LTD and LTP on hippocampal slices 
[107], suggesting important roles for sAPPα in the various physiological and 
pathophysiological processes in which NMDAR participates, including taste memory 
consolidation [710, 711]. 
Moreover, the memory deficit observed in the CTA in J20 and NEPxJ20 mice could also be 
linked to the overexpression of the CTF of APP. The CTFα and CTFβ fragments, are shown 
to be neurotoxic in vitro [115, 712, 713] and their transgenic overexpression in mice induced 
impaired LTP [136, 714], neurodegeneration [137, 138] and cognitive impairments [137, 
714]. Similarly, CTFγ was also shown to induce cytotoxicity in vitro [156, 157], to bind 
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different adaptor proteins (reviewed in [145]) which can lead to transcription of multiple 
known and yet unidentified genes [146, 150, 715]. By competing for adaptor proteins, CTFγ 
overexpression can also influence other transcription pathways [150, 159, 160] potentially 
leading to decreased retention in the CTA paradigm. 
Different studies suggested that oligomers of Aβ, rather than monomers, may be involved in 
the pathology of AD [134, 226, 615]. The fact that neprilysin degrades mostly Aβ monomers 
[405] raised the question about the efficiency of neprilysin overexpression in AD therapy. 
Our data show that, independently of the aggregation state of Aβ species responsible for the 
memory deficit of the J20 mice in the Morris water maze, neuronal neprilysin overexpression 
could prevent their adverse effects. Our data confirm previous studies using APP 
overexpressing mice, including J20, suggesting that Aβ rather than APP is responsible for 
hippocampal related memory deficit [69, 130].  
 
We could not confirm the role of Aβ and the therapeutic effect of neprilysin overexpression in 
the non-cognitive impairments and in the CTA memory deficit observed in the J20 mice. 
However, we found that elevated brain neprilysin levels rescued the spatial cognitive deficits 
caused by abnormal high concentrations of Aβ in the brain of a mouse model of AD, without 
changing APP processing or having other side effects on cognition. Our data support Aβ, but 
not transgenic APP expression, as the pathologically relevant culprit responsible for the 
memory deficit of J20 mice and strength the importance of Aβ-lowering strategies and more 
particularly neuronal neprilysin overexpression for AD therapy. 
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V) CONCLUSION 
 
High brain concentrations of Aβ, a peptide released by the processing of the amyloid 
precursor protein, is associated to the pathology of AD and to cognitive deficits in transgenic 
mouse models. During my Ph.D. thesis, the role and regulation of neprilysin, the major 
enzyme known to degrade amyloid-β in vivo, was investigated in the concept of AD 
pathophysiology using cellular and animal models. While decreased levels of brain neprilysin 
led to increased Aβ levels in the brain of mice and for the first time presence of murine 
amyloid-β plaque-like, its neuronal overexpression prevented Aβ accumulation and the 
memory deficit of mice overexpressing the AD-causing mutated human APP without altering 
the endogenous levels of APP or other substrates of neprilysin in the brain. These data 
emphasize a major role of neprilysin in AD pathology and suggest that upregulation of 
neuronal neprilysin activity represents a valid Aβ-lowering therapeutic approach for AD. 
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 ABREVIATIONS 
 
A Adenosine 
ACE Angiotensin-converting enzyme  
AD Alzheimer’s disease 
Aβ β-amyloid 
AMPA α-amino-3-hydroxy-5-methylisoxazole-4-propionate 
ANOVA Analysis of variance 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
APLP Amyloid precursor like proteins 
α-2M α-2 macroglobulin 
BACE β-site APP cleaving enzyme (β-secretase) 
BDNF Brain-derived neurotrophic factor 
BLA Basolateral nuclei of the amygdala  
bp Base pairs 
BSA Bovine serum albumin 
C Cytosine 
CALLA Common acute lymphoblastic leukemia antigen 
cDNA Complementary desoxyribonucleic acid 
CNS Central nervous system 
CS Conditioned stimulus 
CSF Cerebrospinal fluid 
Ct Cycle threshold 
CTA Conditioned taste aversion 
CTFα C-terminal fragment of APP generated by a α-secretase 
CTFβ C-terminal fragment of APP generated by a β-secretase 
CTFγ C-terminal fragment of APP generated by a γ-secretase 
CMV Cytomegalovirus 
ddH2O Double deionised water 
DEPC Diethylpyrocarbonate 
DINE  Damage induced neuronal endopeptidase 
DMEM Dulbecco’s modified Eagle medium 
DMEM/F12 DMEM/Nutrient Mixture F-12 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
Dnase Deoxyribonuclease 
dNTP Deoxynucleoside triphosphate 
DTT Dithiothreitol 
E. coli Escherichia coli 
ECE Endothelin converting enzyme 
EGFP Enhanced green fluorescent protein 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylen-diamin-tetraacetic acid 
EGTA Ethylene-glycol-bis(2-aminoethyl)-tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay  
EOFAD Early onset familial AD 
FA Formic acid 
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FAD Familial form of Alzheimer’s disease 
FAK Focal adhesion kinase 
FCS Fetal calf serum 
FTD Frontotemporal dementia 
G Guanosine 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFAP Glial fibrillary acidic protein 
GSK-3β Glycogen synthase kinase 3β 
HA Haemagglutinin 
HEK 293 A human embryonic kidney cells 
HEPES N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] 
HPLC High performance liquid chromatography 
HRP Horseradish peroxidase 
HS Horse serum 
ICV Intracerebroventricular 
IL-1α Interleukin-1α 
IL-1β Interleukin-1β 
IL-6 Interleukin-6 
ip Intraperitonealy 
J20 Transgenic mice overexpressing the Swedish and Indiana mutated 
 human APP 
kb Kilobase 
kd Kilodalton 
L/D Light-dark test 
PFA Paraformaldehyde 
KO Knockout 
LB Luria Bertani 
LC-PCR  Light Cycler quantitative real time PCR  
LF2000 Lipofectamine 2000 
LiCl Lithium chlorid 
LOAD Late onset alzheimer disease 
LRP Low density lipoprotein receptor related protein 
LTP Long term potentiation 
MEAP Met-enkephalin-Arg-Phe 
MIC A human microglia cell line 
mRNA Messenger ribonucleic acid 
MWM Morris water maze 
NEP Transgenic mice overexpressing neprilysin  
NEP KO Mice with deletion of both neprilysin gene alleles 
NEP-/- similar to NEP KO 
NEP+/- Mice with deletion of one neprilysin gene allele 
NFT Neurofibrillary tangles 
NMDA N-methyl-D-aspartate 
NPY Neuropeptide Y 
OD Optical density 
ORF Open reading frame 
PAI Plasminogen activator inhibitors 
PBS Phosphate buffered saline containing 0.154 M NaCl, 0.0027 M KCl,  
 0.01 M Na2HPO4.2H20, 0.0018 M KH2PO4 adjusted to pH=7.4 
PC Prostate cancer 
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PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PFA Paraformaldehyde 
Plg KO Plasminogen deficient mice 
POLR2F Polymerase (RNA) II (DNA directed) polypeptide F 
poly-dT Desoxy thymidine polymer 
prp Prion protein  
P/S Penicillin 50 (U/ml) and streptomycin (50 µg/ml) 
PSEN1 Gene encoding Presenilin 1 
PSEN2 Gene encoding Presenilin 2 
qRT-PCR Quantitative real-time PCR 
rAAV Recombinant adeno-associated virus 
RA All trans retinoic acid 
RIA Radioimmunoassay 
RNA Ribonucleic acid 
Rnase Ribonuclease 
Rpm Rotations per minute 
RT Room temperature 
SAP Shrimp alkaline phosphatase 
sAPP sAPPα and sAPPβ 
sAPPα Soluble extracellular fragment of APP generated by α-cleavage 
sAPPβ Soluble extracellular fragment of APP generated by β-cleavage 
sCCa Small cell carcinomas 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamid gel electrophoresis 
SEM Standard error of the mean 
SEP Secreted endopeptidase 
SH-SY5Y A human neuroblastoma cell line 
SP Substance P 
SwAPP Transgenic mice overexpressing human APP with the Swedish double
 mutation 
T Thymidine 
TAE Tris acetate EDTA buffer 
TBS Tris buffered saline 
TEA Triethanolamine 
TGF Transforming growth factor 
TNFα Tumor necrosis factor α 
tPA Tissue-type plasminogen activator  
uPA Urokinase plasminogen activator  
US  Unconditioned stimulus 
UTR Untranslated region 
UV Ultra-violet 
v/v Volume per volume 
v/w Volume per original weight 
WB Western blotting 
WT Wild-type 
w/v Weight per volume  
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